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Abstract 
The interaction between epithelial cells and macrophages is integral to mucosal 
immune fate: determining the decision between tolerance and immune 
activation/inflammation.  Endotoxin tolerisation (ET) is a circumstance where cells 
go through a hypo-responsive state, unable to respond to further endotoxin-LPS 
challenge. Mucosal macrophages (MΦs) have a dual functionality that determines 
tolerance to commensal organisms or immune response to entropathogens such as 
E. coli. In the case of mucosal inflammatory pathologies, such as Crohn’s disease, 
this state of tolerance is broken, resulting in destruction of gut mucosal tissue 
where the macrophage phenotype has been altered from a regulatory M2-like 
subset phenotype to an inflammatory M1-like subset phenotype, responding to 
both pathogenic and commensal bacteria. Chronic inflammation by bacterial 
pathogen related molecular patterns (PAMPs), such as LPS, is well established to 
induce tolerisation. The aims of this project were firstly, to characterise the control 
of macrophage differentiation in a mucosal setting by investigating the 
immunomodulatory effects of PAMPs, such as LPS in presence or absence of TNFα 
and to investigate ET mechanisms associated with MΦ subsets responding to the 
entropathogen E. coli K12-LPS. Secondly, to investigate the effect of epithelial cells 
on macrophage subsets behaviour upon inflammation and ET. M1- and M2-like 
MΦs were generated in vitro from the THP-1 monocyte cell line by differentiation 
with PMA and vitamin D3, respectively, whereas differentiated epithelial cells 
(Caco-2) were obtained by long term culturing for 21 days. A transwell co-culture 
system of Caco2 cells and MΦ subsets was developed to mimic the cell-to-cell 
cross-talk between epithelial cells and immune cells. Mono- and co-culture models 
were pre-treated with either LPS, TNFα or IL-1β prior to stimulation by PAMPs. 
TNFα, IL-1β, IL-18, IL-6 and IL-10 were qualified by ELISA. Cytokines, PRRs and 
endogenous negative regulatory molecules were detected by RT-PCR and WB and 
epithelial barrier function was measured by trans epithelial electrical resistance 
(TEER). ET induced by K12-LPS failed to demonstrate a differential subset-specific 
response in MΦ mono-culture system whereas, LPS differentially suppress LPS 
induced cytokine expression in MΦ co-culture system. Tolerised M1- and M2-like 
MΦs exhibited a significant reduction in expression and secretion of pro-
inflammatory cytokines and comparable levels of anti-inflammatory cytokine, IL-10. 
The suppression of pro-inflammatory cytokine in these MΦs appeared to be linked 
to the differential TLR4 expression and up-regulation of negative regulators, such 
as IRAK-M and Tollip. In addition, MΦ subsets differentially responded to 
inflammation induced by pro-inflammatory cytokines, TNFα and IL-1β in mono- and 
co-culture models. In conclusion, tolerisation induced in MΦs is presented by the 
suppression of pro-inflammatory cytokine, which is associated with corresponding 
up-regulation of IL-10, TLR4 receptor and the negative regulators, in a subset-
independent manner. In the case of cross-talk between epithelial cells and 
macrophages however, a differential sensitivities to ET was displayed. These 
findings allow more understanding of MΦ subsets functions and ET mechanisms, 
which may be beneficial for the development of in-vitro models of MΦ subsets and 
therapeutics targeting Crohn’s diseases. 
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and literature review 
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1.1 Introduction  
1.1.1 Innate immunity in inflammatory bowel disease 
The gastrointestinal mucosa is frequently exposed to bacterial and food antigens from 
varied resident microbial flora (Gill et al., 2006). The intestinal commensal flora is of 
advantage to the host via the metabolism of food elements that are not absorbed and 
the vitamins that are consequently produced such as Vitamin B12 and vitamins C. 
However, the gut lumen might also be the location where pathogenic microorganisms 
enter the body, causing the potential for tissue damage. Consequently, intestinal 
innate immunity is a sensitive system of ensuring a swift, appropriate immune reaction 
towards pathogenic bacteria, whilst simultaneously permitting food and beneficial 
bacterial antigens to enter the body. An effective epithelial boundary and an intricate, 
developed immune system in the gut enable this multi-dimensional objective to be 
achieved. If this delicate compromise is disturbed, then an aberrant inflammatory 
reaction might occur, resulting in chronic intestinal inflammation, for example 
inflammatory bowel disease (IBD). IBD is a chronic inflammatory condition of the 
gastrointestinal tract that incorporates Crohn’s disease (CD) and Ulcerative Colitis (UC). 
Approximately 1 in 1000 individuals suffer from IBD within Europe, with enhanced 
levels of the disorder evident within westernised and industrialised nations (Loftus, 
2004). Both UC and CD have been connected with an enhanced danger of intestinal 
cancers. The predominant symptoms include pain in the abdominal area, rectal 
bleeding and diarrhoea. However, the condition can also occur in extra-intestinal areas, 
such as the eyes, kidneys, skin and joints (Bernstein et al., 2001). Individuals suffering 
from IBD additionally have an enhanced danger of suffering from further chronic 
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immune conditions, including psoriasis, ankylosing spondylitis and primary sclerosing 
cholangitis, the condition of shrinking of the  intra-and extrahepatic biliary tree minor 
to fibrosis and inflammation of the submucosa (Bernstein et al., 2005, Werlin et al., 
1980).  Weaknesses in epithelial barrier function, innate immune recognition and 
immune regulatory mechanisms may increase the aberrant expression of pathological 
inflammatory reactions in IBD (Geboes, 2001). It is commonly suggested that the 
pathogenesis of IBD is a consequence from the irregular immune response to enteric 
bacteria, leading to overproduction of pro-inflammatory cytokines such as TNFα and 
IL-1β, promoting tissue injury of the gut mucosa. Treatments for individuals suffering 
from IBD include attention being paid to their lifestyle and suitable changes introduced, 
as well as medical and surgical processes. The critical implicated of TNFα in IBD 
pathophysiology was emphasised by the successful use of anti-TNF treatments for 
patients who have CD (Targan et al., 1997). The medical stage includes corticosteroids, 
immunosuppressant agents and biologic treatments, including varying anti-tumour 
necrosis factor elements (TNFα compounds) (Baumgart and Sandborn, 2007). Yet none 
of these processes can provide a full cure and each have varying side effects. The 
origins of IBD are still not clear; although it is believed that genetically susceptible 
people are liable to suffer from it due to an unusual immune reaction towards the 
microorganisms of the intestinal flora. There is evidence to indicate that the 
dysregulated innate and adaptive immune pathways result in an abnormal intestinal 
inflammatory reaction in individuals suffering from IBD. The majority of research 
undertaken within the last three decades has placed its emphasis on the function of 
aberrant adaptive immune reactions in the origins of IBD. Whilst CD has frequently 
been perceived as being instigated by a Th1 reaction, UC has tended to be connected 
to an unconventional Th2 reaction (Fuss et al., 1996). As well as typical Th1 and Th2 
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reactions, a function for Th17 cells has also become evident (Geremia and Jewell, 
2012). Progress resulting from genome-wide association studies (GWAS) and 
immunological studies has latterly led the emphasis of IBD’s origins towards mucosal 
innate immune reactions, including innate microbial sensing, epithelial barrier integrity, 
unfolded protein reaction and autophagy (Geremia et al., 2014). 
The innate immune reactions indicate our initial defensive barriers. In contrast to the 
adaptive reaction, it is not a specific response and does not involve long-term 
immunity in the form of memory. The immune cells within the innate system, including 
Dendritic cells (DCs) and macrophages (MΦs), as well as intestinal epithelial 
myofibroblasts, are able to detect the intestinal microbiota and react to pathogen 
associated molecular patterns (PAMPs) in a typical way. This process enables a swift 
and efficient inflammatory reaction against the microbial process to occur. Additionally, 
DCs and MΦs are antigen presenting cells, which initiate T cell commencement and 
lead to the adaptive immune reaction.  
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Figure ‎1.1-1: The role of MΦsand innate cells in primary responses in the 
gut associated lymphoid tissue (GALT). 
GALT contains of Peyers’ Patches (PPs), which consist of follicles consisting of Micro-fold 
cells (M cells), T, B cells, Dendritic cells (DCs), monocytes, and macrophages. T cells 
differentiated into Th1, Th2, Th17, and Tregs. Macrophages differentiated into either 
M1-pro-inflammatory (TNFαhi) or M2-anti-inflammatory (IL-10hi) subsets. Antigens cross 
via M cells through endocytosis or by DCs over, phagocytosis. Antigen processing and 
presentation is prepared by antigen presenting cells (APCs) such as macrophages and 
DCs. APCs present antigens to T cells via MHC class II, recognised by T cells by the T cell 
receptor (TCR). In response to antigen presentation and depending on the type of 
stimuli, T cells either show immune activation or mucosal tolerance. Recognition of 
commensal-derived PAMPs, such as LPS, TLR4 agonist, by the intestinal epithelial cells 
(IEC) induces secretion of the antimicrobial peptide. Microbiota-derived signals induce 
IL-18 production from the IEC through activation of NOD-like family, receptors (NLRs). 
Microbiota-derived sphingolipids presented on CD1d by DC inhibit colonic invariant 
natural killer T cells (iNKT) development. This figure is adapted from information 
presented in (Kabat et al., 2014). 
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1.1.2 Intestinal epithelial barrier function 
The initial physical restriction that intestinal bacteria and food antigens must face is in 
the form of the mucous layer that protects the intestinal epithelium. Mucous is divided 
into an inner firm layer and a looser outer layer, and results from gel-generating 
mucins being polymerised by goblet cells and expand in the lumen because of their 
ability to bind water. The consequential mucin net is generally disinfected, whilst the 
outer mucous sections seems to be more porous and is occupied by commensal 
bacteria that find essential nutrients in the mucin glycans. The importance of mucous 
is in limiting bacterial advancement and intestinal inflammation, which has been 
emphasised by research conducted into MUC2−/− mice that contract colitis and are at 
increased danger of suffering from colorectal cancer (Van der Sluis et al., 2006, Velcich 
et al., 2002). Whilst there is not a mutation within the human MUC2 gene that has 
been connected with disturbing the purpose of the mucosal barrier, limited MUC1 
mRNA has been detected within the inflamed ileum of CD individuals MUC3,4 and 
MUC5B within the uninflamed ileum when a contrast is made with the control (Buisine 
et al., 1999). Gut associated lymphoid tissue (GALT) comprises enterocytes and 
specialised epithelial cells ( 
Figure ‎1.1-1), including goblet cells and Paneth cells. Paneth cells are only evident 
within the foundation of the crypts within the small intestine. Tight junctions, 
adherens junctions and desmosomes are used to preserve the integrity of the 
epithelial barrier. Defective epithelial barrier and enhanced intestinal permeability 
have frequently been detected in individuals suffering from CD and UC (Salim and 
Söderholm, 2011). Yet it was still not obvious whether these changes caused chronic 
inflammation or resulted from it. GWAS data available recently indicates that epithelial 
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barrier difficulties indicate a primary pathogenetic mechanism. Recently, UC has been 
connected with susceptibility single nucleotide polymorphisms in HNF4A. This is a 
transcription factor that controls the compilation of CDH1, the apical junction complex 
(Barrett et al., 2009). This encodes for E-cadherin, which is a prime element of 
adherents junction and a significant element in meditating the process of the epithelial 
intercellular communication, LAMB1, a laminin which occurs within the basal 
membrane of the intestinal epithelium, and GNA12, encoding for a GTPase. This occurs 
at tight junction formation via a combination of ZO-1 and Src (Barrett et al., 2009, 
Anderson et al., 2011). As well as creating a physical defence against infection from 
bacteria, epithelial cells are able to secrete a variety of bactericidal agents such as 
defensins (α-defensins result from Parneth cells whilst the majority of epithelial cells 
produce β-defensins). These agents are either generated constitutively, or through 
being induced via the identification of bacterial elements by pattern recognition 
receptors (PRRs) within epithelial cells (Uehara et al., 2007). The diminished induction 
of the β-defensins HBD2, which targeting Gram-negative bacteria (E. coli) (Harder et al., 
1997), HBD3 and HBD4 has been identified within the inflamed colon of individuals 
with CD in contrast to UC (Wehkamp et al., 2003). Furthermore, individuals with levels 
of ileal CD had reduced levels of the Paneth cell-derived α-defensins (HD5 and HD6) 
(Wehkamp et al., 2005). The diminished expression of HD5 and HD6 is particularly 
evident in patients containing the NOD2 frameshift susceptibility variant, indicating 
that an antimicrobial peptide hindrance might explain at least one of the elements 
accountable for the dangers connected with NOD2 (Wehkamp et al., 2004).  
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1.1.3 Intestinal Macrophages and Macrophage subsets 
Macrophages refer to heterogeneous populations of antigen presenting cells (APCs). 
These are present in most tissues and detect and eradicate pathogens and toxic 
molecules that are invading. MФs were initially described by Elie Metchnikoff in 1882; 
they might be regarded as mononuclear phagocytic immune cells are an important 
element in the early and changing responses of the immune system (Cavaillon, 2011). 
MФs predominantly stem from circulating monocyte precursors, once they move from 
the blood vessels into the endothelium, they eventually reach the tisuse and divide 
into macrophages when exposed to infection or inflammatory stimuli (Hume, 2006). 
Tissue MФs act as a form of specialised-tissue resident macrophage that are present 
across the body, and involved in homeostatic roles, including Kupfer cells in the liver, 
alveolar MФs in the lung, microglial MФs in the brain and osteoclasts in bones. As 
macrophages are present in virtually all organs and tissues within the body, it is to be 
expected that they are involved in preventing and resisting a range of chronic 
conditions. One example of this is cancer, whereby MФs are recruited to the tumour 
microenvironment. They are referred to in this instance as tumour associated 
macrophages (TAMs). TAMs have a central influence in acceleration of the progression 
of tumours and malignancy, such as advancing angiogenesis (Bingle et al., 2006, 
Mantovani et al., 2006).  As such, there is a link between TAMs and poor prognosis 
within virtually 80% of cancer situations in humans (Bingle et al., 2002). Other cases of 
them affecting autoimmune conditions are Crohn’s disease, an infectious inflammatory 
autoimmune condition, connected to the pro-inflammatory cytokines, IL (interleukin)-
12 and IFN (interferons) –γ. This is associated which is linked to the pro-inflammatory 
situation (Bouma and Strober, 2003, Foey, 2015). MФs are also associated with the 
advancement of acute and chronic rheumatoid arthritis (RA), a sterile inflammatory 
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autoimmune condition, in which MФs become active within various inflamed synovial 
membranes (Mulherin et al., 1996, Kinne et al., 2000).  As such, pro-inflammatory 
revealed to have a considerable influence within the pathology of RA via TNFα 
controlled ROS generation (Miesel et al., 1996). As such, pharmacological modulation 
of the MФ immune role may be effective in attempting to resolve inflammation linked 
to disease, such as rheumatoid arthritis. As such, the range of specialised macrophages 
indicate the heterogeneity of the process (Gordon and Taylor, 2005). Anti-TNFα 
therapy has been used for the treatment of gastrointestinal inflammation. MФs have a 
variety of beneficial functions, including eliminating microbial, reacting against 
tumours, and healing wounds (Vega and Corbí, 2006). The range of these functions is 
indicated by the variety of specific distinct macrophage subpopulations, which is 
thought to be influenced by a range of aspects such as microenvironment, 
differentiation and heterogeneity (Foey, 2015).  
Within the colon and small intestinal mucosa, MΦs are located slightly below the 
epithelium within the lamina propria (LP). Within the small intestine, which 
incorporates somewhat reduced amounts of mucosal MΦs in contrast to the colon 
(Lee et al., 1985), they are also evident within the sub-epithelial dome area of Peyers’ 
Patches (PP) ( 
Figure ‎1.1-1). Due to their positioning, mucosal MΦs are suitably located to interact 
directly with the bacteria in the lumen and to identify any microbes or microbial 
processes that might cross the epithelial monolayer. This might happen in varying ways. 
For example, MΦs might act in a similar way to mucosal DC, which have been 
reckoned to convey processes amongst intestinal epithelial cells (IEC) and into the 
lumen when responding to indications that epithelial cells have detected bacteria 
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(Niess et al., 2005, Chieppa et al., 2006). Other potentials include antigen acquisition 
by breaches of the intestinal barrier, or indirectly through uptake of dying epithelial 
cells that have innate antigen (Mowat, 2003). MΦs might obtain bacteria via a non-
direct route, after the transfer process from IEC. It is possible to identify pro-
inflammatory mediators that the IEC releases when detecting products like 
lipopolysaccharide (LPS) (Hornef et al., 2003). Typical MΦs identify microbes as part of 
the PRRs process, which identify structured motifs on prokaryotic and lower eukaryotic 
organisms. The most effective of these are toll-like receptors (TLRs), which detect 
pathogen-associated molecular patterns (PAMPs), like bacterial LPS, lipoprotein, 
lipoteichoic acid, flagellin and unmethylated CpG that incorporate DNA. As a rule, 
macrophages can be divided into two specific forms: M1 (classical) and M2 (alternative) 
macrophages. These are a paradigm of Th1/Th2 (T helper 1/2) polarization (Mills et al., 
2000). When considering macrophage heterogeneity, it is unsurprising that 
macrophages reflect plasticity and fluidity due to their heterogeneity. As such, their 
polarised subsets exhibit a range of response when reacting to environmental stimuli 
(Mantovani et al., 2004). Furthermore, more MΦ subsets have been described, 
particularly related with study of inflammatory pathologies such as atherosclerosis 
include include M4, Mox, HA-mac, M(Hb) and Mhem (Colin et al., 2014, De Paoli et al., 
2014) and reviewed in (Foey, 2015). However, with the absence of defined 
transcription factors that would normally show lineage commitment, it could not be 
agreed that these are distinct subset although they have been described.  
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Figure ‎1.1-2: Functional phenotypes of macrophage subsets. 
Monocytes are differentiated into different macrophage effector phenotypes by a variety of signs. GM-CSF, IFNγ, and LPS trigger the pro-
inflammatory MΦs, M1, while M-CSF, IL-4/IL-13, immune complexes (IC) +TLR ligation, IL-10, TGF-β and glucocorticoidst trigger the anti-
inflammatory MΦs, M2. Macrophage functions are firmed as results of several factors include inducible nitric oxide synthase (iNOS), 
arginase (Arg) expression, transcriptional factors (STAT-1, 3, 6), scavenger receptors (SR) such as mannose receptors MR, MHC II, co-
stimulatory ligands (CD80, CD86) and cytokines (IL-12, IL-23, IL-10, TGF-β), chemokines (CC-and CXC) expression. This figure is adapted from 
information presented in (Foey, 2015, Gordon, 2003, Mantovani et al., 2004).  
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1.1.4 Macrophage polarisation  
Macrophages are part of a heterogeneous myeloid-monocytic lineage that can be 
polarised when responding to a range of environmental symptoms (Mantovani et al., 
2004), such as cytokines, bacterial elements and chemokines. As such, classical 
activation M1s are induced by IFN-y separately or else when combined with classical 
stimuli, including TFNα or LPS. Furthermore, classical M1s can be induced when they 
are combined with the PKC activating DAG analogue (phorbol myristate acetate, PMA) 
(Kielian and Cohn, 1981, Green and Phillips, 1994). Granulocyte macrophage colony 
stimulation factor (GM-CSF) is a further element that can increase the variation of M1s 
within a concept of human monocytes (Finnin et al., 1999). However, M2s are induced 
by the Th2-derived cytokines, IL-4 with IL-13. Together, it is recognised that this results 
in M2-like mediated tumour expansion and advancement (Anderson and Mosser, 2002, 
Mantovani et al., 2002, Gordon, 2003).  
M1s exhibit increased anti-microbial levels and secrete significant amounts of pro-
inflammatory cytokines (TNFα, IL-1β, IL-18, IL-6 and IL-23), and express chemokines 
(CXCL 1, 2, 3, 5, 8, 10, CCL3, 4, 5, 11, 17 and 22; (Figure ‎1.1-2). Another attribute of 
M1s is the fact that they express inducible nitric oxide synthase (iNOS) which is 
incorporated in L-arginine catabolism, culminating with the generation of nitric oxide 
(NO) that is recognised as a significant mediator of macrophage cytotoxicity (Nathan 
and Hibbs, 1991). In fact, it has been indicated that iNOS expression correlates with 
the impact of antimicrobial activity upon NO (Granger et al., 1988). It is notable that 
the iNOS mRNA translation was restrationed by arginase-mediated arginine depletion 
being inducted (Lee et al., 2003). Furthermore, it is recognised that macrophages 
increase the production of ROS, including superoxide anions and hydroxyl radicals in to 
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response virus disease (Sindrilaru et al., 2011, Afonso et al., 2007). Toxic intermediates 
and ROS are regarded as significant elements of classical activation; M1s utilise them 
to enhance their processes of killing bacteria when initially responding to an invading 
pathogen. There is the argument that TLRs, especially TLR 2, 4 and 5, which have a 
direct correlation with NF-ƙB (nuclear factor-kappa B) activation and pro-inflammatory 
cytokine secretion, are a distinct element within LPS-induced M1s (Bosisio et al., 2002, 
Van Ginderachter et al., 2006, Foey, 2015) However, IL-13 and IL-4 mediation of M2 
activation was indicated to oppose these receptors (Bosisio et al., 2002, Gordon, 2003). 
Each of the family receptors (TLRs/ NOD-like receptor (NLRs)) has a pivotal function 
within activating immune cells, including neutrophils and macrophages (Fukata et al., 
2009). M1 activation also incorporates the upregulation of MHC II (HLA-DR, surface 
molecule), co-stimulatory B-7.2 (CD86; cluster distinctiveness 86) and IL-12 improving 
the capacity of activating Th1-mediated reactions to resident pathogens and to 
improve high protection (Fukata et al., 2009, Hölscher et al., 2001, Mosser, 2003). This 
upregulation in expression, coupled with IL-23, as generated by M1s, sustains the 
distinctiveness and purpose of Th17 cells (Stockinger and Veldhoen, 2007). Overall, by 
the expression matrix metalloproteinases, M1s can be identified (MMP-1,-2,-7,-9 and -
12) under inflammatory conditions (Gibbs et al., 1999, Van Ginderachter et al., 2006). 
M1 polarisation can additionally relate to transcription elements such as STAT1, 
utilised by IFNγ and GM-CSF, and nuclear factor (NF)-kB which relate to pro-
inflammatory cytokine expression being inducted (Liu et al., 2008). Activated 
macrophages partake in the role of eliminating micro pathogens, tissue damage and 
pro-inflammatory reactions through deriving Th1 response (Mills et al., 1992, Mills et 
al., 2000). In contrast, M2s (alternative activation) relate to immune control, tissue 
repair capacity, and advancing tumours and angiogenesis by suppression of Th1 
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inflammatory responses and stimulation of the Th2-mediated anti-inflammatory 
response that is consequently stimulated (Anderson and Mosser, 2002, Lopez-Castejón 
et al., 2011, Takeuch and Akira, 2011). It has been proven that M2s contain a notable 
activation feature that incorporates extensive expression (Mantovani et al., 2002, 
Gordon, 2003) of mannose receptor (MR, CD206) which is a notable element within 
the anti-inflammatory phenotype (Figure ‎1.1-2). When activated alongside IL-4, 
additional important markers (arginase I, Arg+ I) have been proven to be upregulated 
within the M2s. This leads to into ornithine and urea. This is subsequently catabolised 
into polyamines and proline, substances essential for cellular proliferation and tissue 
repair (Gordon, 2003, Gordon and Taylor, 2005, Classen et al., 2009, Ochoa et al., 
2001). Arginase has a role in tumour invasion as it generates myeloid immune 
suppressor cells within individuals suffering from cancer (Zea et al., 2005). These 
enable immune inhibitory mechanisms, significantly contributing to the prevention of 
disease (Highfill et al., 2010). Due to the cytokine profile being a form of macrophage 
polarization, M1s have the attributes of IL-12 high and IL-10 low. In contrast, M2 
macrophages are responsible for diminishing  pro-inflammatory cytokines and as such 
their attributes are IL-10 high and IL-12 low (Mantovani et al., 2004). In a manner 
similar to the cases of IL-4 and IL-13, alternative activation stems from being exposed 
to IL-10, M-CSF, glucocorticoids or alternative steroid (vitamin D3) signals (Goerdt and 
Orfanos, 1999, Mantovani et al., 2004). Lastly, alternative M2s can be categorised into 
three groups. M2a can be induced when they are exposed to IL-4 or IL-13 and secrete 
TGF-β (tumour advancement elements- β); IL-1R and IL-1ra, while expressing CCL-17, 
18, 22 and 24 (Figure ‎1.1-2). On the other hand, M2b macrophages can be induced via 
immune complexes (IC) and TLRs agonists or IL-1β receptors, secrete cytokines 
including TNFα, IL-8 and IL-1β and express CCL-1, which recruited M2b. (Figure ‎1.1-2). 
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Immunosuppressive M2c can be induced via IL-10 and TGF-β or glucocorticoids, 
secrete TGF-β and IL-23lo and express CCL-16 and 18, alongside CXC-18. Furthermore, 
M2b and M2c are regarded as being regulatory macrophages (Gordon, 2003, Martinez 
et al., 2009). 
1.1.5 Innate immune recognition  
The primary function of PRRs involves providing a defence towards pathogens. In 
contrast, gut epithelial PRR recognition of conventional commensal PAMPs are 
transitioned into signals for expressing anti-microbial peptide (hBD-2), improving 
barriers (ZO-1 being reallocated), and the proliferation of epithelial cells (Cario and 
Podolsky, 2005). As such, cell signalling being weakened leads to polymorphism in TLR 
and NLR genes that is implicated in the spread of numerous conditions (Franchimont et 
al., 2004, Hedl et al., 2007). PRR signalling cascades lead to NF-ĸB activation with gene 
transcription and the generation of pro-inflammatory mediators lead to a suitable 
innate reactions towards pathogens. TLRs detect PAMPs being located extracellularly 
or within intracellular vacuoles, for instance lysosomes or endosomes. Stimulation of 
TLR by their relevant ligands, triggers intracellular cascades that are classically myeloid 
differentiation primary response gene 88 (MyD88)-dependent and MyD88-
independent pathways which incorporate IL1 receptor associated kinase (IRAK) and 
TNF receptor associated factor 6 (TRAF6) (Akira et al., 2006). The TLR family contains 
the human homologues of the Drosophila Toll protein. The extracellular domain of Toll 
receptors, meanwhile, comprises a leucine-rich repeat (LRR) whilst the cytoplasmic 
domain presents homology alongside the interleukin-1 receptor (IL-1R). This is referred 
as the Toll/IL-R (TIR) domain. TLRs do not only detect and react to pathogen associated 
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molecular trends, but also join with non-pathogenic antigens including heat shock 
proteins(O'Neill and Bowie, 2007). 
The localisation of TLRs and NLRs is a vital function in regulating inflammation and 
preserving the typical gut mucosa. The expression of TLRs differs within cell types and 
cellular localisation. TLRs are expressed within a number of myeloid cells, including 
macrophages and DCs, and on non-myeloid cells, including epithelial cells and 
fibroblast. This expression can be extracellular - for example (TLR1, TLR2, TLR4, TLR5, 
TLR6 and TLR11), intracellular (TLR3, TLR7, TLR8, TLR9) - or both (TLR4, TLR9). The 
immune reaction materialised once PAMPs are detected via PRRs (when the 
extracellular LRR domain interacts with microbial PAMPs), with the recruitment of 
cytoplasmic adaptor (MyD88) then occurring, producing the activation of NF-ĸB 
(Wesche et al., 1997) and reviewed in  (Takeda et al., 2003). 
TLR4 was the first human TLR to be detected. This reacts to LPS from Gram-negative 
bacteria. The lipid A element is required within the LPS molecule to be detected by 
TLR4. This process results in the generation of an array of immunostimulatory 
cytokines and chemokines mediated by signaling intermediate MAPKs (mitogen-
activated protein kinases) and the transcriptional factors AP-1, NF-ĸB and IRF5 
pathways. In terms of signalling, TLR4 is reliant on CD14 and MD-2 being present so as 
to produce a complex (Shimazu et al., 1999). Similar to TLR1, 2 and 3, it was identified 
that TLR4 is expressed by monocytes, as well as by polymorphonuclear (PMN) cells and 
DCs, at reduced levels in B cells, on fibroblasts, astrocytes, keratinocytes, myocytes, 
endothelial cells and epithelial cells (Hornung et al., 2002, Song et al., 2002, Frantz et 
al., 1999, Bsibsi et al., 2002). A number of endogenous ligands for TLR4 have been 
defined but, since many of these investigates were shown with recombinant proteins 
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from E. coli, in reflection it is likely that some of the results stem from the usage of 
contamination with endotoxin (LPS). For example, heat shock protein Hsp70 has been 
explained as being endogenous TLR4 ligand by a variety of groups (Asea et al., 2002, 
Dybdahl et al., 2002). However, subsequent research was unable to verify these 
findings and indicated that tested, LPS-free Hsp70 had no TLR4 dependent effects 
(Bausinger et al., 2002, Gao and Tsan, 2003b, Gao and Tsan, 2003a, Wallin et al., 2002). 
Additional endogenous ligands have subsequently been expressed for TLR4. Yet it was 
not always researched as to if their activating properties could be due to being tainted 
by LPS. Fibrinogen, fibronectin, heparan sulfate, and hyaluronan, extra-cellular matrix 
proteins like, were also presented to stimulate TLR4 as endogenous ligands (Smiley et 
al., 2001, Okamura et al., 2001, Johnson et al., 2002). 
IECs are structurally polarised where they are apically facing the intestinal lumen and 
basolateral facing the basement membrane and the lamina propria. It is suggested that 
TLR signalling in intestine could be regulated according to their location as apical or 
basolateral expression (Abreu, 2010). TLRs polarised expression by IECs at both apical 
and basolateral surface might lead to the discrimination between the pathogen and 
non-pathogen microbial signals (Peterson and Artis, 2014). Differential sensitivity of 
IECs to apical in contrast to basolateral stimulation has been demonstrated in in vitro 
and in vivo models with several TLR ligands (Gewirtz et al., 2001). For instance, 
basolateral contact of IECs to TLR9 ligands consequences in translocation of NF-κB and 
canonical activation whereas, apical contact leads to clear inhibitory result over the 
maintenance of IκB. Therefore the apical signals could induce tolerance to following 
TLR stimulation, represent a different cross tolerance alteration of microbial 
recognition pathways for the a differential responses to PAMPs signals according to 
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structural location (Lee et al., 2006). Another study assumed that TLRs expression 
might be selectively regulated in association with IBD and these modifications may be 
particular to the IBD type either CD or UC. Consequently, TLR3 and TLR4 are 
differentially regulated in the intestinal epithelium of IBD patients (Cario et al., 2000). 
Additionally, in the human foetus, it was presented that TLR2 and TLR4 were expressed 
on the basolateral side of ileal basement enterocytes (Fusunyan et al., 2001). The 
expression of TLR2 and TLR4 is low in healthy colon whereas, TLR4 is highly expressed 
on colon apical side in Crohn’s disease patients (Cario and Podolsky, 2000). Other TLRs 
also seem to be polarised in IECs. Depending on the polarised cell line, LPS apical 
stimulation of Caco-2 cells results in NF-κB activation and IL-8 production (Lenoir et al., 
2008). The different reactions following to apical or basolateral TLR activating are 
consistent with the suggestion that inflammatory and possibly negative TLR reactions 
to PAMPs must only happen when these has been a break in the epithelial barrier 
upon inflammation. In this manner, aggressive bacteria, mostly pathogenic bacteria, 
which can breach the epithelial barrier, provoke pro-inflammatory reactions; however, 
bacteria that cannot cross the barrier, generally non-pathogenic bacteria, stay on the 
apical side eliciting a homeostatic atmosphere and anti-inflammatory response (Abreu, 
2010). 
LPS, an important inducer of the inflammatory reaction to Gram-negative bacteria, is a 
large molecule comprising of O antigen, core, and lipid A. It incorporates two forms 
smooth and rough (Moreno et al., 1979). Furthermore, it functions as an endotoxin, 
and instigates a notable immune reaction via the Lipid A portion (Raetz and Whitfield, 
2002). Indeed, the removal of O antigen leads to rough LPS, resulting in the bacterial 
cell membrane becoming more permeable and thus it is not so difficult for AMPs to 
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damage it. LPS is predominantly detected via TLR4 (Beutler, 2000), especially joining 
the lipid A section of rough LPS when CD14 and MD-2 were present (Taniguchi et al., 
2009). In contrast, smooth LPS binds LPS binding protein (LBP) within the form of CD14 
and MD-2 (Wright et al., 1990). It has been identified that MD-2 protein results in a 
complex with TLR4. This is crucial for surface expression and LPS responsiveness. As 
such, MD-2 plays a role in mediating the signal between TLR4 and LPS (Shimazu et al., 
1999). 
CD14, a co-factor for LPS signalling, described as a glycosylphosphatidylinositol (GPI)-
linked membrane protein. This does not have the capacity to implement a trans-
membrane signal, as it does not contain the cytoplasmic domain. As such, in order to 
mediate signalling, it is required to combine with other proteins. There are varying 
purposes to CD14 expression. Jean et al. (2001) asserted that LPS is only precisely 
cross-linked TLR4 and MD-2 when it interacts with CD14 (da Silva Correia et al., 2001). 
As well as its function in LPS detection, CD14 also notes bacterial PAMPs; 
peptidoglycan (PGN), mycobacterial lipoarabinomannan and streptococcal cell wall 
polysaccharides (Pugin et al., 1994, Soell et al., 1995, Weidemann et al., 1997, Wright 
et al., 1990). Therefore, it has the capacity to detect and join elements of both Gram-
negative and Gram-positive bacteria and to serve as a co-receptor for TLR4 and TLR2. 
Additionally, CD14 can cause natural reactions to non-self-molecules that have the 
potential to infect, whilst also combining with apoptotic cells, to act as a scavenger 
receptor in macrophage cells (Devitt et al., 1998, Pradhan et al., 1997). CD14 has two 
types, soluble and membrane bound protein, which are expressed by a wide array of 
cells including monocytes/macrophages and epithelial cells (da Silva Correia et al., 
2001). Recent research has confirmed that endogenous molecules or damage-
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associated molecular patterns (DAMPs) exuded by damaged tissues have the capacity 
to activate CD14, the co- receptor of TLR4 and TLR2 (Yu et al., 2012).  
TLR2 detects microbial PAMPs for both Gram-negative and Gram-positive bacteria, 
such as bacterial lipopolypeptides, peptidoglycan (PGN), lipoteichoic acid (LTA), and 
zymosan originating from cell wall component, yeast. It has a role in detecting Gram-
positive bacterial products (PGN) as well as CD14 (Von Meyenburg et al., 2004). TLR2 
expression has a major purpose in preserving gut mucosa. Latterly, researchers have 
indicated that TLR2 being induced by epithelial cells, as part of a reaction to 
conventional non-pathogenic microbiota, plays a part in the process of inducting the 
regulatory cytokine, IL-10, by macrophages and Tregs resident in the lamina propria 
resulting i gut tolerance (Round et al., 2011). As well as this, Cario (2008), utilising 
findings from recent animal model and human research, suggested that the 
shortcomings of TLR2 signalling might result in inconsistencies with the commensal-
dependent intestinal epithelial barrier defences, leading to mucosal injury. Research 
indicated that polymorphism of TLR2 is linked to extensive bacterial infections, 
including Staphylococcus and Mycobacterium infection (Cario, 2008). This indicates 
that the TLR2 gene might increase the restriction of the host response to a particular 
array of microbial pathogens (Lorenz et al., 2000, Texereau et al., 2005), resulting in 
the initiation of intestinal injuries (Candia et al., 2012). 
TLR5 recognises flagellin, the predominant structural protein of the flagella on Gram-
negative and Gram-positive bacteria (Oshima et al., 2010). TLR5 has a significant 
function in preserving gut mucosa by inducing anti-microbial peptides, especially hBD-
2 (Schlee et al., 2007); as such, the absence of it is connected with gut injury (Carvalho 
et al., 2012). 
 
21 
 
TLR9 detects unmethylated CpG bacterial DNA (Minns et al., 2006). The expression of 
TLR9 by epithelial cells has a significant function in controlling innate immunity via its 
function in degranulation of antimicrobial peptides such as defensins by Paneth cells 
(Rumio et al., 2004). Conventionally, the expression of TLR9 occurs basolateraly on 
epithelial cells; on the other hand, it is additionally on the apical cell surface in reaction 
to pathogenic microbial infection (Ewaschuk et al., 2007). Apical expression of TLR9 
permits the cells to detect pathogenic bacterial DNA; basolateral expression, in 
contrast, detects commensal non-pathogenic bacteria instead (Lee et al., 2006). 
TLR3 detects double stranded viral RNA (Alexopoulou et al., 2001), expressed by 
mature colonic epithelium towards viral infection. After the initiation of the TLR3 
expression, there follows the intracellular activation downstream of the cells that are 
unrelated to the myeloid differentiation factor 88 (MyD88) pathway. This contrasts 
from other TLR cell initiation pathways (O'Neill, 2008, Yamamoto et al., 2003) 
1.1.6 Toll like receptor signalling pathways 
Detection of microbial ligands by epithelial TLRs is regarded as the initial process in 
regulating innate immune reactions. When microbial ligands are detected, TLRs are 
dimerised and initiate a signalling cascade, resulting in the pro-inflammatory cytokines 
becoming activated. There are five adaptor proteins that arbitrate TLR signalling; 
MyD88, TIR-associated protein (TIRAP) or Mal, TIR domain containing adaptor protein 
inducing IFN-β (TRIF), TRIF-associated adaptor molecules (TRAM), and Sterile-alpha 
and Armadillo motif comprising protein (SARM) (O'Neill and Bowie, 2007, Yamamoto 
et al., 2002). Two signalling pathways are induced by microbial ligands; MyD88-
dependent activates (TLR 2, 4, 5, and 9) and MyD88-independent (TLR3 and 4) (Akira 
and Takeda, 2004, Takeda and Akira, 2005). MyD88 serves a crucial role as a necessary 
 
22 
 
adaptor molecule for TLR and IL-1, which connected to the ligand induced expression 
of IL-6. MyD88 additionally has a role in phagocytosis and the bacterial pathogens 
being eradicated. If this process does not occur, then the phagocytotic immune 
response is not able to undertake its role. MyD88 have an integral role in the initiation 
of specific cytokines that are responsible for the activation of TNFα and IL-1 that occur 
in receptor ligation (Inoue et al., 2007). The joining of TLR and MyD88 recruits IL-1 
receptor-associated kinase 4 (IRAK-4), enabling the connection of IRAK-1. Following 
phosphorylation by IRAK-4, IRAK-1 joins with TNF receptor activated elements 6 (TRAF-
6), a process opposed by the negative regulator, IRAK-M (Pålsson‐McDermott and 
O'neill, 2004). TRAF-6 activation is stimulated, transforming the PGF-β activated kinase 
(TAK-1), which phosphorylates MAP kinases and the inhibitory kB kinase (IKK) complex 
resulting in triggered IKK complexes. The initiation of IKK complexes will phosphorylate 
IkB, providing freedom to NF-ĸB from its restrictions and permitting nuclear 
translocation of NF-ĸB, culminating in genes for inflammatory cytokines going through 
transcription and co-stimulatory molecules (Banerjee and Gerondakis, 2007) 
(Figure ‎1.1-4). The array of mechanisms appears to be having an influence in regulating 
TLR initiation by the intestinal epithelium, as the persisting and extensive initiation of 
TLRs can prime uncontrolled inflammation. These processes regulate the shared 
results of a range of negative regulators, such as IRAK-M, Tollip, SIGIRR, A20, and NOD-
2 (Shibolet and Podolsky, 2007).  Tollip has been referred to as a negative regulator of 
NF-ĸB signalling, activated by a range of stimuli including LPS (Burns et al., 2000). The 
prime role of Tollip,  located in the Golgi apparatus (Li et al., 2004), is to negatively 
regulate TLR signalling by restricting the processes of IL-1 receptor-associated kinase 
(IRAK). The limitations of the activity of IRAK result in restrictions to the inflammation 
that is connected with the up-regulation of TLR2 and TLR4 expression (Zhang and 
 
23 
 
Ghosh, 2002). Furthermore, research into animal and human cell line models 
additionally indicated Tollip regulates the magnitude of inflammatory cytokine 
production in relation to IL-1β (Didierlaurent et al., 2006). As such, maintaining steady 
intestinal homeostasis at the gut epithelial cell location necessitates a range of 
functions of the epithelial cell hypo-responsiveness to LPS. One of these roles does 
concern the expression of Tollip. Interleukin-1 receptor connected kinase (IRAK)-M is a 
protein that has a role in several immune and epithelial cells. IRAK-M is an efficient 
negative regulator of TLR signaling within MyD88, reducing the signalling via NF-ĸB and 
the expression of pro-inflammatory such as TNFα and IL-1β (Kobayashi et al., 2002). 
SIGIRR is a negative regulator that has a role within the signal transduction of several 
receptors of the TLRs. Overexpression of SIGIRR can limit NF-ĸB-dependent luciferase 
expression as controlled by TLR4 and TLR9 (Figure ‎1.1-4) (Zhao et al., 2012). The 
inhibition of cytokine signalling (SOCS) is induced by TLR, which plays an important 
function within the negative regulation of TLR signals (Yoshimura et al., 2007). In 
general, these negative regulatory molecules have the role of down-regulating the 
mechanisms and extent of immune reactions that present a danger to the effective 
functioning of the relevant immune system in question.  
1.1.7 NOD-like receptor (NLRs) 
Cytoplasmic NLR detect an extensive array of microbial ligands and toxins in addition 
to particular damage-associated molecular patterns (DAMP) of the host cell. NODs and 
NALPs are significant groups that are suitably attributed within the NLR family 
(Williams et al., 2010). Nucleotide Oligomerisation domains (NODs) are a family of 
cytosolic proteins that function as PRRs and initiate a signalling cascade that results in 
an inflammatory reaction. The NLR family members NOD1 and NOD2 are activated by 
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varying elements of bacterial peptidoglycan. NOD1 signals via TRAF2 and TRAF5 and 
NOD2 signals via RIPK2 leading to NF-ĸB initiation. Additional NLRs are involved in the 
inflammasome being devised that results in caspase-activation and IL-1 secretion 
(Clarke and Weiser, 2011, Martinon et al., 2009). NOD2 was the first risk gene to be 
recognised to confer increased risk to CD (Hugot et al., 2001, Ogura et al., 2001). NOD-
2, sometimes referred to as Caspase activating and recruiting domain (CARD15), is a 
component within the NOD family and identifies intra-cytoplasmic PAMPs of muramyl 
dipeptide (MDP), the smallest bioactive elements of PGN (Girardin et al., 2003a). NOD-
2 is expressed by monocytes/macrophages, dendritic and intestinal epithelial cells 
when responding to intracellular microorganisms. The activation of NOD-2 by invading 
intracellular pathogenic microorganisms like Salmonella and Shigella comes before the 
amplification of inflammation process which occurs via up-regulating the generation of 
pro-inflammatory cytokines (Girardin et al., 2003b). That said, commensal bacteria like 
Lactobacillus casei strain Shirota (LcS) is additionally detected via NOD-2. However, 
they result in advantageous outcomes via limiting inflammatory cytokines, thus 
resulting in an enhanced gut mucosa within the IBD model (Matsumoto et al., 2009). 
NOD-2 has a pivotal function in controlling the gut mucosa (van Heel et al., 2005); 
NOD-2 gene polymorphism initiates defects in PGN signalling. This occurs when the 
recognition of commensal PGN results in amplifying the immune reaction connected to 
the up-regulation of the inflammatory cytokines.  
Three uncommon SNPs in NOD2 are connected to vulnerability to ileal CD with an odds 
ratio equal to 2.4 in heterozygote people and 17.1 in homozygotes or compound 
heterozygotes. This can be recognised as the most significant link with IBD identified 
thus far (Economou et al., 2004). This connection has been widely extrapolated across 
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European ancestry, but no such link has been identified in Asian and African–American 
societies (Yamazaki et al., 2002, Kugathasan et al., 2005). Ten years on, the functional 
purpose of NOD2 mutations remains widely debated, yet research that has hitherto 
been undertaken indicates that they are loss-of-function mutations that result in 
diminished NF-ĸB initiation (Abraham and Cho, 2006). This insufficient reaction might 
lead to diminished reduced antibacterial agent generation and pathogenic microbial 
invasion (Wehkamp et al., 2004). Additional research indicates that the loss of the role 
of NOD2 might cause a reduction in the limitations of TLR2 stimulation, resulting in the 
initiation of inflammatory pathways and excessive Th-1 reactions (Watanabe et al., 
2004c). Additionally, the distinct NOD2 3020insC has been demonstrated to limit IL-10 
expression within human monocytes. This has initiated the theory that NOD2 
mutations might lead to insufficient immune regulation (Noguchi et al., 2009). NOD2 
single nucleotide polymorphisms have additionally been recognised in further chronic 
inflammatory disorders, including leprosy, Blau syndrome, an autosomal dominant 
chronic granulomatous inflammatory disorder that influences upon the joints, and 
early onset sarcoidosis (EOS). From this, it appears that NOD2 is a significant immune 
receptor within the process of inflammation (Zhang et al., 2009, Henckaerts and 
Vermeire, 2007). 
Furthermore, CD has been linked with mutations in ATG16L1 and IRGM genes. These 
have a part in autophagy, a importantly conservative cellular practice where a double-
membrane vesicle is created to surround the invading intracellular bacteria or cellular 
cytoplasmic material to permit effective degradation (Hampe et al., 2007, Parkes et al., 
2007). Autophagy conventionally materialises because of stress or starvation to reuse 
crucial cellular proteins and amino acids. Whereas immune stimulation via TLRs have 
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been identified as initiating autophagy (Delgado et al., 2008), research conducted 
recently has connected NOD2 with inducing autophagy and have demonstrated that 
NOD2 and ATG16L1 alternatives both induce modified autophagy, antigen 
presentation and intracellular bacterial handling by DCs (Cooney et al., 2010, Travassos 
et al., 2010).  
1.1.8 Cytokines association with IBD 
The change association of cytokine expression in inflammatory disease versus the 
homeostatic state is the key marker. Cytokines are intracellular messengers. They 
provide the signals that activate and control inflammatory reactions to pathogens and 
injury. The release pathway for cytokines within macrophages occur via extensive TNF 
signalling (Li et al., 2012). Activated macrophages generate a cascade of pro-
inflammatory and/or anti-inflammatory cytokines such as TNFα, IL-1β, IL-18, IL-6, IL-10 
and IL-12. TNFα is a multi-functional cytokine that is able to control numerous cellular 
and biological practices, including immune purpose, cell distinctiveness, proliferation, 
apoptosis and energy metabolism (Cawthorn and Sethi, 2008).  
 Pro-inflammatory cytokine, TNFα  1.1.8.1
TNFα is a pro-inflammatory cytokine that is generated by initiation macrophages as a 
form of reaction to microbes, particularly in response to stimulation by LPS of Gram 
negative bacteria. TNFα is a significant mediator of acute inflammation and regulates 
the recruitment of macrophages to locations of infection via activating endothelial 
cells to secrete adhesion chemokines (Kigerl et al., 2009). TNFα generate chemokines, 
which are chemotactic cytokines, and activates the hypothalamus to result in fever. 
TNFα additionally advocates the secretion of acute phase proteins. Furthermore, it has 
deep autocrine influences, its predominant cellular origin, triggering them and 
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improving their cytotoxic prospects (Beutler and Cerami, 1988). These contrasting 
influences of TNFα might partly be due to the presence of two distinct signaling 
pathways mediated through TNF receptor 1 (TNFR1; p55) and TNFR2 (p75). It is 
reckoned that TNFR1 mediates the deaths of cells, whilst TNFR2 progresses cell death 
or advocates cell initiation, expansion or proliferation (Arnett et al., 2001). 
Macrophages are regarded as the main aspect generating a potent pleiotropic pro-
inflammatory cytokine, TNFα. Rather paradoxically, they are very sensitive to this 
process themselves (Vassalli, 1992, Parameswaran and Patial, 2010). In fact, it has 
been indicated that TNFα has an important function in controlling the inflammatory 
reactions of macrophages (Parameswaran and Patial, 2010). Overall, the initiation of 
macrophages and TNFα generation materialise through an array of activatory signals. 
The LPS-mediated signalling pathway is one of these instances (Sweet and Hume, 1996, 
van der Bruggen et al., 1999). LPS signalling happens via LPS-binding protein (LBP) in 
plasma (Ulevitch and Tobias, 1995). Hence, the LBP/LPS complex joins the surface 
bound receptor of CD14 on monocyte/macrophage (Tobias et al., 1993, Delude et al., 
1994). LPS is subsequently transmitted to a signalling transmembrane molecule, TLR4 
(Beutler and Rietschel, 2003). The TLR4/LPS joining results in the initiation of differing 
intracellular pathways, including the NF-ĸB pathway that is initiated by MyD88 and 
IRAK. This controls the phosphorylation and ubiquitination of IkBα. Resultantly, IkBα is 
dispelled and NF-ĸB is activated (Chen et al., 2005, Kawai and Akira, 2007, Karin, 2009). 
Active NF-ĸB (p50/p65) is ultimately translocated into the nucleus (Sun and Ley, 2008). 
As such, LPS-induced NF-ĸB activation leads to the secretion of the TNFα gene 
expression in macrophages (Shakhov et al., 1990). Following such signalling cases, a 
pro forma form of II transmembrane TNFα containing a molecular mass of 26 KDa is 
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generated. This manifests itself as a membrane bound precursor that can be 
proteolyticaly cleaved by TACE (TNF-alpha-converting enzyme), a disintegrin and 
metalloproteinase (ADAMs) (Black et al., 1997, Moss et al., 1997, Peschon et al., 1998). 
Furthermore, the way in which TNFα expression is induced is additionally activated by 
networks of signalling pathways like mitogen-activated protein kinase (MAPK) 
pathways incorporating extracellular signal-regulated kinases (ERK 1, 2), p38 and c-Jun 
N-terminal kinase (JNKs). Further transcription aspects include initiated protein-1 (AP-1) 
(Tsushima and Mori, 2001, Beutler and Rietschel, 2003, Sun and Ley, 2008). The 
initiation of JNKs (Swantek et al., 1997), p38 and ERK1, 2 (Geppert et al., 1994, Lee and 
Young, 1996) in RAW 264.7 is essential for LPS-induced TNFα generation. Furthermore, 
NF-ĸB can be triggered independently of the MyD88 initiation pathway via protein 
kinases C (PKC α and β) when reacting to LPS and PMA stimulation (Martin et al., 2003, 
Foey and Brennan, 2004). This said, TNFα is necessary for the role of macrophage 
immune and host defence, with unrestricted TNFα generation occasionally causing 
tissue damage (Parameswaran and Patial, 2010). For example, extensive generation for 
TNFα was revealed to detrimentally impact upon the pathology of inflammatory 
disorders as in autoimmune conditions as extended TNFα secretion results in tissue 
disruption being caused within the rheumatoid arthritis (Drexler et al., 2008) or an 
extreme reaction to infectious agents in sepsis (Conte et al., 2006, Smith et al., 2006). 
As such, a controlling function must develop to diminish the extreme generation of 
pro-inflammatory TNFα. This might be beneficial in forming therapeutic possibilities 
for disease-associated inflammation. 
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  Inflammasome activation and IL-1β & IL-18  1.1.8.2
The initiation of neutrophils and macrophages to overwhelm pathogens and to free 
toxic oxygen and nitrogen radicals relies on pro-inflammatory cytokines like IL-1β and 
IL-18 that are mainly generated by monocytes/ macrophages (Dinarello, 1996, 
Dinarello, 1999). The inactive precursors of IL-1β and IL-18 (pro-IL-1β and pro-IL-18) 
differ from other pro-inflammatory cytokines in that they depend upon cleavage into 
the bioactive cytokines via an enzymatic process. One of the most significant enzymes 
in determining the activation of pro-IL-1β and pro-IL-18 is the intracellular cysteine 
protease caspase-1 (Dinarello, 1996). Multimeric protein platforms called the 
inflammasome are important regulators of this process (Latz, 2010). The 
inflammasome characteristically comprises a nucleotide joining domain leucine-rich 
repeat (NLR) protein, the adaptor molecule apoptosis-associated speck-like protein, 
which comprises a CARD (ASC) domain, and caspase-1. Four inflammasome complexes 
have been referenced hitherto include NLRP3, NLPC4 etc. The inflammasome resulting 
from the NLR family member Nlrp3 and the adapter protein ASC is the most widely 
studied. It is possible to initiate the Nlrp3 inflammasome via an important quantity of 
stimuli. Some have a bacterial foundation (MDP, bacterial RNA and double-stranded 
RNA) whilst some are danger -associated molecular trends (DAMPs including uric acid 
crystals and amyloid-β). Furthermore, exogenous compounds including asbestos, silica 
or alum adjuvant have been referenced as initiating the Nlrp3 inflammasome 
(Martinon et al., 2004, Dostert et al., 2008, Kanneganti et al., 2006, Eisenbarth et al., 
2008). Whilst advances have been achieved in raising our awareness of the control of 
IL-1β processing, contention is still evident in terms of the ability of TLR ligands, for 
instance LPS, to initiate caspase-1 and free IL-1β. The monocyte-like leukemia cell line 
THP-1 does generate dynamic IL-1β when reacting to LPS stimulation. Some have 
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argued that the mere presence of LPS is not sufficient to activate IL-1β release 
(Martinon et al., 2004). However, the findings from research indicate that IL-1β exudes 
from monocytes after a single stimulation with a TLR ligand (Dinarello et al., 1986, 
Dinarello et al., 1987). Research has recently provided new insights in this debate, 
suggesting that the synthesis and release of IL- 1β vary across human monocytes and 
macrophages (Netea et al., 2009). Monocytes have the capacity to initiate caspase-1 
by autocrine generation of ATP. Thus, stimulation with a TLR ligand can swiftly result in 
active IL-1β in monocytes being released via the induction of IL-1β transcription. This 
does not rely on the requirement for a second signal from the environment to initiate 
caspase-1 (Figure ‎1.1-3). However, macrophages, dendritic cells and the monocytic cell 
line THP-1 depend upon two particular signals to instigate IL-1β transcription and 
translation and to activate caspase-1. These two signals will consequently produce IL-
1β processing and secretion (Figure ‎1.1-3) (Netea et al., 2009). Whilst caspase-1 is 
evident in freshly acquired human blood monocytes, secretion of dynamic IL-1β 
remains reliant on inflammasome aspects, especially ASC (Netea et al., 2009). In 
research conducted of turpentine-induced inflammation, IL-1β –/– mice face defence 
against inflammation but caspase-1-deficient mice are not (Fantuzzi et al., 1997, Horai 
et al., 1998). Additionally, caspase-1 seems to be dismissed when defending against 
particular forms of microorganisms, like Chlamydia trachomatis. That said, IL-1β affects 
the inflammatory reaction induced by these microorganisms (Cheng et al., 2008, 
Prantner et al., 2009). The findings indicate that caspase-1 and inflammasome 
initiation is vital within a few but not every form of IL-1β-driven inflammation. 
Caspase-1 initiation is only one role for cleavage of IL-1β and IL-18, and hence the 
presence of contrasting pathways of IL-1β and IL-18 initiation, which do not rely on the 
inflammasome, must be recognised. Additionally, there is not much chance that a 
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whole form of trend identifying receptors have developed to merely be used for 
initiating caspase-1. Consequently, the objective should be set of further investigating 
the roles of NLRs that surpass the function they play in instigating caspase-1. In the 
pathophysiology of IBD, interleukin-1 is a dominant component in the regulation of 
inflammation in the mucosal gastrointestinal tract (Dukovich et al. 1986). It has been 
reported that IL-1β levels increase in gut tissue in intestinal inflammation of animal 
models and in the mucosa of IBD patients (McCall et al. 1994; Reinecker et al. 1993). IL-
18  has been reported to be upregulated in IBD patients as it is capable to stimulate IL-
1β as well as IL-8 from activated macrophages, consequently modulating the 
concluding pathway of CD immune pathogenesis. Therefore, it is possible that IL-18 
will be the essential as a primary initiating cytokine in Th1-mediated diseases, such as 
CD (Pizarro et al., 1999). 
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Figure ‎1.1-3: Signalling events associated with IL-1β and IL-18 production, 
inflammasome activation.  
TLR4/MD2 signal through either MyD88 to activate NF-ĸB. Activation of NF-ĸB results in 
increased transcription of nlrp3. Inflammasome activation occurs in response to such 
agonists as extracellular ATP.  If TLR4 signaling increases NLRP3 protein levels such as 
with MyD88-competent LPS then the activation event permits the newly expressed 
NLRP3 pro-caspase-1, leading to caspase-1 processing to its active form and 
inflammasome assembly. Pro-IL-1β and pro-IL-18, which is associated with the 
inflammasome, is processed to mature IL-1β and IL-18 and secreted into the 
extracellularly. Adapted from (Chilton et al., 2012) 
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IL-1 is an inflammatory cytokine that functions in a way that has similarities with TNFα. 
The IL-1 process comprises two agonists, IL-1α and IL-1β, a particular initiation process 
(IL-1-converting enzyme, or ICE, caspase 1), a receptor antagonist (IL-1ra) which has 
varying isoforms, and two high affinity surface-binding molecules (Sims et al., 1993). IL-
1β is secreted into localised interstitial fluid and blood circulation within inflammation 
and governs extensive pro-inflammatory processes. IL-1β affects the activation of the 
inflammatory reaction. Evidence indicates that IL-1β has a significant function within 
the pathogenesis of intestinal inflammation in IBD. In animal models of intestinal 
inflammation, IBD individuals have enhanced forms of IL-1β in their intestinal tissue 
(Ligumsky et al., 1990, Spiller et al., 2000, Casini-Raggi et al., 1995, Isaacs et al., 1992). 
There is a link between developing forms of IL-1β and the extent of intestinal 
inflammation which has been proven (Reinecker et al., 1991). An imbalance between 
IL-1β and its antagonist IL-1ra is present within the intestinal mucosa of IBD patients, 
indicating that the limited anti-inflammatory types of IL-1 to oppose the enhanced 
extent of IL-1β might be a significant pathogenic shortcoming (Cominelli et al., 1990). 
In line with this prospect, the way in which the rIL-1ra was administered helped to 
avoid the intestinal inflammation in a rabbit model of colitis (Cominelli et al., 1992). 
Research has also indicated the presence of IL-1β gene polymorphisms in IBD 
individuals that impacts the course and the extent of increase intestinal inflammation 
(Nemetz et al., 1999). 
Interleukin-18 was initially outlined in 1989 as “IFNγ-inducing factor” which was 
remote within the serum of mice after an intraperitoneal injection of endotoxin. 
Subsequently, it was referred to as IL-18. Unexpectedly, the emerging cytokine was 
connected to IL-1 and especially to IL-1β. In a similar manner to IL-1β, IL-18 is still an 
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intracellular cytokine (Dinarello et al., 2013b). Various human autoimmune conditions 
are linked to enhanced generation of IFNγ and IL-18. These disorders include systemic 
lupus erythematosus, rheumatoid arthritis, Type-1 diabetes, Crohn’s disease, psoriasis, 
and graft versus host disease, all of which are perceived to be at least partly governed 
by IL-18 (Dinarello et al., 2013b). After cleavage by caspase-1, mature IL-18 is secreted 
from the monocyte/macrophage. However, in excess of 80% of the IL-18 precursor is 
not processed within the cell (Fantuzzi et al., 1999). Interleukin-18 displays attributes 
of alternative pro-inflammatory cytokines, including advances in cell adhesion 
molecules, nitric oxide synthesis, and chemokine generation. Opposing IL-18 activity 
diminish metastasis within a mouse model of melanoma; this is because of a decline in 
IL-18-induced expression of vascular call adhesion molecule-1 (Vidal-Vanaclocha et al., 
2000). Because IL-18 can increase IFNγ generation, opposing IL-18 activity in 
autoimmune disorders is an appealing therapeutic objective because anti-IL-12/23 
limits this variety of Crohn’s disease in addition to psoriasis. There is a probability that 
IL-18, being constitutive in the intestinal epithelium (Pizarro et al., 1999), has a 
regulatory function because the cytokine results in the maintaining the intestinal 
barrier. With of the loss of the barrier, the microbial products activate macrophages in 
the lamina propria and caspase-1 dependent generation of IL-18 outcomes in 
inflammation. In this particular instance, restriction of IL-18 generation in caspase-1-
deficient mice or wild-type mice being treated with neutralizing anti-IL-18 antibodies 
or caspase-1 inhibitors is protective (Dinarello et al., 2013b). 
 IL-6 and IL-10  1.1.8.3
IL-6 is a pleiotropic cytokine that has a significant influence in inflammation, immune 
control, hematopoiesis, and oncogenesis (Hirano et al., 1990, Kishimoto, 1989). 
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Research has increasingly suggested that an IL-6 signalling pathway shows a crucial 
part in the uncontrolled intestinal inflammatory activity of IBD (Atreya and Neurath, 
2005, Ishihara and Hirano, 2002) . IL-6 works as both a pro and anti-inflammatory 
cytokine (Kigerl et al., 2009). It is secreted by T cells and macrophages to initiate a 
response from the immune system to injury, particularly burns or other tissue damage. 
IL-6 has a crucial function in forming defence towards bacteria, such as Streptococcus 
pneumonia (Chapman et al., 2013). IL-6’s role, as an anti-inflammatory cytokine, is 
activated via its inhibitory influence on TNFα and IL-1 (Chapman et al., 2013). In the 
intestinal mucosa, IL-6 has been identified in macrophages, lymphocytes such as B cells 
and T cells, and intestinal epithelial cells (Stevens et al., 1992, Jones et al., 1993, 
Kusugami et al., 1995). Research has indicated signal transducer and activator of 
transcription 3 (STAT3) as a downstream signaling pathway of IL-6 (Alonzi et al., 2004). 
Advanced rates of phosphorylated STAT-3 was connected with the disorder activity in 
individuals suffering from IBD as well as in some animal models of colitis or enteritis 
(Suzuki et al., 2001). STAT-3 activation, especially in mucosal T cells, is a significant 
inflammatory event within the progression of IBD. SOCS genes are involved in negative 
regulation of the JAK/STAT pathway induced by cytokine signaling (Yoshimura et al., 
2003). Present thought is that SOCS3 and STAT-3 are both extensively expressed within 
human IBD and in animal IBD models (Suzuki et al., 2001). The levels of SOCS3 in the 
inflamed intestine are probably inadequate to prevent STAT-3 activation, thus inducing 
chronicity of inflammation (Mitsuyama et al., 2006) (Figure ‎1.1-4). 
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Figure ‎1.1-4: Association between TLR4 signalling pathway and JAK/STAT signaling pathway.  
E.coli Lipopolysaccharide LPS (K12-LPS); TLR4, Toll-like receptor 4; TLR2, Toll-like receptor 2; CD14; MD2, myeloid 
differentiation protein-2; MyD88, myeloid differentiation primary response 88; MyD88s, myeloid differentiation 
primary response 88 short version; IRAK-1,2,4 &M, IL-1 receptor-associated kinase; Tollip, Toll interacting protein; 
TRAF6, TNF receptor-associated factor-6; SIGIRR, Single Immunoglobulin IL-1 Receptor Related molecule; IKKs, IκB 
kinases; NF-κB, nuclear factor kappa B; P38, P38 mitogen-activated protein kinases; SOCS3, Suppressor of cytokine 
signaling proteins. As adapted from (Zhu et al., 2015, Cavaillon and Adib-Conquy, 2006a, Wang et al., 2011). 
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In contrast, activated macrophages and Th2 cells generate IL-10, and it is primarily an 
inhibitory cytokine or anti-inflammatory cytokine. It restricts the generation of IFN-γ by 
Th1 cells, which transition the reactions of the immune system towards a Th2 type. IL-
10 restricts the generation of cytokines by activated macrophages and the expression 
of MHC II on macrophages, which leads to immune reactions being diminished (Walsh 
et al., 2013). Transformation growth factor beta (TGFβ) arises from proteins generated 
by an array of cell forms that regulate the proliferation of cellular variation. It is 
generated by numerous cell forms and macrophages where it materialises on their 
surface bound to CD36 (Yoshimura et al., 2007). Extensive levels of TGF-β are evident 
within the majority of tissues (Bensinger and Tontonoz, 2008). IL-10 restricts the 
generation of TNFα and macrophage inflammatory protein-2 (MIP-2) and maintains 
hemodynamic boundaries (Ding et al., 2003). In vitro research has indicated that IL-10 
restricts the release and role of IL-1β, IL-6, TNFα, granulocyte-macrophage colony-
stimulating factor, and IL-12 (Cassatella et al., 1993, de Waal Malefyt et al., 1991), 
consequently implying a conventional endogenous feedback tool for the regulation of 
immune outcomes and inflammation. Furthermore, in vivo research has indicated the 
direct suppressive impact of IL-10 on pro-inflammatory outcomes (Asadullah et al., 
1998). Activation of STAT-3 is crucial for the entirety of the acknowledged outcomes of 
IL-10 (Lang et al., 2002, Takeda et al., 1999). IL-10 joins to its cognate receptor (IL-10R), 
a tetramer comprised of two notably specific chains (IL-10R1 and IL-10R2). As such, the 
findings of IL-10 appear to be restricted to particular cells of the immune system. IL-10 
joining to IL-10R initiates the IL-10/JAK1/STAT-3 cascade, where phosphorylated STAT-
3 homodimers translocate to the nucleus in a matter of seconds to initiate the target 
genes being expressed (Hutchins et al., 2013). 
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 Endotoxin Tolerisation (ET) 1.1.8.4
Immune destruction can result from immune activation or deactivation mechanisms. 
ET involves cells undergoing a process involving a transient unresponsive condition, 
and not being able to react to additional obstacles with endotoxin (e.g. LPS), after 
encountering a particular extent of endotoxin. ET has been researched in vivo and in 
vitro in both humans and animals (Biswas and Lopez-Collazo, 2009). Suppression of 
pro-inflammatory reactions result in autoimmunity and cancer within the host (Foster 
and Medzhitov, 2009). In contrast, anti-inflammatory restriction is against the 
pathogen. Gut mucosal MΦs are necessary for ET due to their distinctiveness and 
initiation process. ET induced by MΦ is present in varying ways, such as the launch of 
anti-inflammatory cytokines (e.g. IL-10 and TGFβ), the down-regulation of PRRs 
(e.g.TLR4) or the shedding of cytokine receptors and PRRs and /or induction of 
negative regulatory molecules, like Tollip, Myd88s, SARM, sTLRs, sCD14 and SIGIRR 
(O'Neill, 2008) also reviewed in  (Foey and Crean, 2013). 
The immune-suppression of anti-inflammatory M2 MΦ characterise up regulation for 
anti-inflammatory cytokine (such as IL-10) and present down regulation for pro-
inflammatory cytokines (such as TNFα) (Mantovani et al., 2005). Yet, it is excessively 
simplistic to allocate endotoxin tolerisation phenomenon to a specific MΦ subset due 
to the varieties of MΦ phenotypes in their variation, activation and tolerisation state 
(Cavaillon and Adib-Conquy, 2006b). The initial in vitro research of ET in human 
monocytes (Cavaillon and Adib-Conquy, 2006b, del Fresno et al., 2009) has revealed 
that the most restricted genes in terms of re-stimulation with LPS were the pro-
inflammatory cytokines and chemokines like TNFα, IL-6, IL-1β, CCL3 and CCL4 (del 
Fresno et al., 2009, Draisma et al., 2009, Foster and Medzhitov, 2009, Mages et al., 
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2007).  However, genes of anti-inflammatory cytokines such as IL-10 and TGFβ and 
negative regulators like IRAK-M were up regulated (Biswas and Lopez-Collazo, 2009).  
Research has indicated that initiation of tolerance is associated with suppression of 
TLR expression (Nomura et al., 2000, Wang et al., 2002). Down-regulation of 
downstream immune reactions is connected with diminishing expression of TLR4 
surface protein and the lack of the necessary co-receptor subunits MD2 and CD14 
(Abreu et al., 2001, Cario and Podolsky, 2000b, Otte et al., 2004). Additionally, MD-2B, 
an alternatively spliced type of MD-2 might restrict the dynamic type of MD-2 via 
competing for joining to TLR4, culminating in LPS tolerance (Otte et al., 2004). It has 
been recognised in vitro research that there are shortcomings in the TLR4 pathway in 
ET. That is, there appears to be a link between ET and the decline of TLR4-MyD88 
complex progression, elimination of IRAK-1 activity, and disturbance in NF-ĸB initiation 
(Biswas and Lopez-Collazo, 2009, Fan and Cook, 2004). While the heterodimers 
p65/p50 NF-ĸB is activating the TNFα and IL-12 expression in the early stages of 
inflammation, the homodimers p50/p50 NF-ĸB in ET would tolerise the expression of 
these genes and enhance the expression of the IL-10 and TGFβ genes instead. Yes, this 
basis stemmed from the argument that the plasticity of NF-ĸB role within varying 
stages of inflammation might acquire separate phenotypes from inflammatory to anti-
inflammatory reviewed in (Biswas and Lopez-Collazo, 2009). 
As well as TLRs, the cytoplasmic nucleotide-binding oligomerisation domain (NOD) 
proteins, NOD1 and NOD2, might have a role within the natural immune reaction 
(Cario and Podolsky, 2005). It has been proposed that NOD2 might govern the TLR-
signalling pathway in a detrimental manner. As such, restriction of TLR2-driven Th1-
cytokine reactions by targeting NF-ĸB initiation seemed to arise from stimulation with 
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the NOD2 ligand, MDP. Netea et al, 2004, discovered that stimulation with 
peptidoglycan stimulation or synthetic lipopeptide stimulation, given the lack of NOD2 
CARD15 mutation in Crohn’s Disease, might result in NF-ĸB dysregulation and the 
subsequent inconsistency of cytokine generation (rise of IL-12, reduction of IL-10) 
through TLR2 (Netea et al., 2004, Watanabe et al., 2004b) possibly having an influence 
on the pathogenesis of Crohn’sDisease (Cario and Podolsky, 2005). The removal of 
MΦs and the restriction of pro-inflammatory cytokines in ET are frequently connected 
with the expansion in anti-inflammatory cytokine generation, like IL-10 and TGFβ 
(Cavaillon and Adib-Conquy, 2006a, Schroder et al., 2003, Sfeir et al., 2001). 
Endogenous suppressors like IRAK-M, ST2, and short version of MyD88 (MyD88s) are 
connected with TLR4 downregulation and an absence of LPS reaction. IRAK-M 
expression has been suggested and verified within both human and mice ET models 
(Biswas and Lopez-Collazo, 2009).  
Extensive research has utilised in vitro and in vivo concepts to develop our awareness 
of ET. Foey and Crean (2013) indicate that MΦ subsets, resulting from the THP-1 cell 
line, demonstrated varying reactions to PG-LPS activation when they were pre-treated 
with Porphyromonas gingivalis LPS (PG-LPS). In other words, pre-stimulation with PG-
LPS of M1-like MΦs did not restrict TNFα, IL-6 or IL-1β generation when treated with 
PG-LPS. In contrast, it did restrict the generation of TNFα and IL-6 but not IL-1β by M2-
like MΦ when treatment with PG-LPS was applied. PG-LPS-stimulated M1 CD14hi MΦs 
expressed a greater degree of TNFα, IL-1β and IL-6 in contrast to M1 CD14lo MΦs. 
However, PG-LPS- stimulated M2 CD14lo MΦs generated an enhanced extent of TNFα, 
IL-1β and IL-6 in contrast to the M2 CD14hi MΦs (Foey and Crean, 2013). 
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An additional piece of research by Sun et al (2014) placed its emphasis on the THP-1 
cell line. They discovered that the level of secreted TNFα and IL-1β following 
retreatment by either PG-LPS or E. coli -LPS was beneath the extent of secreted 
cytokines following stimulation only once. In contrast, IL-10 level was enhanced. Sun 
additionally discovered that utilising the identical stimulus (homo-tolerance) resulted 
in the degree of TNFα and IL-1β being reduced more than (hetero-tolerance) (Sun et al., 
2014). 
In contrast, Foey and Crean (2013) asserted a separate theory in relation to the notion 
of (hetero-tolerance). Cross-tolerisation has been identified across varying microbial 
species, their PAMPs and the analogous PRRs, (Foey and Crean, 2013). Numerous 
research has presented cross-tolerisation between HK-PG and PG-LPS, HK-PG and PG-
LPS +LTA, PG-LPS and E. coli K12-LPS and furthermore PGN tolerisation (Foey and 
Crean, 2013, Sun et al., 2014). Additionally, the cross tolerisation between TLR4 and 
NOD2, which is linked with the enhanced vulnerability of one suffering from Crohn’s 
disease, or LPS and MDP has been asserted in (Sun et al., 2014). The argument has 
been proposed that NOD2 might control the TLR-signaling pathway in a detrimental 
manner. As such, the restriction of TLR2-driven cytokine reactions by targeting NF-ĸB 
instigation seemingly arises from the stimulation with the NOD2 ligand MDP. Netea et 
al (2004) concluded that stimulation with peptidoglycan stimulation or synthetic 
lipopeptide stimulation, in the absence of NOD2 such as CARD15 mutation in Crohn’s 
Disease, could result in NF-ĸB dysregulation and a following discrepancy of cytokine 
secretion (growth of IL-12, decline of IL-10) through TLR2 (Netea et al., 2004, 
Watanabe et al., 2004b) possibly influencing the pathogenesis of Crohn’s Disease 
(Cario and Podolsky, 2005). 
 
42 
 
One piece of research indicated that the induction of ET is to an extent dictated by the 
processes of NF-κB and the expression of CD14 (Foey and Crean, 2013). The up-
regulation of the negative regulatory molecules (e.g. IRAK-M, ST2, MyD88s and SIGIRR) 
indicated an element of ET of NF-ĸB-dependent (Biswas and Lopez-Collazo, 2009, 
O'Neill, 2008). 
E. coli-LPS has the capacity to induce ET in MΦs. While PG-LPS is generally identified by 
TLR2 more than TLR4, there have been arguments that E. coli-LPS is primarily dictated 
by TLR4 instead of TLR2 (Foey and Crean, 2013). Overall, it is still not known in the 
molecular foundation regarding how macrophages transition between an 
inflammatory and an immunosuppression phase (Biswas and Lopez-Collazo, 2009). 
 
1.2 Aim and objective  
 
This research study aimed to investigate the immune modulating effect of 
entrapathogen E. coli K12-LPS on macrophage immune responses in homeostatic and 
inflammatory environment by developing the THP-1 cell line in generating MΦ-like 
subsets as a model for the current study. Initially, production of pro- and anti-
inflammatory cytokines was investigated in resting and activated macrophages derived 
from THP-1 cells, differentiated with either PMA, to generate M1-like macrophages, or 
vitamin D3, to generate M2-like macrophages. To understand more about MΦ subset 
regulation, the intention was, firstly, to establish cytokine profiles upon stimulation of 
MΦ subsets by either K12-LPS as well as other PAMPs such as PG-LPS, LTA and PGN 
(homeostatic environment) or pro-inflammatory cytokines, TNFα and IL-1β, 
(inflammatory environment) and to study the effect of E. coli LPS on inflammasome 
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 activation in macrophage subsets (reported in Chapter 3). Secondly, to investigate the 
effect of endotoxin tolerisation on MΦ subsets, PRRs and negative regulatory 
molecules involved in ET, IL-10 effect on K12-LPS induced pro-inflammatory cytokine 
production in MΦs and to study the cross-tolerance in response to different PAMPs 
include K12-LPS, PGN and LTA (Chapter 4).  Finally, to explore the modulation induced 
by K12-LPS (homeostatic environment), pro-inflammatory cytokines (TNFα, IL-1β) 
(inflammatory environment)  and ET on MΦ subsets in co-culture model considering 
their effect on epithelial cells relative to intestinal mucosal MΦ interacting with the 
epithelial cells (Chapter 5). 
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1.3 The research plan of experiments. 
 
Figure ‎1.3-1: The research investigation plan for the whole project chapter 3, 
chapter 4 and chapter 5. 
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Chapter 2: Materials and Methods 
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2.1 General Material  
Refer to Appendix 1. 
2.2 Methodology  
2.2.1 Human cell culture methods 
All reagents and Antibodies used for tissue culture experiments are listed in appendix 1, 
table I-1. 
 THP-1 human monocytic cell line 2.2.1.1
Human pre-monocytic cell line, THP-1 cell line, was obtained from European collection 
of cell culture (ECACC, UK) and routinely used for this research. THP-1 cells were grow 
in Roswell park memorial institute-1640 medium RPMI-1640 medium supplemented with 
10% v\v foetal calf serum (FCS), 2mM L-glutamine and 100U/ml Penicillin/ 100 µg/ml 
Streptomycin (R10). The cells were incubated at 37 0C and 5% CO2 in incubator and 
sub-cultured every 3-4 days at a ratio of 1:4. Passages 7 to 32 were used for 
experiments (Foey and Crean, 2013).  
 Caco2 intestinal epithelial cell line  2.2.1.1.1
Human colon adenocarcinoma cell line (Caco2 epithelial cells) were cultured in 
Dulbecco’s Modified Eagles’ Medium DMEM medium supplemented with 10%v/v FCS, 
2 mM L-glutamine and 100 U/ml penicillin, 100 μg/ml streptomycin (D10). Cells were 
plated out at a density of 5x105 cells/ml/well in transwell, 12 well pore size 0.4  µm 
(Greiner bio-one, Stonehouse UK) plates and incubated in a humidified atmosphere of 5% 
CO2 at 37 0C for 21 days for full cell differentiation (Habil, 2013, Hilgers et al., 1990). 
Caco2 were sub-cultured every 3 days or once achieving 70% confluence. This process 
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was performed by removing the old medium followed by washing cells twice with 
Dulbecco's Phosphate-Buffered Saline (DPBS) and detaching cells by adding 2-3 ml of 
0.25% v/v versene/trypsin EDTA (TE). Then, cells were incubated for 10-15 min at 37 0C. 
The cells were checked during the time of incubation by light microscopy, and gently 
agitated until detached. To deactivate Trypsin, D10 medium was added (Habil, 2013) 
and cells re-suspended in a suitable volume of D10 medium before seeding according 
to the designed experiment.  
 Determination of total cell number and cell viability  2.2.1.2
After each passage, evaluation of the number of cells and cell viability was checked. 
This was done by staining Ten microliters of cell suspension were mixed with 90 μl of 
0.1% (v/v) Trypan blue and counting using a Neubauer haemocytometer. Furthermore, 
cells were stimulated with PAMP’s and viability was assessed afterwards. 
 Storage of human cell lines  2.2.1.3
 Storage of THP-1 cell line 2.2.1.3.1
THP-1 cells were centrifuged at 1200 rpm for 5 min then the supernatant was 
discarded and the cell pellet was suspended in 1 ml of cryopreservation media (see 
Table1-1 appendix1) afterwards the cells were frozen and stored at -80 0C or liquid 
Nitrogen.  
 Storage of Caco-2 cell line 2.2.1.3.2
Caco-2 cells were developed to 80% confluence trypsinised, and harvested by 
centrifugation at 1200 rpm for 5 min, the supernatant was removed, and cell pellets 
was re-suspended gently in 1 ml of storage medium and then stored at -80 0C or liquid 
Nitrogen. 
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2.2.2 Immune cell differentiation  
 Macrophage cell differentiation  2.2.2.1
M1-like Pro-inflammatory and M2-like anti-inflammatory MΦ subsets were generated 
by differentiation of THP-1 cells in the presence of 25ng/ml phorbol-12-myristate 
acetate (PMA) for 3 days for M1-like or 10nM 1,25-(OH)2Vitamin D3 for 7 days for M2-
like MΦ, respectively (Foey and Crean, 2013, Schwende et al., 1996). M1-like was 
washed out after 3 day to remove PMA and incubated for one more day prior to use in 
experiment.  
 Epithelial cell differentiation  2.2.2.2
Caco2 cells differentiation into the small intestine enterocyte-like cells were achieved 
by long term culturing for 21 days in D10 medium (Amano and Oshima, 1999, Habil, 
2013) then they were used depending on  designed experiment.  
2.2.3 Activation of macrophage cell subsets and epithelial cells  
 Macrophage subset stimulation 2.2.3.1
THP-1 derived M1- and M2-like MΦs were stimulated by the bacterial pathogen 
associated molecular patterns (PAMPs); TLR4 ligand; E. coli K12-LPS [0.001 – 1µg/ml], 
TLR2/4 ligand; PG-LPS [0.001 - 1µg/ml], TLR2 ligand; Lipoteichoic acid LTA [0.01 - 10 
µg/ml] and NOD1/2 ligand; Peptidoglycan PGN [0.01- 10 µg/ml] and incubated for 18h 
at 37 oC/5% CO2. Afterwards, cells were harvested and supernatants stored at-20 
0C 
until required for cytokine assay by enzyme-linked immunosorbent assay, sandwich 
(ELISA). 
 THP-1-derived M1- and M2-like MΦs were stimulated by 100 ng/ml K12-LPS at 37 
0C/5%CO2 for different time periods ranging from 30 min to 48 h; unstimulated cells 
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were used as control. The final density of cells was 1x106 cells/ml plated out in 12 well, 
flat-bottomed tissue culture plates. Cells were harvested and supernatants and lysates 
were stored at -20 0C. Supernatants were required for cytokine assay by sandwich 
ELISA and the cell lysates were used for detection of gene expression by Real Time 
polymerase chain reaction (RT-PCR). 
 Macrophage subset tolerisation 2.2.3.2
THP-1-derived M1- and M2-like MΦs were pre-treated with 100 ng/ml K12-LPS for (1: 
24h). The final density of cells was 1x106 cells/ml plated out in 12 well flat-bottomed 
tissue culture plates. Before re-stimulation with 100 ng/ml K12-LPS the medium was 
removed carefully and the cells were washed in fresh R10. Afterwards the cells were 
incubated with 100 ng/ml K12-LPS for 18h at 37 0C/5% CO2.  Negative controls for 
tolerisation and stimulation were included in the experiment. The cells were harvested 
for either cell lysis or RNA extraction and supernatant were separated and stored at-20 
0C until required for a cytokine assay by sandwich ELISA (supernatants) where cell lysis 
was for detection of gene expression by RT-PCR or Western blot (WB).  
 Epithelial cell stimulation 2.2.3.3
Caco2 cells were treated with PAMPs (100 ng/ml K12-LPS) and pro-inflammatory 
cytokines (10 ng/ml TNFα, or 5 ng/ml IL-1β) and cultured for 24h. Cell supernatants 
were collected and kept at -20 0C until required for evaluation by ELISA and the cell 
lysate for of gene expression analysis by (RT-PCR). 
 TNFα modulation on LPS-induced MΦ cytokines; (chronic 2.2.3.4
inflammation) 
A concentration of 10 ng/ml of TNFα was used to treat MΦ subsets using the pulse 
chase method for detecting TNFα cytokine release by MΦs. The pulse chase method 
 
50 
 
was performed for detection TNFα cytokine release. The pulse chase method was done 
by stimulating the cells with TNFα for different time points (0, 1, 2, 4, 6, 9, 12, 18, 24, 
48, 72 and 96 h) followed by washing the cells with fresh medium and incubating them 
with or without LPS for 18h. For detecting other cytokines such as IL-6, IL-18 and IL-10, 
cells were treated with TNFα (0, 1, 2, 4, 6, 9, 12, 18, 24, 48, 72 and 96 h) followed by 
washing the cells with fresh medium and incubating them with or without LPS for 18h. 
The cell supernatants were collected after 18h LPS stimulation and kept at -20°C until 
used for cytokine detection by ELISA. 
 Epithelial cell- macrophage co-culture system 2.2.3.5
A co-culture model was created to mimic the inflammatory gut pathology 
(homeostatic and inflammatory) where epithelial cells cross-talked with macrophage 
subsets in the presence of LPS, TNF α or IL-1β. The co-culture system was made using 
Caco2 human epithelial cells and THP-1 monocyte-derived macrophage cell subsets 
M1- or M2-like macrophages (Watanabe et al., 2004a) . Briefly, three groups of Caco2 
cells were seeded on 12 trans well cell culture insert (greiner bio-one) plates (0.4 μm 
pore size) at a cell density of 5x105 cells/500μl/well and cultured in D10 medium in a 
humidified 5% CO2 incubator at 37 
0C for 21 days allowing for full cell differentiation. 
Two groups of Caco2 cells grown in transwell inserts were incubated with M1- or M2-
like MΦs for 24h in the presence of TNFα or IL-1β apically in the co-culture system 
followed by basolateral stimulation with 100 ng/ml K12-LPS, for 18h. The third group 
of Caco2 cells was left without co-culture as a control as well as MΦ subsets controls. 
The apical and basolateral cell supernatant were collected and stored at -20 0C for 
analysing by ELISA. Trans epithelial electrical resistance (TEER) assay to test barrier 
function was determined for each treatment group (Figure ‎2.2-1). 
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Figure ‎2.2-1: Experimental setup of the co-culture comprising of intestinal 
epithelial cell line (Caco2) and either macrophage subsets (M1-like or M2-like 
MΦs). 
For mimicking gut mucosal tissue, co-culture model of Caco-2 cells which were cultured 
in transwell insert, with THP-1 derived M1-like MΦs (inflammatory model) or M2-like 
MΦs (homeostatic model), apically treated with LPS, TNFα or IL-1β, and stimulated with 
LPS in basolateral side depending on  designed experiment. 
 
2.2.4 Trans epithelial electrical resistance (TEER) assay 
Transepithelial electrical resistance (TEER) measurement was used routinely to study  
the paracellular transport properties (permeability) of epithelial cells grown on 
permeable filters and barrier integrity. TEER measurement was done according to the 
modified protocol by Teoh et al (2000). Caco2 cells were cultured in transwell inserts 
for 21 days, incubated either alone or with M1- or with M2-like MΦs. During the 
differentiation time and after the treatment, cells were washed twice with DPBS and 
0.5 ml of the DPBS was added to the inner and 1 ml to the outer of the transwell. The 
electrical resistance was calculated using EVOM Epithelial Voltammeter (Pharma, UK), 
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where each well reading multiplied by the surface area of the transwell (0.33 cm2) to 
calculate the final value in Ωcm2. 
2.2.5 Cytokine measurement 
The production of pro-inflammatory cytokines (TNFα, IL-1β, IL-18 and IL-6) and anti-
inflammatory cytokines (IL-10) were measured by using sandwich ELISA. The 96 
immuno-absorbance well plates were coated with commercially available capture 
antibodies. Anti-TNFα (0.5 µg/ml), anti-IL-1β (1 µg/ml), anti-IL-18 (0.5 µg/ml), anti-IL-6 
(1 µg/ml), anti-IL-8 (2 µg/ml), anti-IL-10 (0.5 µg /ml) and incubated overnight at 4 0C. 
The plates were washed twice with washing buffer before being blocked with 2%w/v 
BSA/PBS for 4h at room temperature (RT). Then, plates were washed three times by 
washing buffer and incubated with serially diluted recombinant cytokine standards and 
test samples and incubated at 4 0C overnight. Next day, plates were washed three 
times by washing buffer followed by incubation with biotinylated anti-TNFα (0.5 
µg/ml), anti-IL-1β (100 ng/ml), anti-IL-18 (1 µg/ml),  anti-IL-6 (10 n/ml), anti-IL-8 (5 
ng/ml), and anti-IL-10 (1 µg/ml) for 4h at RT. Plates were washed three times with  
washing buffer and incubated with 50ul/well biotinylated streptavidin horseradish 
peroxidase (HRP) at 1/250 dilution in 2%w/v BSA/PBS for 1 h at RT. Finally, the plates 
were washed three times with washing buffer followed by the addition of colour 
reagent (Tetramethylbenzidine-TMB, Middlesex UK) until the colour is developed at RT. 
The reaction was stopped by adding 100 µl of 1.8 M sulphuric acid to each well. 
Colorimetric development was determined spectrophotometrically by the 
OPTIMaxtuneable microplate reader at 450nm and analysed by Softmax Pro version 
2.4.1 software (Molecular Devices Corp., Sunnyvale, CA, USA). Protocols are applied 
according to manufacturer’s instruction. Standard curves, between ranges (7 to 5000 
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pg/ml), were used to determine the cytokine concentration and compared with the 
recognized international standards available from (NIBSC, Potter’s Bar, UK). Reagents 
and Antibodies used for ELISA  are available in  appendix 1,Table ‎2-1. 
 
Figure ‎2.2-2: Standard calibration curve of ELISA.  
Standard curves, between ranges (7 to 5000 pg/ml), were used to determine the 
cytokine concentration and compared with the recognized international standards 
available from (NIBSC, Potter’s Bar, UK). The absorbance (OD) was determined in a 
micro-plate reader at 450 nm. Data displayed is a representative experiment with 
triplicate samples of n= 3 replicate experiments. 
 
2.2.6 Detection of IL-10 membrane bound protein by macrophage 
subsets  
Endogenous cell-associated IL-10 was examined depending on anti-inflammatory 
activity of IL-10 to down-regulate LPS-induced TNFα (Fleming and Campbell, 1996). 
M1- and M2-like MΦs were incubated with 10 mg/ml 9D7 neutralising anti-IL-10 
antibody obtained from Biolegend (San Diego, USA) or irrelevant, isotype-matched 
control antibody for 30 min then stimulated with 100 ng/ml K12-LPS and cultured for 
18h at 37 0C, 5% CO2. Furthermore, MΦ sensitivity to exogenous IL-10 was evaluated 
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by pre-treating M1 and M2 MΦs with exogenous IL-10 (0, 0.2, 2 and 20 ng/ml) (NIBSC, 
Potter’s Bar, UK) for 30 min prior to challenge with 100 ng/ml K12-LPS for 18h. 
Supernatants were harvested for TNFα secretion valuation by sandwich ELISA. MΦ 
viability was routinely checked by Trypan blue exclusion (viability routinely >85%). 
2.2.7 Role of caspase-1 in macrophages cell signaling 
The role of Caspase-1 in macrophages cell signaling was evaluated by using Caspase-1 
Inhibitor Z-WEHD-FMK obtained from (R&D SYSTEM, Abingdon UK). THP-1 derived M1- 
and M2-like MΦs were pre-treated with range of concentration of Caspase-1 Inhibitor 
(0 µM, 10 µM, 20 µM and 50 µM) for 1 h prior to stimulation with 100 ng/ml K12-LPS 
for a further 18h incubation at 37 0C, 5% CO2. Cell viability was checked by Trypan blue 
exclusion and supernatant was collected and stored at -20 0C for human IL-1β and IL-
18 ELISA.  
2.2.8 Protein analysis methods 
 Cell lysis  2.2.8.1
After specific treatments, M1- and M2-like Macrophage cells were washed gently with 
PBS followed by adding lysis buffer, RIPA buffer supplemented with a protease/ 
phosphatase inhibitor cocktail. Then, cell lysate was centrifuged at 3,500 rpm at 4 0C 
for 10 minutes to spin down cell remains into a pellet. Supernatants were carefully 
separated without disturbing the pellet and stored at -20 0C for protein concentration 
to be determined by the Bradford method prior WB (refer appendix 1Table ‎3-1). 
 Protein quantification 2.2.8.2
The method that was used to quantify the protein of interest was the Bradford method 
(Bradford, 1976) modified for the micro-plate reader. This method is suggested for 
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common use, particularly detection of protein of cell segments and secreted 
extractions (Ernst and Zor, 2010). This assay aims on the determination the absorbance 
maximum for an acidic solution of Coomassie Brilliant Blue G-250 shifts from 465 nm 
to 595 nm when involvement with protein existence (Bradford, 1976). Bovine Serum 
Albumin (BSA) protein was used as standards between 7 μg/ml and 5 mg/ml which 
were prepared by dissolving BSA in distilled water followed by adding an equal volume 
of dye reagent (Bradford) then incubating for 5 min at RT. The absorbance was 
measured in a micro-plate reader (Molecular Devices, Manchester, UK) at 595 nm 
where standard curve was shaped between absorbance value and protein 
concentrations, and the experiment samples were calculated according to 
extrapolation from the standard curve (Figure ‎2.2-3). 
 
Figure ‎2.2-3: Standard calibration curve of BSA by Bradford assay 
BSA’s standard curve of Bovine serum albumin (BSA) protein *7 μg/ml: 5 mg/ml]. The 
absorbance (OD) was determined in a micro-plate reader at 595 nm. Data displayed is a 
representative experiment with triplicate samples of n= 3 replicate experiments. 
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 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis 2.2.8.3
(SDS–PAGE)  
SDS-PAGE is an analytical technique for recognition complex mixtures of proteins. This 
method was applied using a Laemmli discontinuous buffer system. To prepare SDS gel, 
glass plates (BIO-RAD, UK) were cleaned with detergent and washed with deionised 
water, followed by 70% v/v ethanol then left to dry. The final concentration of the 
determining gel was 12.5% w/v. The required gel solutions were firstly mixed with 
fresh 1% w/v ammonium per sulphate (APS) and Tetramethylethylene diamine (TEMED) 
(see appendix 1Table ‎3-1) for polymerisation and immediately loaded into the 
preformed space between the glass plates and filled to two thirds the height of the 
largest glass plate. Two ml of 10% v/v water saturated isopropanol was loaded 
immediately on top of the deciding gel making a layer on top of the gel to release the 
air bubbles. The gel was kept for polymerisation for 30 min at RT. Then, the 
isopropanol layer was detached and the stacking gel 3%w/v was prepared depending 
on the recipe mentioned in followed by adding APS and TEMED, and then immediately 
loaded on top of the prepared gel. Then to make wells for sample’s loading, a comb 
was inserted into the stacking gel and left the gel for few min for polymerisation and 
transferred it to the electrophoresis container. The container was filled with running 
buffer covering the top of the gel. The comb was then carefully removed and the wells 
were washed with running buffer. Twelve μl of each protein sample and 3 μl of loading 
buffer were boiled for 3 min to denature the protein, quenched on ice for 2 min, 
briefly vortexed, centrifuged at 12000 rpm for 30 sec then loaded into each well of the 
gel. The gel was run at 100 V for 2 h and the dye marker was observed (Hyper Page 
pre-stained protein Marker, Bio line, UK). The gel was removed from the 
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electrophoresis system container, plates were removed, and the gel was ready for 
transfer to PVDF blotting membrane. 
 Western blotting (WB) 2.2.8.4
Western blotting is commonly applied for identifying specific proteins stained with 
specific antibodies in a specified complex sample protein. Proteins of interest in this 
investigation include: TLR4, IRAK-M, Tollip, SIGIRR, Phospho-STAT3, total STAT3, and 
GAPDH (refer appendix 1, Table ‎3-1 for more information). Proteins are detected by 
SDS-PAGE or Criterion Xt precast gel (Bio-Rad Laboratories Ltd) then proteins were 
transferred to polyvinylidene fluoride (PVDF) membranes by using an electro-blotter 
system (Criterion blotter, BIO-RAD, UK), which were cut to the same size as the gel, 
along with two pieces of filter papers. In order to prepare PVDF, it was soaked in 
methanol (100%v/v) for 15s then distilled water for 2 min then in transfer buffer for 5 
min. The blotting device system was gathered as follows: black plastic cassette plate at 
the bottom, gauze, filter papers, gel, PVDF blotting paper, filter papers, gauze, and red 
plastic cassette at the top. The cassette was firmly closed prior to removing the air 
bubbles with a roller, and then the cassette was inserted in the tank where the red 
side towards the cathode (red electrode). Cold transfer buffer was added to the tank, 
an ice pack was placed at the bottom as well as a magnetic stirrer for cooling supply, 
and to avoid the overheating of the buffer, which might affect the blotting system.  
Blotting system was connected to the power and the gel was electro blotted at 100 V 
for 35-45 min. When blotting is complete, the PVDF membrane was blocked with 
blocking (refer to appendix table 3-1) solution  at RT for 1h on the roller followed by 
incubation the membranes overnight with the specific interest primary antibody in 1% 
BSA in TBST at 4 0C on the roller. Next day, primary antibody was placed into an empty 
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falcon tube and stored at -20 0C (can be used twice), and PVDF membrane was washed 
with TBST three times, 5 min each at RT on the roller. Then, the membranes were 
incubated for 2h at RT with suitable secondary antibodies together with horseradish 
peroxidase (HRP). The membranes were washed three times for 5 min with TBST at RT 
on roller followed by washing once for 5 min with TBS on roller to remove traces of 
Tween-20. To detect peroxidase activity from HRP-conjugated antibody, developing 
colour for protein detection was achieved by using Luminata Crescendo Western HRP 
substrate, 100ml (Millipore Corp/ Merck Group, Hertfordshire UK). After washing with 
TBS, the membrane was removed and laid out on a plastic sheet. Developing solution 
was carefully loaded over the entire membrane for few min. The protein bands were 
pictured by a gel documentation system using EC3 imaging system (UVP ultra violet 
product, Ca, UK). Band densities were quantitated by ImageJ 1.47t software then the 
ratio of optical density compared to the negative control that was normalized to 
GAPDH controls. 
2.2.9 Gene expression analysis methods  
(Refer to appendix 1 Table 4-‎4-1for material and reagents) 
 Total RNA extraction 2.2.9.1
Total RNA was extracted using a Sigma GenElute mammalian total RNA extraction kit 
following the manufacturer’s procedure for each treatment of the cells. Adherent M1-
macrophages were washed twice with PBS, then adherent cells were harvested by a 
sterile rubber cell scraper (Sterlin, UK), whereas, M2 cells were collected by 
centrifugation at 1200 rpm for 5min. After washing step, the cells were re-suspended 
in 500 µl of lysis buffer provided by the kit, supplemented with 5 µl 0.02% v/v 2- 
mercaptoethanol for denaturation of RNase (reducing disulphide bonds and destroying 
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the enzyme functionality of RNases released during the lysis step of RNA isolation). 
DNase digestion with RNase-Free DNase was used according to the protocol, to 
remove potential DNA contamination. This was done by adding 10 µl of DNase and 70 
µl of digestion buffer on the top of each filter of the column used for RNA isolation and 
the columns were incubated for 15 min at RT. Extracted RNA from each sample was 
eluted in 50 µl of elution buffer provided with RNA extraction kit. 
 RNA quantification and evaluation  2.2.9.2
RNA quantification was done by using spectrophotometer, Nanodrop measuring both 
the concentration of RNA and purity (contamination of proteins and DNA). The ratio of 
OD260/OD280 has to be between 1.8 and 2.0 to exclude any contamination in the RNA 
sample extracted (Liu et al., 2003). Purified RNA was immediately stored at -20 0C until 
required for gene expression analysis. The integrity of RNA sample was checked by 
running 1% formaldehyde agarose gel according to the protocol of Van Dessel et al 
2004. In brief, the formaldehyde agarose gel was prepared by mixing 87.5 ml distilled 
sterile water. 1.5 g agarose, 10 ml 10xMOPS prepared in flask and heated in 
microwave for 2 min to dissolve all agarose. Subsequently, 7µl of Syber safe or red gel 
was added into small gel set followed by shaking to mix all the components of agarose 
liquid then cooled to 60 0C prior to adding 26 µl formaldehyde with stirring in the fume 
hood. The mixture was poured out into the BIO-RAD gel set and left for casting. The gel 
was mounted in an electrophoresies tank and overlaid with 1xMOPS electrophoresis 
buffer. For loading buffer, the mixture was prepared as follows (2µl 1-x MOPS, 3.5 µl 
formaldehyde, 10 µl formamide, 0.4%w/v Bromophenol blue) a volume of 15.5µl of 
loading buffer and 4.5µl of sample were mixed together and incubated for 10 min at 
65 0C to control RNase contamination and denaturation, quenched on ice for 10 min, 
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followed by brief centrifugation and loaded into the gel well. The gels were run at 40-
60 volts for 60 min, de-stained by using deionised water for 45 min, and reviewed 
under UV light using the documentary gel reviewer (Gel DocTM.XR, BIO-RAD, CA). 
 Reverse transcription of total RNA  2.2.9.3
Total RNA was reversed transcripted to complementary DNA (cDNA) by M-MLV 
Reverse transcription reaction Kit. Following a modified manufacture’s protocol, 10µl 
containing 1µg/ml RNA of sample and 1µl of 10mM dNTP mixture, 1µl of random 
nanomer topped up with nuclease free water to make cDNA from a template of 1 
µg/ml total RNA. The mixture was incubated at 70 0C for 10 min, after that the mixture 
was placed on ice for at least 2 min. A total of 10 µl containing 1ul M-MLV enzyme, 2µl 
of buffer, 0.5 µl of RNAase inhibitor and 6.5 µl of nuclease free water was added to 
each sample. The cDNA synthesis was achieved after incubation at 37 0C for 50 min 
where reaction was terminated immediately by heat inactivation for 10 min at 95 0C 
before chilling at 4 0C. 
 Design of primers  2.2.9.4
The full length sequences of the gene of interest were identified using the National 
Centre of Biotechnology Institute (NCBI). Primer express software provided with step 
one PCR machine (Applied  Biosystems, Lingly House, Warrington, UK), was used to 
design the primer based on the sequence number of the nucleotides, and melting 
temperature. The following setting were used for primer design ( Primer Tm: 60-65 
0C, 
primer length: 20-28 bp, Amplicon size: 100-160 bp) to ensure that the primers were 
designed match the same gene map sequenced, the primers were plasted by using 
NCBI blast software at http://blast.ncbi.nlm.nih.gov/, and the primers characteristics 
were assessed using Sigma DNA calculator website http://www.sigma-
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genosys.com/calc/DNACalc.asp. The primers were synthesised by Eurofin MWG/ 
Operon (Germany). The lyophilized primers were dissolved in appropriate volumes of 
nuclease free water to prepare 10 pmol of each primer depended on MWG instruction 
and then stored at -20 0C. In this study the expression of TNFα, IL-6, IL-1β, IL-10, TLR2, 
TLR4, NOD-2, Tollip, IRAK-M and SIGIRR gene expression were quantified using RT-PCR 
(refer to appendix 1 Table 4-‎4-2 for primers details) . 
 Real Time PCR 2.2.9.5
RT-PCR assay relies on the assumption that the housekeeping gene levels of expression 
remain constant in different cells, samples, and treatments. Consequently, 
housekeeping gene have been used to normalise the data. According to a modified 
manufacturer's protocol (Applied Bio systems, Warrington, Cheshire, UK), a total 
volume of 12 μl composed of 1 μl cDNA of each sample, 0.25 μl of 10 pmol of specific 
primers for each target (forward and reverse), 3.5 μl of Power SYBER Green® (Applied 
Biosystem, UK) and 7.0 μl of nuclease free water was plated out into 96-well plates 
(Applied Bio system, UK), and then sealed with adhesive film. RT-PCR was applied using 
Step One Plus thermal cycler whereby the amplification of target was carried out 
under the following conditions; pre-heating at 95 0C for 10 minutes, followed by 40 
cycles at 95 0C for 30 seconds, 60 0C for 1 minute and 72 0C for 1 minute and hold the 
samples at 4 0C. RT-PCR data were analysed following 2-ΔΔCt method as described in 
literature, Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) as an endogenous 
control and resting cells as a reference sample (Livak and Schmittgen, 2001). Therefore, 
the comparative quantity of the target transcript is defined as fold change relative to 
the reference sample (resting cells) and GAPDH using the following equation:  
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2.2.10 Statistical analysis 
Measure of statistical significance was analysed using a balanced analysis of variance 
(General Linear Model, Minitab version 16). All data were tested for normality using 
the Anderson-Darling test (with P < 0.05 indicating that the data were non-normal). 
Levene’s test was used to check that there were no significant differences in variance 
between each group (P < 0.05 indicated a significant difference in variance between 
groups). For normally distributed data, significant differences were determined using one 
way ANOVA   followed by Bonferroni tests as post hoc multiple comparison tests for 
normal data, a multiple comparison test (ns= no significant difference). Significance 
was set at p values; (*p<0.05, **p<0.01and ***p<0.001). 
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Chapter 3: Validation of THP-1 
derived MΦs as a model of M1- & 
M2-like MΦs in homeostatic and 
inflammatory environments. 
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3.1 Introduction  
Macrophages (MΦs) are phagocytic cells of the innate immune system, which occur in 
most tissues of the human body. These cells reveal a wide selection of functional 
features including phagocytic clearance, microbial killing, antigen processing and 
presentation, inflammation, anti-inflammatory processes, tissue repair and immune 
suppression. This variety of immune functionality is revealed in macrophage subset 
heterogeneity. Present finding classify MΦ subsets according to activation status 
(classical or alternative) or differentiation (M1 or M2) reviewed in (Foey, 2012). 
Mucosal macrophages have an essential part in tolerance; while in inflammatory 
bowel disease, (IBD) dysfunctional macrophages initiate the breakdown of tolerance 
and commensals perpetuate inflammation. Gut macrophages control immune 
homeostasis, driving tolerogenic reactions to food and commensal bacteria or immune 
inflammatory responses to pathogens (Smith et al., 2011). In the gut environment, 
tolerance regulation is associated with an M2-like phenotype, whereas inflammatory 
activation is associated with an M1-like phenotype (Gordon and Taylor, 2005). M2-like 
macrophage is the subset that predominates in a healthy gut mucosa. Disruption of 
tissue homeostasis by pathogenic microbial infection leads to macrophage activation, 
which is related with macrophage phenotype alterations from M2s to M1s depending 
on the signals received from the tissue environment (Platt and Mowat, 2008). 
Human THP-1 cells were used as a macrophage model in the current study. It has been 
reported that when THP-1 cells were treated with PMA, the cells differentiated into 
macrophage-like cells, which mimic native monocyte-derived macrophages in many 
respects (Auwerx, 1991, Schwende et al., 1996). This delivers a valued model for 
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macrophage differentiation and regulation studying. Several studies have used this 
method of THP-1 cells line differentiation by PMA or Vit.D3 to characterise macrophage 
subsets see (Table ‎3.1-1). 
It has been established, according to modification in markers expression, that the THP-
1 cell line can be differentiated to two distinct macrophage subsets; M1-like and M2-
like, upon treatment with PMA or Vit.D3 respectively. The present study aimed to 
determine the effect of PAMPs and pro-inflammatory cytokine TNFα and IL-1β 
treatments on modulation of the immune responses of these macrophage subsets. 
Then lipid A flows into the blood, binds to the immune cell surface through contact 
with TLR4/MD-2/CD14 and triggers the immune responses associated with fever, 
diarrhoea, and septic shock. Certainly, activation of the NF-ĸB transcription factor is a 
result of LPS stimulation of MΦs, which orchestrates a gene expression schedule 
resulting on inflammation, cell proliferation (Th1), differentiation (Th17), through the 
release of chemokines and cytokines. 
The pro-inflammatory cytokine TNFα, produced by monocytes and macrophages 
directly after recognition of pathogen, has an important role in innate immunity, 
mutually directly and indirectly by increase of TLR-induced production of additional 
pro-inflammatory cytokines such as IL-1β, IL-18, IL-12, IL-6, and IL-8 (Beutler, 1999). 
Uncontrolled secretion of TNFα lead to development and progression of chronic 
inflammation and autoimmune diseases such as IBD, rheumatoid arthritis (RA) and 
psoriasis (Williams et al., 2007). 
Another important cytokine that plays a crucial role in many inflammatory conditions 
of the gut immune system is IL-β. IL-1β has a role in both the initiation and 
amplification of the inflammatory response, which result in intestinal injury. IL-1β also 
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is involved in the pathogenesis of intestinal inflammation in IBD and animal models of 
intestinal inflammation. In the case of imbalance between IL-1β and its antagonist, IL-
1ra exists in the intestinal mucosa of IBD patients. This imbalance proposes that the 
absence of anti-inflammatory role of IL-1 to respond the raised levels of IL-1 could be a 
significant pathogenic fault (Al-Sadi and Ma, 2007). 
 Inflammasomes are key signaling machines of the innate immune system that drive 
the production of the highly inflammatory cytokine IL-1β via caspase-1 activation in 
response to microbial and nonmicrobial danger signals (Schroder and Tschopp, 2010). 
Some individual inflammasomes have been identified; each differentiated by specific 
motivators, NLR/ALR family members, and caspase effectors. The typical or recognised 
inflammasome complex contains of a cytosolic sensor (a nucleotide-binding domain 
and leucine-rich-repeat-containing [NLR] protein or an AIM2-like receptor [ALR] 
protein), an adaptor protein (apoptosis-associated speck-like protein containing a 
CARD [ASC]), and an effector caspase pro-caspase-1 (von Moltke et al., 2013). ASC is a 
divided molecule that comprises mutually an N-terminal Pyrin domain (PYD) and a C-
terminal caspase initiation and recruitment domain (CARD), allowing it to link the 
receptor (NLRs or ALRs) and the effector pro-caspase-1 (Rathinam and Fitzgerald, 
2016). The Inflammasome Part Pycard Is Essential for the Activation of Caspase-1 and 
Caspase-5. It has been demonstrated that caspase initiation was observed in lysates in 
the presence of two different anti-Pycard antibodies (a polyclonal [α-Pycard] or a 
monoclonal antibody [α-ASC]), activation of both caspase-1 and caspase-5  (Martinon 
et al., 2002). Caspase-1 in turn regulates the proteolytic maturation of interleukin-1β 
and IL-18, as well as a rapid, noxious, inflammatory form of cell death termed 
pyroptosis (Rathinam et al., 2012a). 
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Table ‎3.1-1: Validation markers involved in THP-1 derived macrophage subsets 
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In this chapter, the investigations focused on determining the influence of E.coli K12-
LPS and PAMPs on modulation of MΦ subset behaviour via cytokine production. This 
was evaluated in MΦ subsets derived from THP-1 human monocytic cell line 
resembling either infiltrating pro-inflammatory MΦ, M1s, or mucosal resident 
homeostatic MΦ, M2s. In addition, the roles of pro-inflammatory cytokines, TNFα 
challenge, in long and short term, in modulation of K12-LPS-induced MΦs was 
investigated. Finally, inflammasome activity in MΦ subsets has been studied in this 
chapter concerning IL-1β and IL-18 production, role of caspase-1 as well as IL-β 
challenge.   
The particular hypotheses to be verified in this investigation are:  
Hypothesis 1: THP-1 derived MΦs; M1- and M2-like, differentially respond to different 
PAMPs include TLR4 agonist; E. coli LPS, TLR2 agonist PG-LPS, and LTA and NOD1/2 
agonist PGN. 
Hypothesis 2: pro-inflammatory cytokines, TNFα and IL-1β, can modulate K12-LPS 
induced cytokine production in macrophage subsets. 
Hypothesis 3: E. coli LPS is able to modulate inflammasome activation in macrophage 
subsets. 
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3.2 Results 
3.2.1 PAMPs modulate M1- & M2-like MΦs effector function. 
 M1- & M2-like MΦs stimulated by K12-LPS induce separate pro- and 3.2.1.1
anti-inflammatory cytokine profiles.  
In order to obtain full cytokine production profile by macrophage subsets and to find 
the right concentration of K12-LPS, this experiment was designed. Macrophage subsets 
differentially respond to different concentrations of E. coli LPS. Challenge these MΦs 
was comparable between the two subsets and according to the concentrations. 
Overall, when stimulated by K12-LPS, pro-inflammatory M1 MΦs expressed higher 
levels of TNFα, IL-18, IL-6 and IL-10 cytokines compared to anti-inflammatory M2-like 
MΦs, which interestingly produced higher level of IL-1β (Figure ‎3.2-1). The production 
level for TNFα was low with no significant between M1 and M2 when stimulated with 
0.01 µg/ml K12-LPS or less. TNFα induced by M1-like MΦs was significantly higher than 
TNFα induced by M2-like MΦs when stimulated by 0.1 0.5 and 1 µg/ml K12-LPS and P= 
0.001 with all concentrations. The 50% effective dose (ED50) of K12-LPS was 0.482 
µg/ml and 0.45 µg/ml for M1- and M2-like MΦs, respectively. On the other hand, IL-1β 
was induced significantly in higher levels by M2-like MΦs by all used concentrations 
and the concentration of IL-1β increased gradually in parallel with stimulus 
concentration by both MΦ subsets. The P ˂ 0.001 in all concentrations of LPS expect 
0.5 µg/ml where P= 0.006. Remarkably, M1-like MΦs produced a certain amount of IL-
1β in absence of K12-LPS, which might be in response to PMA. Remarkably, ED50of 
K12-LPS was 0.25 µg/ml for both M1- and M2-like MΦs. The level of pro-inflammatory 
cytokine, IL-18, was slightly higher by M1-like with low LPS concentrations, 0.001 and 
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0.01 µg/ml and the P≤ 0.05 for both concentrations. IL-18 was produced significantly in 
high level by M1-like, with higher concentrations; 0.1 µg/ml P= 0.008, 0.5 µg/ml P= 
0.02 and 1 µg/ml P= 0.009. However, ED50 of K12-LPS was 0.03 µg/ml and 0.35 µg/ml 
for M1- and M2-like MΦs, respectively. IL-6 level was significantly higher by M1 MΦs 
upon LPS stimulation with most concentrations. The lowest concentration that 
displayed significant difference in IL-6 level between M1 and M2 MΦs is 0.01 µg/ml P= 
0.029. IL-6 cytokine concentration increased steadily in parallel with LPS dose 
dependency concentration. Remarkably, ED50 of K12-LPS was 0.41 µg/ml for both M1- 
and M2-like MΦs. IL-10 level was significantly higher by M1 MΦs upon stimulation 
with the same concentration. IL-10 production was comparable between M1 and M2 
MΦs with all concentrations of K12-LPS with P˂ 0.001. However, ED50 of K12-LPS was 
0.17 µg/ml and 0.12 µg/ml for M1- and M2-like MΦs, respectively. After challenge 
with 0.1 µg/ml K12-LPS, M1-like MΦs induced cytokines TNFα, IL-1β, IL-18, IL-6 and IL-
10 at a ratio of 93:4:284:8:11 compare to unstimulated control. On the other hand, M2 
MΦs induced TNFα, IL-1β, IL-18, IL-6 and IL-10 in ratio of 31:8:68:3:0.5 when 
stimulated by 0.1 µg/ml K12-LPS. The cytokine expression between these two MΦ 
subsets was significant where P= ˂ 0.001 for TNFα, P˂ 0.001 for IL-1β, P= 0.008 for IL-
18 P= 0.001 for IL-6 and P= 0.001 for IL-10 (Figure ‎3.2-1). 
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Figure ‎3.2-1: K12-LPS stimulated M1 & M2 MΦ subsets exhibited 
different cytokine profiles. 
THP-1-derived M1 and M2 MΦs were generated by differentiating THP-1 monocytes 
with either 25 ng/ml phorbol 12-myristate 13-acetate (PMA) for 3 days or 10 nM 1,25-
(OH)2  vitamin D3 for 7 days, respectively.  M1 (Red) and M2 (Blue) MΦ subsets were 
stimulated in the presence or absence of K12-LPS at concentration titration of [0.001, 
0.01, 0.1, 0.5 and 1 µg/ml] for 18h. Cytokine production is expressed as the mean ± SD 
in pg/ml for TNFα (a), IL-1β (b), IL-18 (c), IL-6 (d) and IL-10 (e). Data displayed 
represents triplicate samples for n= 3 replicate experiments. Significant differences in 
cytokine production between K12-LPS activated M1 and M2 MΦs are indicated as * p 
< 0.05, ** p < 0.01, *** P < 0.001 and ns= not significant. 
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 M1 & M2 MΦs display differential IL-10 profiles in response to 3.2.1.2
K12-LPS. 
In general, M1 and M2 MΦs produce different cytokine profiles. M1s show a 
predominantly pro-inflammatory profile while M2s display a more anti-
inflammatory/regulatory profile. This study was undertaken to establish whether M1 
and M2 MΦs respond differently with respect to production of IL-10 in response to E. 
coli LPS. Certainly, E. coli LPS [100ng/ml] induced individual subset-specific cytokine 
profiles. Remarkably, K12-LPS induced minimal secretion of IL-10 by M2-like MΦs (P= 
0.014, near to lower level of sensitivity of ELISA), compared to M1 MΦs (Figure ‎3.2-2 a). 
However, IL-10 production by M1 was measured at high levels (217 ± 10 pg/ ml, p < 
0.001). Besides to secretion, bearing in mind membrane bound IL-10 that has been 
demonstrated (Fleming et al., 1999), this endogenous activity was also studied using 
neutralising anti-IL-10 antibody in the context of TNFα down-regulation. No 
endogenous activity was displayed by unstimulated MΦs (Figure ‎3.2-2 b & c). After 
K12-LPS stimulation however, MΦ subsets displayed differential production of 
endogenous IL-10 activity. K12-LPS failed to produce an endogenous suppressive IL-10 
activity in M1s; induction of TNFα did not display a statistically significant modification 
(P= 0.12) between isotype-matched control and neutralising anti-IL-10 antibody 
(Figure ‎3.2-2 b). K12-LPS did, on the other hand, produce an endogenous IL-10 activity 
expressed by M2-like MΦs. Neutralisation of IL-10 activity increased TNFα production 
by 40% (P˂ 0.001) (Figure ‎3.2-2 c). 
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Figure ‎3.2-2:M1 & M2 MΦs display differential IL-10 profiles in response to 
K12-LPS. 
THP- 1-derived M1 and M2 MΦs were generated by differentiating THP-1 monocytes 
with either 25 ng/ml phorbol 12-myristate 13-acetate (PMA) for 3 days or 10 nM 1, 25-
(OH)2 vitamin D3 for 7 days, respectively. Secretion of IL-10 (a) is depicted where M1 (red) 
and M2 (blue) MΦ subsets were stimulated with or without (control) 100 ng/ml K12-
LPS. Endogenous IL-10 activity, upon treatment with 10 µg/ml neutralising anti-IL-10 
compared to an isotype-matched control antibody (IC), is represented for K12-LPS-
stimulated and unstimulated (b) M1-like and (c) M2-like MΦs TNFα secretion. Cytokine 
secretion is expressed as the mean ± SD in pg/ml for IL-10 (a) and TNFα (b & c). Data 
displayed represents triplicate samples for n= 3 replicate experiments. Significant 
differences in cytokine production between activated M1 and M2 MΦs and 
unstimulated controls and between isotype control and neutralising IL-10 antibody 
treatment are indicated as *p < 0.05, **p < 0.01, ***P < 0.001 and ns, not significant. 
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 M1- & M2-like MΦs differentially produced TNFα cytokine upon 3.2.1.3
stimulation by the TLR2 agonist, PG-LPS. 
Macrophage subsets differentially respond to different concentrations of 
Porphyromonas gingivalis   LPS, PG-LPS, which is associated with oral pathology. THP-1 
derived macrophage subsets, M1- and M2-like, exhibited a differential response to PG-
LPS by inducing comparable level of TNFα between pro-inflammatory M1 and anti-
inflammatory M2 MΦs (Figure ‎3.2-3). TNFα production between M1- and M2-like MΦs 
varies depending on the concentrations used for PG-LPS stimulus. Challenge these MΦ 
subsets was not comparable between the two subsets when the concentration of PG-
LPS is lower or higher than 0.1 µg/ml. However, stimulation of MΦ subsets by 0.1 
µg/ml of PG-LPS resulted in production of comparable level of TNFα between M1 like 
and M2 like. TNFα production ratio between M1 like and M2 like MΦs was 2:1 and the 
cytokine expression was approaching significant to P= 0.05. However, ED50 of PG-LPS 
was 0.036 µg/ml and 0.34 µg/ml for M1- and M2-like MΦs, respectively. 
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Figure ‎3.2-3: TNFα production by PG-LPS stimulated M1 & M2 MΦ subsets. 
THP-1-derived M1 and M2 MΦs were generated by differentiating THP-1 monocytes 
with either 25 ng/ml phorbol 12-myristate 13-acetate (PMA) for 3 days or 10 nM 1,25-
(OH)2 vitamin D3 for 7 days, respectively. M1 (Red) and M2 (Blue) MΦ subsets were 
stimulated in the presence or absence of PG-LPS at concentration titration of [0.001, 
0.01, 0.1, 0.5 and 1 µg/ml] for 18h. TNFα production is expressed as the mean ± SD in 
pg/ml. Data displayed represents triplicate samples for n= 3 replicate experiments. 
Significant differences in cytokine production between PG-LPS activated M1 and M2 
MΦs are indicated as *p < 0.05 and ns= not significant. 
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 Dose dependency of MΦ TNFα production upon stimulation by 3.2.1.4
the TLR2 agonist, LTA.   
Macrophage subsets differentially respond to different concentrations of Lipoteichoic 
acid (LTA) TLR2 ligand. THP-1 derived macrophage subsets displayed a differential 
response to LTA by inducing comparable level of TNFα by pro-inflammatory M1 and 
anti-inflammatory M2 MΦs (Figure ‎3.2-4). TNFα production between M 1 and M 2 
varies depending on the LTA stimulus concentrations used. Stimulate these MΦ 
subsets was not comparable between the two subsets when the concentration of LTA 
was lower than 10 µg/ml. However, stimulation of MΦ subsets by 10 µg/ml of LTA lead 
to comparable production level of TNFα between M1-like and M2-like MΦs. The 
relative ratio between M1-like and M2-like for ratio  of 95:18 of LPS induced cytokine 
express over unstimulated response  and P˂ 0.001. However, ED50 of LTA was 4.1 
µg/ml and 6.5 µg/ml for M1- and M2-like MΦs, respectively. 
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Figure ‎3.2-4: TNFα production by LTA stimulated M1 & M2 MΦ subsets. 
THP-1-derived M1 and M2 MΦs were generated by differentiating THP-1 monocytes 
with either 25 ng/ml phorbol 12-myristate 13-acetate (PMA) for 3 days or 10 nM 1,25-
(OH)2 vitamin D3 for 7 days, respectively. M1 (Red) and M2 (Blue) MΦ subsets were 
stimulated in the presence or absence of LTA at concentration titration of [0.01, 0.1, 1, 
10 µg/ml] for 18h. TNFα production is expressed as the mean ± SD in pg/ml. Data 
displayed represents triplicate samples for n= 3 replicate experiments. Significant 
differences in cytokine production between LTA activated M1 and M2 MΦs are 
indicated as ***P < 0.001 and ns= not significant. 
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 TNFα cytokine differentially induced by M1- & M2-like MΦs 3.2.1.5
upon NOD1/NOD2 agonist, PGN stimulation.  
Bacteria can also be sensitive PAMP upon internalisation where there is internal 
receptors that can recognise different forms of PGN; NOD1 and NOD2 (Chamaillard et 
al., 2003). Macrophage subsets differentially respond to different concentrations of 
peptidoglycan (PGN), NOD1/NOD2 agonist, which is associated with NF-ҡB activity. 
TNFα production by M1- and M2-like MΦs varies depending on the concentrations 
used for PGN stimulus (Figure ‎3.2-5). Stimulation of MΦ subsets by 1 µg/ml of PGN 
resulted in production of comparable level of TNFα between M1-like and M2-like MΦs. 
The ratio of TNFα level by M1-like and M2 like MΦs was 90:40 and the cytokine 
expression was slightly significant to P= 0.044. However, ED50 of PGN was 4.75 µg/ml 
and 4.6 µg/ml for M1- and M2-like MΦs, respectively. 
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Figure ‎3.2-5: TNFα production by PGN stimulated M1 & M2 MΦ subsets. 
THP-1-derived M1 and M2 MΦs were generated by differentiating THP-1 monocytes 
with either 25 ng/ml phorbol 12-myristate 13-acetate (PMA) for 3 days or 10 nM 1,25-
(OH)2 vitamin D3 for 7 days, respectively. M1 (Red) and M2 (Blue) MΦ subsets were 
stimulated in the presence or absence of PGN at concentration titration of [0.01, 0.1, 1, 
10 µg/ml] for 18h. TNFα production is expressed as the mean ± SD in pg/ml. Data 
displayed represents triplicate samples for n= 3 replicate experiments. Significant 
differences in cytokine production between PGN activated M1 and M2 MΦs are 
indicated as *p < 0.05, **p < 0.01, and ns= not significant  
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 Time course optimisation of cytokine production by K12-LPS 3.2.1.6
stimulated MΦs subsets.  
Macrophage subsets differentially respond to E. coli LPS [100 ng/ml] in different time 
points of stimulation. Distinct cytokine profiles were exhibited by THP-1 derived 
macrophage subsets in response to K12-LPS. The results, as shown in (Figure ‎3.2-6) 
revealed that the cytokine production between stimulated K12-LPS M1 MΦs and M2 
MΦs is time dependent. The results displayed that pro-inflammatory MΦs M1 
produced higher level of TNFα, IL-18, IL-6 and IL-10 cytokines than anti-inflammatory 
MΦs M2. However, M2 MΦs produced higher level of IL-1β cytokine than M1 MΦs 
upon the time course. Over the same time point, TNFα did not go above 100pg/ml for 
both M1 and M2 control (data not shown). TNFα concentration induced by M1 MΦs 
sharply increased after 1h of incubation with stimulus from [183 pg/ml] to [9752 pg/ml] 
at 9h incubation. The level of TNFα production was constant after 9 h with little 
decrease at 48h. On the other hand, TNFα concentration produced by M2 MΦs, rose 
from [68 pg/ml] after 1h incubation with K12-LPS to [2468 pg/ml] at 2h incubation. 
Then, the level of TNFα production was continuous after 2h with slight drop at 48h to 
[1710 pg/ml]. The peak of TNFα cytokine productions was at 24h for M1 MΦs and at 9 
h for M2 MΦs.  IL-1β and IL-18 did not go above 20 and 100 pg/ml, respectively, for 
both M1 and M2 control over the same time point (data not shown). IL-1β 
concentration produced by M1 MΦs increased gradually from [28 pg/ml] at 2h 
incubation with K12-LPS to [163 pg/ml] at 48h. Nevertheless, IL-1β concentration 
induced by M2 MΦs sharply increased after 2h of incubation with K12-LPS from 
[2pg/ml] to [343 pg/ml] at 9h incubation. The level of IL-1β production increased 
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steadily to the peak at 24h before it decreased to [321 pg/ml] at 48h. The peak of IL-1β 
cytokine production was at 48h for M1 MΦs and at 24h for M2 MΦs. IL-18 
concentration induced by M1-like and M2-like MΦs was very low level for the first 9h. 
After 9h, IL-18 level icreased sharply to the highest level at 3632 pg/ml by M1-like at 
18h time point whereas it steadily increased to the peak of 1160 pg/ml at 12h 
incubation time by M2-like MΦs. After peak time, IL-18 level dropped down in low 
level by both M1 and M2 MΦs until the end of treatment time, 48h. Over the same 
time point, IL-6 and IL-10 did not go above 20 pg/ml for both M1 and M2 control (data 
not shown). IL-6 concentration induced by M1 MΦs regularly increased after 4h of 
stimulation with K12-LPS from [55pg/ml] to [451 pg/ml] at 24h then it dropped to [223 
pg/ml] at 48h. In contrast, IL-6 concentration produced by M2 MΦs increased slowly to 
the peak of [87 pg/ml] at 18h then decreased to [62 pg/ml] and [46 pg/ml] at 24h and 
48h respectively. IL-10 concentration induced by M1 MΦs steadily increased after 
stimulation by K12-LPS to the peak of [611 pg/ml] at 48h incubation time. On the other 
hand, IL-10 production by M2 MΦs exhibited significant different comparing to 
controls at only two time points; 12h  and 48h with level of IL-10 equal [53 pg/ml] and 
[45 pg/ml], respectively. The peak of IL-10 cytokine production was at 48h for M1 MΦs 
and at 12h for M2 MΦs.  
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Figure ‎3.2-6: Time course of cytokine production by K12-LPS stimulated M1 
& M2 MΦ subsets.  
M1 (Red) and M2 (Blue) MΦ subsets were stimulated in the presence or absence of [100 
ng/ml] K12-LPS in different time points [0, 30 minutes, 1, 2, 4, 6, 9, 12, 18, 24 and 48h] in 
density of (1x106 cells/ml). Cytokine production is expressed as the mean ± SD in pg/ml 
for TNFα (a), IL-1β (b), IL-18 (c), IL-6 (d) and IL-10 (e). Data displayed represents triplicate 
samples for n= 3 replicate experiments. Significant differences, in cytokine production 
between K12-LPS activated M1 and M2 MΦs in each time point, are indicated as * p < 
0.05, ** p < 0.01, *** P < 0.001 and ns= not significant. 
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 Gene expression of pro-inflammatory and anti-inflammatory 3.2.1.6.1
cytokines by K12-LPS-stimulated MΦs. 
Macrophage subsets differentially respond to E. coli LPS in different time points of 
stimulation. Distinct cytokine gene expression profiles were exhibited by THP-1-
derived macrophage subsets in response to K12-LPS. The results displayed that pro-
inflammatory M1 MΦs produced higher level of mRNA of TNFα cytokine than anti-
inflammatory M2 MΦs. However, mRNA of IL-10 in M1 MΦs seemed to be more 
stable in the same time points. The peak of TNFα mRNA was within 2h for M1 and M2 
MΦs whereas the peak of IL-10 mRNA was within 6h and 4h for M1 MΦs and M2 MΦs, 
respectively (Figure ‎3.2-7). 
 
Figure ‎3.2-7: Gene expression of pro- and anti-inflammatory cytokines by 
K12-LPS-stimulated MΦs. 
 M1 (Red) and M2 (Blue) MΦ subsets were stimulated with 100 ng/ml K12-LPS for a time 
course (0-24h). RNA was extracted from cells to test the mRNA expression of TNFα (a) 
and IL-10 (b). Gene expression (mRNA level) is expressed as fold change using GAPDH as 
reference gene and resting cells as a calibrator sample as described by (Livak et al, 2001) 
using 2-∆∆ct. Data displayed is a representative experiment with duplicate samples of n=2 
replicate experiments. Significant effects compared to the negative controls 
(unstimulated cells) are indicated as * P< 0.05, ** P< 0.01 *** P< 0.001 and ns= not 
significant. 
a
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3.2.2 TNFα differentially modulates MΦ subject-specific responses to 
K12-LPS. 
In order to mimic a chronic inflammatory environment, MΦ subsets were challenged 
with TNFα for different time point prior to treatment with K12-LPS. The effect of TNFα 
on MΦ subsets were determined by quantifying cytokine production and secretion 
(TNFα, IL-18, IL-1β, IL-6 and IL-10). As described above, the pulse-chase method was 
performed to find out TNFα cytokine production whereas treatment without washing 
cells after TNFα stimulation was used to detect the other cytokines. Figures below 
showed that MΦ subsets differentially sensitive to TNFα stimulation in present or 
absent of LPS. When incubated M1-like MΦs with TNFα for 4h or 24h, they are able to 
produce TNFα, although they had been washed and incubated for 18h. The level of 
TNFα released by M1-like MΦs after 4h and 24h was 20% less than the TNFα produced 
upon LPS stimulation. Interestingly, TNFα was upregulated when M1-like MΦs were 
challenged by TNFα followed by LPS and increased significantly by 70% (P= 0.01) and 
20% (P= 0.02) upon 4h and 24h TNFα treatment, respectively, for a control level at 
2839 pg/ml. On the other hand, the level of TNFα produced by M2-like MΦs after 4h 
and 24h was 45% and 75% less than the TNFα produced upon LPS stimulation. 
Remarkably, there was no significant change in the level of TNFα produced by M2-like 
MΦs after 4h and 24h compared to LPS stimulated MΦs (Figure ‎3.2-8 a). The gene 
expression modulation of TNFα was reflected similarly to the modulation on secreted 
protein. The level of TNFα mRNA expressed by M1-like MΦs after 4h and 24h was 
about six folds less than the TNFα mRNA level upon LPS stimulation. Interestingly, 
TNFα gene was upregulated when M1-like MΦs were challenged by TNFα, after both 
pre-treatment time points, followed by LPS and increased by about 14 folds higher 
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than positive control. On the other hand, the level of TNFα produced by M2-like MΦs 
after 4h and 24h was 18 fold less than the TNFα produced upon LPS stimulation. 
Remarkably, there was a significant decrease in the level of TNFα gene in M2-like MΦs 
after 4h (by 21 fold) and 24h (18 fold) compared to LPS stimulation, (Figure ‎3.2-8 b). 
Pro-inflammatory M1-like MΦs showed different results for IL-1β production in 
response to TNFα challenge.  To illustrate, when incubated M1-like MΦs with TNFα for 
4h, IL-1β was released 40% less than positive control. However, there was no 
significant change in the level of IL-1β production when M1-like MΦs were treated 
with TNFα only for 24h nor when pre-treated with TNFα for 4h and 24h followed by 
18h LPS stimulation. The control level was 611 pg/ml. Anti-inflammatory M2-like MΦs 
did not release IL-1β in response to 4h TNFα challenge but it produced 40% IL-1β less 
than IL-1β produced upon LPS stimulation. IL-1β was down-regulated when M2-like 
MΦs were challenged by TNFα followed by LPS and decreased significantly by 40% (P= 
0.003) and 70% (P= 0.002) upon 4h and 24h TNFα treatment, respectively, for a control 
level at 668 pg/ml (Figure ‎3.2-9 a). The level of IL-18 produced by M1-like, after 4h and 
24h of TNFα challenge, was roughly 30% less than IL-18 produced upon LPS stimulation. 
However, LPS-stimulated M1-like MΦs produced higher amount of IL-18 upon pre-
treatment with TNFα. The upregulation obtained after 4h and 24h of pre-treatment 
was significant as 25% (P=0.002) and 45% (P= 0.001), respectively, compared to a 
control level at 3794 pg/ml. The level of IL-18 produced by M2-like, after 4h and 24h of 
TNFα challenge, was 90% less than the IL-18 level produced upon LPS stimulation. 
Interestingly, pre-stimulation with TNFα contribute to suppress the production of IL-18 
by LPS-stimulated M2-like MΦs. The observed suppression was 35% (P= 0.001) after 
4h and 45% (P= 0.006) after 24h of TNFα pre-treatment (Figure ‎3.2-9 b) where the 
control level was 1842 pg/ml. M1-like MΦs produced very low level of IL-6 production 
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upon 4h and 24h TNFα treatment, which was similar to unstimulated cells. 
Interestingly, pre-treatment with TNFα followed by LPS stimulation enhanced M1-like 
MΦs to increase the production of IL-6. The upregulation was 72% (P= 0.14) and 120% 
(P˂ 0.001) higher than positive control for 4h and 24h pre-treatment, respectively. The 
level of IL-6 produced by M2-like MΦs after TNFα treatment for 4h and 24h was 40% 
and 60% less than the IL-6 produced upon LPS stimulation. There was no significant 
change in the level of IL-6 production when M2-like MΦs were pre-treated with TNFα 
for 4h prior to LPS stimulation (P= 0.433), whereas treatment for 24h before LPS 
stimulation enhanced IL-6 production by 140% (P= 0.014)(Figure ‎3.2-10 a). The control 
level was 27 pg/ml for M1-like and 50 pg/ml for M2-like MΦs. Anti-inflammatory 
cytokine, IL-10, was only released after 24h of TNFα treatment by M1-like MΦs by 20% 
less than IL-10 produced upon LPS stimulation. Interestingly, LPS-stimulated M1-like 
MΦs significantly decreased IL-10 production by 30% upon TNFα pre-treatment for 4h 
(P= 0.042) and 24h (P= 0.016) for a control level at 133 pg/ml. IL-10 was released only 
after 24h of TNFα treatment by M2-like MΦs by 30% less than IL-10 produced upon 
LPS stimulation. IL-10 cytokine was upregulated by 25% (P= 0.433) and 70% (P= 0.014) 
upon 4h and 24h TNFα treatment, respectively, when M2-like MΦs were challenged by 
TNFα prior to LPS as the control level was 41 pg/ml (Figure ‎3.2-10 b).  
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Figure ‎3.2-8: Differential sensitivity of K12-LPS-induced MΦ TNFα to TNFα.  
M1 (Red) and M2 (Blue) MΦ subsets were stimulated by 10 ng/ml TNFα for 4h and/or 24h 
followed by washing the cells with fresh medium and incubating with or without 100 
ng/ml LPS for 18h. TNFα production (a) is expressed as the mean ± SD in pg/ml. RNA was 
extracted from cells to test the mRNA expression of TNFα (b). Gene expression (mRNA level) is 
expressed as fold change using GAPDH as reference gene and resting cells as a calibrator 
sample as described by (Livak et al, 2001) using 2-∆∆ct. Data displayed represents duplicate 
samples for n= 2 replicate experiments. Significant differences in cytokine production between 
LPS activated M1 and M2 MΦs and TNFα/LPS treated MΦs are indicated as *p˂  0.05, **p< 
0.01 and ns= no significant. 
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Figure ‎3.2-9: Differential sensitivity of K12-LPS-induced MΦ IL-1β and IL-18 to 
TNFα. 
M1 (Red) and M2 (Blue) MΦ subsets were stimulated by 10 ng/ml TNFα for 4h and/or 24h 
followed by incubating with or without 100 ng/ml LPS for 18h. IL-1β (a) and IL-18 (b) 
production is expressed as the mean ± SD in pg/ml. Data displayed represents duplicate 
samples for n= 2 replicate experiments. Significant differences in cytokine production between 
LPS activated M1 and M2 MΦs and TNFα/LPS treated are indicated as **p < 0.01, ***P < 
0.001 and ns= not significant. 
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Figure ‎3.2-10: Differential sensitivity of K12-LPS-induced MΦ IL-6 and IL-10 to 
TNFα. 
M1 (Red) and M2 (Blue) MΦ subsets were stimulated by 10 ng/ml TNFα for 4h and/or 24h 
followed by incubating with or without 100 ng/ml LPS for 18h. IL-6 (a) and IL-10 (b) 
production is expressed as the mean ± SD in pg/ml. Data displayed represents duplicate 
samples for n= 2 replicate experiments. Significant differences in cytokine production between 
LPS activated M1 and M2 MΦs and TNFα/LPS treated are indicated as *p < 0.05, ***P < 0.001 
and ns= not significant. 
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3.2.3 Differential sensitivity of K12-LPS-induced MΦ cytokines to IL-1β.  
In order to mimic a chronic inflammatory environment, MΦ subsets were challenged 
with IL-1β for a specific time (24h) before treatment with K12-LPS. The effect of IL-1β 
on MΦ subsets was determined by quantifying cytokine production (TNFα, IL-6 and IL-
10). Figures below showed that MΦ subsets were differentially modulated by IL-1β 
upon stimulation by LPS. It was shown above that M1 and M2 MΦs in response to LPS 
stimulation can secrete pro- and anti-inflammatory cytokines such as TNFα and IL-10. 
However, when MΦ subsets were stimulated with IL-1β the produced cytokine profile 
was different (Figure ‎3.2-11). Overall, M1-like MΦs secreted 934 pg/ml TNFα in 
response to IL-1β challenge whereas M2-like MΦs did not show any significant 
production of TNFα 31 pg/ml only compared to TNFα production upon LPS stimulation. 
Compared to a control of LPS stimulation at 2255 pg/ml, TNFα production by M1-like 
MΦs decreased significantly by 84% (P= 0.001) upon 24h of IL-1β stimulation prior to 
LPS stimulation. Additionally, TNFα production by M2-like MΦs decreased slightly 
significant by 70% (P= 0.02) compared to a control of LPS stimulation at 918 pg/ml 
(Figure ‎3.2-11 a). Interestingly, both M1- and M2-like produced cytokines in response 
to IL-1β. Upon IL-1β stimulation, M1-like and M2-like MΦs produced higher level of IL-
6 by 115 pg/ml and 59 pg/ml, respectively. The control level was 80 pg/ml for M1-like 
and 54 pg/ml for M2-like MΦs.  Remarkably, IL-6 production significantly increased by 
131% (P=0.04) by M1-like MΦs and 181% (P= 0.03) M2-like MΦs upon 24h of IL-1β 
stimulation prior to LPS stimulation (Figure ‎3.2-11 b). Dissimilar readout for IL-10 
cytokine by both MΦ subsets. IL-1β stimulated-M1 MΦs produced lower IL-10 (135 
pg/ml) and LPS-stimulated M1 produced (185 pg/ml). However, M2 MΦs produced 
higher IL-10 (210 pg/ml) upon IL-1β challenge and (150 pg/ml) upon LPS stimulation. 
M1-like MΦs produced IL-10 cytokine upon 24h of IL-1β stimulation prior to LPS 
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stimulation at similar level of LPS stimulation. However, IL-10 cytokine 265% 
significantly higher by M2-like MΦs upon 24h of IL-1β stimulation prior to LPS 
stimulation (P= 0.02) for the level of control at 150 pg/ml (Figure ‎3.2-11 c). 
 
Figure ‎3.2-11: Differential sensitivity of K12-LPS-induced MΦs cytokines to 
IL-1β. 
M1 (Red) and M2 (Blue) MΦ subsets were pre-treated with 10 ng/ml IL-1β for 24h 
followed by 18h incubation with or without 100 ng/ml LPS. TNFα, IL-6 and IL-10 
production is expressed as the mean ± SD in pg/ml. Data displayed represents duplicate 
samples for n= 2 replicate experiments. Significant differences in cytokine production 
between LPS activated M1 and M2 MΦs and IL-1β /LPS treated are indicated as *p < 
0.05, ***P < 0.001 and ns= not significant. 
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3.2.4 M1 and M2 MΦs secretion of IL-1β and IL-18 display a 
differential dependence on caspase-1. 
As shown previously, MΦ subsets are able to display inflammasome activation upon 
K12-LPS stimulation. To investigate whether IL-1β and IL-18 secretion is caspase-1 
dependent from LPS-activated MΦs, IL-1β and IL-18 secretion was examined by LPS-
activated MΦs with and without caspase-1 (Z-WEHD-FMK) inhibitor. Range of 
concentration of caspase-1 inhibitor was used in this study between 10 µϺ and 50 µϺ. 
The production of IL-1β significantly dropped upon treatment with 10 µϺ of caspase-1 
inhibitor before LPS stimulation by both MΦ subsets, M1 and M2, by 50% (P= 0.002) 
and 60% (P= 0.001), respectively. IL-1β secretin by both MΦ subsets was decreased 
gradually in parallel with the increase of caspase-1 inhibitor concentration. The level of 
IL-1β after treating  with 50 µϺ before LPS stimulation was significantly low by 68% 
less (P˂ 0.001) for M1-like and 88% less (P= 0.003) for M2-like MΦs. The control level 
was 273 pg/ml for M1-like and 343 pg/ml for M2-like MΦs. Moreover, 50% inhibitory 
control test (ICT) of caspase-1 (Z-WEHD-FMK) inhibitor was  48 µϺ for M1-like MΦs 
and 32.5 µϺ for M2-like MΦs. Interestingly, the case with IL-18 production was 
different i.e. IL-18 cytokine seems to be caspase-1 dependent by M1-like MΦs whereas 
it is not associated with caspase-1 in M2-like MΦs. To illustrate, M1-like MΦs reduced 
IL-18 production by 50%, when 20 and 50 µϺ caspase-1 inhibitor were used before LPS 
stimulation as (P˂ 0.001) for 50 µϺ treatment and (P= 0.003) for 50 µϺ treatment, 
where the control was 152 pg/ml. On the other hand, M2-like MΦs showed no 
significant change in the level of IL-18 production using acaspase-1 inhibitor before LPS 
Stimulation.  
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Figure ‎3.2-12: Caspase 1 inhibitor differentially modulates IL-1β and IL-18 
secretion by LPS-activated MΦs. 
M1-like MΦ (red) and M2-like MΦ (blue) were incubated with rang of concentration (0, 
10, 20 and 50µϺ) of caspase-1 (Z-WEHD-FMK) inhibitor for 1h prior to stimulation for 
18h with or without 100 ng/ml LPS. IL-1β and IL-18production is expressed as the 
mean ± SD% LPS induced for cytokine production. Data displayed represents duplicate 
samples for n= 2 replicate experiments. Significant differences in cytokine production 
between activated M1- and M2-like MΦs are indicated as **p < 0.01, ***P < 0.001 and 
ns= not significant. 
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3.3 Summary of chapter 3 results 
Table ‎3.3-1: Cytokine production by 100 ng/ml K12-LPS stimulated M1 & M2 MΦ 
subsets. 
 M1-like MΦ M2-like MΦ 
 Cytokine Level 
Pg/ml 
ED50 Cytokine Level 
Pg/ml  
ED50 
TNFα 3096 0.482 µg/ml 806 0.45 µg/ml 
IL-1β 126 0.25 µg/ml 230 0.25 µg/ml 
IL-18 8512 0.030 µg/ml 2031 0.035 µg/ml 
IL-6 254 0.41 µg/ml 90 0.41 µg/ml 
IL-10 327 0.17 µg/ml 13 0.12 µg/ml 
Table shows the cytokine production [pg/ml] upon stimulation with 100 ng/ml K12-LPS 
and ED50 obtained from concentration titration of K12-LPS [0.001, 0.01, 0.1, 0.5 and 1 
µg/ml]. 
Table ‎3.3-2: TNFα production by M1 & M2 MΦ subsets stimulated with different 
PAMPs. 
 M1-like MΦs M2-like MΦs 
Cytokine Level ED50 Cytokine Level  ED50 
K12-LPS [100 ng/ml] 
(TLR4) 
3096 0.482 µg/ml 806 0.45 µg/ml 
PG-LPS [100 ng/ml] 
(TLR2/4) 
1694 0.036 µg/ml 799 0.34 µg/ml 
PGN [10 µg/ml] 
(NOD2) 
25293 4.75 µg/ml 12820 4.6 µg/ml 
LTA [10 µg/ml] 
(TLR2) 
3340 4.1 µg/ml 674 6.5 µg/ml 
Table shows TNFα cytokine production [pg/ml] upon stimulation with PAMPs and ED50 
obtained from concentration titration of indicated PAMPs. 
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Table ‎3.3-3: Differential sensitivity of K12-LPS-induced MΦs cytokines to TNFα 
 M1-like MΦs M2-like MΦs 
 4h TNFα before (LPS): LPS only (%) 
TNFα 67% ↑ 2%  ↔ 
TNFα mRNA 130% ↑ 24% ↓ 
IL-18 25% ↑ 33%  ↓ 
IL-1 β 18% ↑ 44%  ↓ 
IL-6 72% ↑ 3% ↔ 
IL-10 29%  ↓ 24% ↑ 
 
 24h TNFα before (LPS): LPS only (%) 
TNFα 24% ↑ 10% ↔ 
TNFα mRNA 140%  ↑ 39%  ↓ 
IL-18 44%  ↑ 46%   ↓ 
IL-1 β 6%  ↔ 68%   ↓ 
IL-6 119%  ↑ 137% ↑ 
IL-10 32%   ↓ 70%  ↑ 
Percentage (%) change in LPS response. Note: “↑”, “↓,”and “↔”means up-regulation, 
down-regulation, and no-modulation of the indicated target, respectively. 
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Table ‎3.3-4: Differential sensitivity of K12-LPS-induced MΦs cytokines to IL-1β. 
 M1-like MΦ M2-like MΦ 
 24h IL-1β before LPS (%) 
TNFα  41% ↓ 97% ↓ 
IL-6  45%  ↑ 8.5%  ↔ 
IL-10  27% ↓ 29% ↑ 
Note: “↑”, “↓,”and “↔”means up-regulation, down-regulation, and no-modulation 
of the indicated target, respectively. 
 
Table ‎3.3-5: The effect of Caspase 1 inhibition on K12-LPS-induced MΦs 
 M1-like MΦ M2-like MΦ 
 IL-1β IL-18 IL-1β IL-18 
LPS only 100% 100% 100% 100% 
10 µϺ* + LPS   51% ↓ 2% ↓ 60% ↓ 8% ↑ 
20 µϺ* + LPS 59%  ↓ 50% ↓ 80% ↓ 9% ↑ 
50 µϺ* + LPS  68% ↓ 64% ↓ 88% ↓ 7% ↓ 
(*) Caspase-1 inhibitor concentrations added before LPS inhibitor + LPS 
Note: “↑”, “↓,”and “↔”means up-regulation, down-regulation, and no-modulation 
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3.4 Discussion  
3.4.1 THP-1 monocytes differentiated macrophage subsets and 
cytokines profiles  
There are several conclusions from this investigation with respect to MΦ subsets 
behaviour in responses to PAMPs include K12-LPS, PG-LPS, PGN and LTA and pro-
inflammatory cytokines such as TNFα and IL-1β. Numerous studies have verified that 
gut macrophages have two subsets, classically activated pro-inflammatory M1 MΦ and 
alternative anti-inflammatory M2 MΦ (Gordon, 2003, Mosser and Edwards, 2008). 
Using THP-1 human monocytic cell line to generate macrophage cell subsets as a 
model in this study demonstrated the validation of different distinct macrophage cell 
phenotypes representative of M1-like, and M2-like macrophages. The cytokines TNFα, 
IL-1β and IL-6 that are a main cytokines of gut pathology (Zuo et al., 2010) as well as IL-
18 and IL-10, were used as indicators to discriminate between macrophage subsets in 
response to K12-LPS stimulation. Indeed, cytokine readout showed that monocytes 
differentiated by PMA, M1-like, varied from monocytes differentiated by Vitamin D3, 
M2-like, producing different cytokine levels, and profiles. Firstly, the PAMP-induced 
profile of pro-inflammatory and anti-inflammatory cytokine production is dependent 
on the route of MΦ differentiation. Overall, in response to K12-LPS, M1-like MΦs were 
characterised as TNFαhi, IL-1βlo, IL-18hi and IL-6hi, whereas M2-like MΦs were TNFαlo, 
IL- 1βhi and IL-18 and IL-6lo. The induction of the anti-inflammatory cytokine, IL-10, by 
M1-like MΦs was higher than M2-like MΦs. Secondly, M1-like MΦs were 
characterised as TNFαhi and M2-like MΦs were TNFα lo when challenge with either PG-
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LPS, PGN or LTA. To produce similar amount of TNFα upon stimulation by different 
PAMPs, the concentration of these PAMPS was various. 
In this study, K12-LPS was able to activate inflammasome in MΦ subsets and the 
readout was the production of pro-inflammatory cytokines IL-1β and IL18. PMA alone 
was able to encourage IL-1β secretion by M1. It was suggested that pro-IL-1β induction 
is provoked either by a short stimulation with LPS or by stimulation of THP-1 
maturation into macrophage-like cells with PMA (Tsuchiya et al., 1982). Briefly, IL-1β 
augmentation and inflammatory caspase initiation was specially persuaded upon 
mechanical disruption of the integrity of THP-1 cells and noticed in the subsequent 
cytoplasmic fractions. As they resemble primary monocytes, THP-1 cells were applied 
where they constitutively express high levels of caspase-1, caspase-5, NALP1 and 3 
(Martinon et al., 2002). This finding can explain the reduction of IL-1β production upon 
using caspase-1 inhibitor as discussed below.  
This finding supports that LPS is capable to activate inflammasome and encourages 
both MΦ subsets to release IL-1β and IL18 (Dinarello et al., 2013a). In contrast to our 
understanding of pro-inflammatory and anti-inflammatory MΦ subsets, M2-like MΦs 
produce higher levels of IL-1β in response to E. coli LPS. It is suggested that IL-1β is 
involved in mediating anti-inflammatory responses via its ability to induce IL-10 
expression (Foey et al., 1998). As described below, it is interesting to note that M1-like 
MΦs produced a considerable amount of the pro-inflammatory cytokine, TNFα, in 
response to IL-1β challenges, whereas M2-like MΦs did not.  
Although it is believed that IL-6 is a pro-inflammatory cytokine, it has been described 
that IL-6 showed anti-inflammatory properties. The nature of IL-6 production and 
function is probably reflected in different signalling profiles (Tilg et al., 1994). Anti-
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inflammatory effects of IL-6 is reflected over initiation of SOCS proteins and STAT-3 
activation (Xing et al., 1998) and reviewed in (Heinrich et al., 2003). In fact, SOCS-3 is 
associated with M1 classical MΦ polarisation and can suppress the anti-inflammatory 
signal and expression of IL-6 and IL-10. On the other hand, SOCS-3 knockdown favours 
M2 polarisation (Liu et al., 2008). Therefore, the mutual association between SOCS-3 
and STAT-3 would seem to balance pro- or anti-inflammatory outcome of IL-6 and the 
polarisation of MΦs between M1 and M2 subsets. M1 MΦs produced significantly high 
level of IL10, although it is expected that the higher level of IL-10 production will be by 
M2 MΦs. The high release of IL-10 from M1 MΦs might be elucidated by the point that 
LPS is known to induce IL-10 production in human macrophages differentiated with M-
CSF (Kwan et al., 2007).  However, it has been observed in a previous study that there 
is a chance that IL-10 in M2 MΦs is expressed endogenously or as membrane bound 
protein (Fleming and Campbell, 1996). Additionally, IL-10 mRNA is less stable in M2s 
than M1s as shown in gene expression results (Figure ‎3.2-7 b). As M1 MΦs display 
TNFαhi, IL-1βlo, IL-6lo, IL-10lo and NF-ĸBhi, they are demonstrative of recruited and pro-
inflammatory pathological MΦs. However, M2 MΦs, which demonstrate TNFαlo, IL-1βhi, 
IL-6hi, IL-10hi, TGFβhi and NF-ĸBlo, they are demonstrative of regulatory, anti-
inflammatory mucosal MΦs. Moreover, mucosal MΦs are described to occur in these 
distinct functional subsets, administrated by environmental stimuli  (Foey, 2012, 
Smythies et al., 2005). 
3.4.2 TNFα differentially modulate LPS-induced MΦ subset cytokine. 
As well known that macrophages exhibit a variety of functional features, which include 
establishment of inflammation, tissue repair and anti-inflammatory responses or 
immune-suppression (Foey, 2014). Mucosal MΦs drive tolerogenic behaviour in a 
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homeostatic environment while, at the same time, maintaining an effective phagocytic 
reaction. As mentioned before, pro-inflammatory M1 MΦs encourage inflammation 
and have a damaging effect on tissues, whereas anti-inflammatory/regulatory M2 
MΦs induce convenient effects on the tissues and reduce inflammation (Weber et al., 
2015). It is suggested that TNFα has a vital role in modulation of inflammation of IBD 
whereas TNFα inhibition will play an essential role in Crohn’s disease. While LPS 
activation can lead to pro- and anti-inflammatory cytokine production, these 
responses can be modulated by other factors. From that knowledge, it was  
hypothesised that THP-1 monocytes differentiated macrophage subsets, M1-like and 
M2-like may deferentially respond to TNFα challenge long term or short term with or 
without LPS. TNFα-induced innate activation in the presence or absence of LPS to 
investigate the segregation of a pro- and an anti-inflammatory cytokine in MΦ subsets. 
Certainly, pro-inflammatory cytokines, TNFα, as expected, differentially modulated 
K12-LPS induced cytokine production in macrophage subsets. In the case of an 
inflammatory environment (TNFα long-term stimulation), M1-like MΦs were able to 
produce more pro-inflammatory cytokines such as TNFα and IL-18 and less anti-
inflammatory cytokines, IL-10, compared to LPS control. M2-like MΦs, on the other 
hand, produced less pro-inflammatory cytokines such as TNFα and IL-18 and high anti-
inflammatory cytokines, IL-10. Thus, the specific TNFα activation through its receptors 
was shown to increase inflammation via M1-like by production of pro-inflammatory 
cytokines, in the presence of LPS to mimic inflammatory environment. In contrast, M2-
like MΦs showed remarkable tolerance induction. It is suggested that TNF α signal 
transduction pathway may converge, through activation of TRAF2, at the level of NF-ĸB 
inducing kinase leading to nuclear translocation of NF-ĸB. It could be that down-
regulation of this pathway is a primary mechanism for interaction between TNFα and 
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K12-LPS, since potential post-receptor convergent signal transduction pathways are 
triggered in reaction to LPS and TNFα (Song et al., 1997). Ferlito et al verified that pre-
treatment with TNFα in THP-1 cells line can induces a degree of cross-tolerance to LPS. 
The TNFα tolerance suppressed LPS-induced ERK phosphorylation and encouraged an 
NF-ĸB-binding pattern involving of augmented p50 homodimers similar to LPS 
tolerance in addition to decreased LPS-induced TxB2 production (Ferlito et al., 2001). 
Other studies have proven that pre-treatment with TNFα in vivo leaded to cross-
tolerance to LPS-induced lethality in rats and encouraging macrophage functional 
phenotype typical of LPS tolerance (Zingarelli et al., 1995). Interestingly, the 
upregulation of IL-6 secretion by both macrophage subsets might explain the duel 
function of IL-6 cytokine as pro- and anti-inflammatory cytokine. 
3.4.3 IL-1β differentially modulate LPS-induced MΦ subset cytokine. 
As mentioned above, it was remarkable that MΦ subsets deferentially response to IL-
1β stimulation. To illustrate, M1s produced a higher amount of TNFα in response to IL-
1β stimulation whereas M2s did not produce any considerable TNFα. It  cannot be 
assumed that IL-1β cytokine could not stimulate M2s because M2-like MΦs produced 
significant level of IL-6 similar to level upon LPS stimulation and even higher level of IL-
10 than positive control. It might be that IL-1β cytokine is not associated with 
downstream signalling events that lead to activate TNFα synthesis. This demonstration 
was also found in study by Ferlito et al who aproved that IL-1β does not induce TNF α 
in THP-1 cells (undefferentiated).  It was also reported that IL-1β did not display an 
activation in NF-ĸB-DNA and did not result in degradation of IκBα  which was degraded 
by LPS stimulation (Ferlito et al., 2001). This may be related similarly to Vit.D3 
differentiated THP-1, M2-like MΦs that was used in this study.  
 
102 
 
3.4.4 Inflammasome activation in response to K12-LPS stimulation.  
Finally, inflammasome activity in MΦ subsets has been investigated by several 
methods such as quantifying the production of IL-1β and IL-18 in response to K12-LPS, 
determination of sensitivity of K12-LPS-induced MΦs cytokines to IL-1β and 
investigating the effect of caspase-1 inhibitor on IL-1β and IL-18 production by LPS-
stimulated MΦ subsets. It was demonstrated that IL-1β and IL-18 produced in different 
processes in LPS-stimulated MΦ subsets. The production of IL-1β and IL-18 proteins 
was obviously dependent on the activation of caspase-1 pathway in M1-like MΦs. 
However, IL-1β production was caspase-1 dependent in M2-like MΦs whereas IL-18 
production seems to be caspase-1 independent. This advises that in macrophages 
there are different regulatory mechanisms for IL-1β and IL-18 secretion. It was 
reported that there are examples where caspase-1 processing of IL- 18 is not required 
where active IL-18 in caspase-1-deficient murine macrophages was release upon Fas 
ligand (FasL) stimulation (Tsutsui et al., 2000). Additionally, it was demonstrated that 
the signalling of IL-1β and IL-18 are related independently of NLRP3 or RIP3 (Dinarello 
et al., 2013a). It was suggested that even if caspase-1 inhibitor similarly inhibited the 
secretion of IL-1β and IL-18, they are seemingly regulated in a different way during 
infecti 
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Chapter 4: Endotoxin Tolerisation 
of MΦ subsets 
(Homo- and hetero-tolerisation) 
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4.1 Introduction 
 Endotoxin tolerisation (ET) is a circumstance where cells go through a hypo-responsive 
state, unable to respond to further endotoxin-LPS challenge. ET has been studied in 
vivo and in vitro in both animals and humans (Biswas and Lopez-Collazo, 2009). Both 
host and pathogen would take benefits from ET and destructiveness alike; suppression 
of pro-inflammatory responsiveness leads to autoimmunity and cancer in the host 
(Foster and Medzhitov, 2009), while anti-inflammatory suppression is good for the 
pathogen. Gut mucosal MΦs are essential to ET because their differentiation and 
activation status determine whether the mucosal environment is harmful to the host 
tissue or pathogen. MΦs induced by ET exist by different mechanisms: presentation of 
anti-inflammatory cytokines (e.g. IL-10 and TGFβ), down-regulation of pattern 
recognition receptors (PRRs e.g. TLR4) or shedding of cytokine receptors and PRRs and 
/or induction of negative regulatory molecules, which have an inhibition role of TLR4 
signal transduction, such as Tollip, Myd88s, SARM, IRAK-M and SIGIRR, reviewed by 
(Foey and Crean, 2013). 
Mucosal macrophages MΦs have a dual functionality that determines tolerance to 
commensal organisms or immune response to entropathogens such as E. coli K12-LPS.  
The immune-suppression roles of M2 MΦs resemble to the feature of the endotoxin 
tolerance. To illustrate, M2 MΦs exhibit up-regulation of anti-inflammatory cytokine 
(e.g.IL-10) and show down-regulation of pro-inflammatory cytokines (e.g. TNFα) 
(Mantovani et al., 2005) however, it is an oversimplification to assign endotoxin 
tolerisation phenomenon to a specific MΦ subset because of the verities of MΦ 
phenotypes exhibited  a consequence of differentiation, stimulation and tolerisation 
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(Cavaillon and Adib-Conquy, 2006a). Down-regulation of downstream immune 
responses in the tolerance to LPS is associated with reducing expression of TLR4 
surface protein, Toll like receptor members, and /or absence of required co-receptor 
subunits MD-2 and CD14  (Cario and Podolsky, 2000a, Otte et al., 2004, Abreu et al., 
2001). The endogenous suppressors such as Tollip, IRAK-M, SIGIRR and short version of 
MyD88 (MyD88s) are linked with down-regulation of the TLR4 receptor and LPS 
unresponsiveness (Biswas and Lopez-Collazo, 2009). Previously, tolerisation studies 
showed differential suppression between M1 (pro-inflammatory) and M2 (regulatory) 
MΦs in response to LPS of an oral pathogen, Porphyromonas gingivalis. It has been 
shown that the pro-inflammatory M1-like subset was refractory to tolerance induced 
by P. gingivalis, whereas, M2-like subset was sensitive to tolerance induced by P. 
gingivalis and suppressed the inflammatory cytokines (Foey and Crean, 2013).  E. coli is 
an gut mucosal pathogen and E. coli-LPS is already understood to be able to induce ET 
in macrophages (Sun et al., 2014, Biswas and Lopez-Collazo, 2009). 
Since IL-10, the anti-inflammatory cytokine, can suppress inflammatory responses of 
MΦs (Moore et al., 2001) it could play an important role in ET modulation. It is vital to 
investigate IL-10 functionality and signalling in MΦ subsets because the therapeutic 
value of IL-10 as well as its limited success in clinical trials (Fedorak et al., 2000, Tilg et 
al., 2002). It has been reported that IL-10 signaling is essential for the regulation of 
chronic and acute inflammation e.g., Crohn’s disease and sepsis, respectively (El Kasmi 
et al., 2006). The signals of IL-10 are recognised by IL-10Rα and IL-10Rβ receptor 
complex prior to a signal cascade involving JAK1/TYK2 and STAT-3 (Foey et al., 2017, 
Fiorentino et al., 1991). STAT-3 is related with anti-inflammatory function, MΦ 
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stimulation inhibition, the expression of IL-10 (Benkhart et al., 2000, Donnelly et al., 
1999). 
The circumstance of cross-tolerisation has been defined between different microbial 
species, related PAMPs and the analogous PRRs, which might be involved in IBD, which, 
in addition to E. coli, is commonly determined in the gastrointestinal tract (GIT). It was 
suggested that cross-tolerisation is demonstrated between LPS, PGN and/or LTA 
(Biswas and Lopez-Collazo, 2009, Foey and Crean, 2013). It was interesting to 
investigate this process with respect to the distinct MΦ subsets profiles. 
 The main hypothesis of the research is to characterise the molecular mechanisms of 
ET in immune cells in vitro and to clarify the molecular basis of ET of other aspects’ 
negative regulation of inflammation, Toll-like receptor TLR signalling, adaptor 
molecules and transcriptional factors and identification of novel molecules through 
genetic testing in addition to systems biology.  The new findings and attempts to 
present an integrated and updated mechanistic view of ET might lead to improvement 
of the clinical significance with respect to several pathological conditions. 
The aim of this study was to investigate the susceptibility of MФ subsets to E. coli K12-
LPS-tolerisation. Additionally, this investigation aimed to evaluate whether a range of 
PAMPs can induce cross-tolerance to K12-LPS and vice versa in THP-1 cells derived 
macrophage subsets M1 and M2. 
The particular hypotheses to be verified in this investigation are:  
Hypothesis 1: Endotoxin tolerisation by E. coli LPS (homo-tolerisation) can be induced 
in THP-1-derived MΦ subsets. 
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Hypothesis 2: PRRs and negative regulatory roles in ET induced in THP-1-derived MΦ 
subsets. 
Hypothesis 3: anti-inflammatory cytokine, IL-10, modulate K12-LPS induced pro-
inflammatory cytokine production in macrophage subsets. 
Hypothesis 4: THP-1-derived MΦ subsets can induce cross-tolerance (Hetero-
tolerisation) in response to different PAMPs include K12-LPS; TLR4 agonist, PGN; NOD2 
agonist and LTA; TLR2 agonist.  
4.2 Results 
4.2.1 Expression of pro-inflammatory and anti-inflammatory 
cytokines mRNA in tolerised-MΦs. 
 Suppression of pro-inflammatory cytokines mRNA in endotoxin 4.2.1.1
tolerised MΦs. 
In order to investigate ET molecular effects on MΦ subsets, gene expression of pro-
inflammatory and anti-inflammatory cytokines have been investigated. Macrophage 
challenge with Escherichia coli (K12-LPS) differentially suppresses MΦ subset gene 
expression of cytokine of interest upon stimulation with the same pre-treatment 
challenges (homo-tolerisation). Gene expression of TNFα relative to GAPDH gene 
expression and comparing to LPS-stimulated MΦs, positive controls, was suppressed in 
both M1- and M2-like MΦs when pre-treated and then later challenged with K12-LPS 
in the two time points 4h and 24h.  When pre-treated for 4h, TNFα gene expression 
level in M1 were significantly downregulated by 62%, P= 0.095 and downregulated but 
insignificant in M2 and 83%, P= 0.15 (Figure ‎4.2-1 a). Twenty-four hours of tolerisation 
showed similar level of TNFα gene expression reduction by M1 with 58%, P= 0.038 and 
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higher and significant reduction by M2 with 93%, P= 0.012 (Figure ‎4.2-1 b). IL-1β 
relative to GAPDH gene expression was also suppressed by both M1- and M2-like MΦs 
in the two time points 4h and 24h. IL-1β gene expression level, when pre-treated for 
24h were suppressed by 61%, P= 0.019 in M1 and 64%, P= 0.045 in M2 (Figure ‎4.2-1 c). 
However, 24h of tolerisation displayed insignificant level of reduction by M1 with 69%, 
P= 0.278 and significant reduction by M2 with 97.5%, P= 0.006 (Figure ‎4.2-1 d). The 
expression of pro-inflammatory IL-18 mRNA was downregulated significantly by M1-
like MΦs in 4h of tolerisation time 37% P= 0.041 whereas there was no change 
observed by M2-like MΦs (Figure ‎4.2-1 e). However, it was significant in both MΦ 
subsets after 24h tolerisation where M1 and M2 MΦs showed 68% suppression, P= 
0.032 and 45%, P= 0.008, respectively (Figure ‎4.2-1 f). 
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Figure ‎4.2-1: Suppression of pro-inflammatory cytokine mRNA in endotoxin 
tolerised MΦs. 
M1 (Red) and M2 (Blue) MΦ subsets were pre-stimulated with 100 ng/ml K12-LPS for 4h 
(a, c & e) and 24h (b, d & h) prior to stimulation with 100 ng/ml K12-LPS incubated for a 
further 18h (-) = no LPS, whereas (+) = LPS added for both pre-stimulated and stimulated 
cells. mRNA was extracted from cells to test the mRNA expression of TNFα (a, b), IL1β (c, 
d) and IL-18 (e, f) gene. Gene expression (mRNA level) is expressed as fold change using 
GAPDH as reference gene and resting cells as a calibrator sample as described by (Livak 
et al, 2001) using 2-∆∆ct. Data displayed is a representative experiment with duplicate 
samples of n= 2 replicate experiments. Significant effects compared to the positive 
control (-/+) are indicated as * P < 0.05, ** P < 0.01 and ns= no significant. 
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 Differential expression of anti-inflammatory cytokines mRNA in 4.2.1.2
endotoxin tolerised MΦs. 
IL-6 plays a vital role as anti-inflammatory cytokines via its ability to directly trigger the 
signal transducers and activators of transcription (STAT) factors STAT-1 and STAT-3, via 
the JAK/ STAT pathway (Hodge et al., 2005). There was no significant change in IL-6 
gene expression comparing to positive controls (stimulation by K12-LPS without prior 
treatment) by M1 and M2 upon 4h pre-treatment. Nevertheless, after 24h pre-
treatment, M1-like MΦs clearly suppressed IL-6 gene expression reduced by 95%, P= 
0.002 but M2-like MΦ showed no significant change in IL-6 gene expression P= 0.12 
(Figure ‎4.2-2 a & b). Interestingly, gene expression of anti-inflammatory; IL-10 showed 
significant upregulation by both MΦ subsets upon tolerisation in 4h time point. The 
increase level in IL-10 gene expression was 50% higher in M1- and M2-like MΦs, P= 
0.006 and P= 0.005, respectively (Figure ‎4.2-2 c). M1-like showed no significant change 
in IL-10 gene expression while M2-like MΦs did after 24h and the level of rise was 80%,  
P= 0.006 (Figure ‎4.2-2 d).  
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Figure ‎4.2-2: Differential expression of anti-inflammatory cytokine mRNA in 
endotoxin tolerised MΦs. 
M1 (Red) and M2 (Blue) MΦ subsets were pre-stimulated with 100 ng/ml K12-LPS for 4h 
(a & c) and 24h (b & d) prior to stimulation with 100 ng/ml K12-LPS incubated for a 
further 18h (-) = no LPS whereas (+) = LPS added for both pre-stimulated and stimulated 
cells. mRNA was extracted from cells to test the mRNA expression of IL-6 (a, b) and IL-10 
(c, d) gene. Gene expression (mRNA level) is expressed as fold change using GAPDH as 
reference gene and resting cells as a calibrator sample as described by (Livak et al, 2001) 
using 2-∆∆ct. Data displayed is a representative experiment with duplicate samples of n= 2 
replicate experiments. Significant effects compared to the positive control (-/+) are 
indicated as ** P < 0.01, *** P < 0.001 and ns= no significant. 
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4.2.2 Effect of endotoxin tolerisation induced by E. coli LPS on cytokine 
secretion of macrophage subsets 
 K12-LPS suppresses the pro-inflammatory cytokines secreted 4.2.2.1
by MΦs. 
In order to compare with previous observed results in (Figure ‎4.2-1), 4h and 24h 
periods of pre-treatment with K12-LPS before stimulation with same challenges 
showed different levels of protein secretion of pro-inflammatory and anti-
inflammatory cytokines. Macrophage challenge with E. coli K12-LPS differentially 
suppresses MΦ subset cytokine secretion upon stimulation with the same pre-
treatment stimulus compared to positive controls, stimulation by K12-LPS without 
prior treatment (-/+). Four hours as earliest time point of tolerisation induction, and 
24h as latest time point of tolerisation induction, of pre-treatment with K12-LPS before 
stimulation with same stimulus for 18h showed different levels of cytokine production 
(determined as optimal time course for production of all cytokines TNFα, IL-1β, IL-6 
and IL-10, data not shown). Both M1- and M2-like MΦs significantly suppressed TNFα 
production when they pre-treated and then later challenged with K12-LPS in the two 
time points 4h and 24h.  When pre-treated for 4h TNFα level produced by M1 and M2 
were suppressed by 68%, P= 0.003 and 95%, P= 0.003, respectively (Figure ‎4.2-3 a). 
Twenty-four hours of tolerisation showed greater reduction of TNFα secretion by M1-
like MΦs with 92%, P= 0.002 and M2 with 97%, P= 0.008 (Figure ‎4.2-3 b). IL-1β 
cytokine production by tolerised M1-like MΦs was partially suppressed depending on 
time point of pre-treatment. M1-like MΦs failed to show any significant suppression of 
IL-1β after 4h, whereas it was strongly suppressed after 24h pre-treatment reduced by 
80%, P= 0.007. M2-like MΦs presented a significant suppression after 4h and 24h pre-
treatment reduced by 60%, P= 0.014 and reduced by 55%, P= 0.056, respectively 
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(Figure ‎4.2-3 c & d). Both M1- and M2-like MΦs significantly suppressed IL-18 
production when they pre-treated and then later challenged with K12-LPS in the two 
time points 4h and 24h.  When pre-treated for 4h IL-18 level produced by M1- and M2-
like MΦs were suppressed by 60%, P= 0.004 and 42%, P= 0.035, respectively 
(Figure ‎4.2-3 e). Twenty-four hours of tolerisation showed similar reduction of IL-18 
secretion by M1-like with 60%, P= 0.003, whereas  M2-like showed higher reduction 
comparing to 4h results with 57%, P= 0.015 (Figure ‎4.2-3 f). 
 
Figure ‎4.2-3: Suppression of pro-inflammatory cytokine secretion by endotoxin 
tolerised MΦs. 
M1 (Red) and M2 (Blue) MΦ subsets were pre-stimulated with 100 ng/ml K12-LPS for 4h (a, c 
& e) and 24h (b, d & f) prior to stimulation with 100 ng/ml K12-LPS incubated for a further 18h 
(-) = no LPS whereas (+) = LPS added for both pre-stimulated and stimulated cells. Cytokine 
production is expressed as the mean secretion ± SD in pg/ml/106 cells for TNFα (a & b), IL-1β (c 
& d) and IL-18 (e & f). Data showed represents triplicate samples for n= 3 replicate 
experiments. Significant effects on suppression compared to the untolerised LPS control for 
the specified MΦ subset are indicated as * p < 0.05, ** p < 0.01 and ns= no significant.   
 
114 
 
 
 Anti-inflammatory cytokines by endotoxin tolerised MΦs. 4.2.2.2
There was no significant change in IL-6 cytokine production compared to positive 
controls, stimulation by K12-LPS without prior treatment (-/+), by both M1 and M2 
upon 4h pre-treatment. However, after 24h pre-treatment, M1-like MΦs clearly 
suppressed K12-LPS induced IL-6 (reduction by 92%, P= 0.021) but M2-like MΦs 
showed no change in IL-6 secretion (Figure ‎4.2-1 a & b). Pro-inflammatory M1-like 
MΦs showed no change in IL-10 production when they were pre-treated by K12-LPS 
for either 4h or 24h. On the other hand, anti-inflammatory M2-like MΦs showed up-
regulation on IL-10 production upon 4h tolerisation with 66%, P= 0.035 and 13%, P= 
0.03 upon 24h tolerisation (Figure ‎4.2-4 c & d).  
 
Figure ‎4.2-4: Differential sensitivity of MΦ-derived anti-inflammatory 
cytokines to endotoxin tolerisation. 
M1 (Red) and M2 (Blue) MΦ subsets were pre-stimulated with 100 ng/ml K12-LPS for 4h 
(a & c) and 24h (b & d) prior to stimulation with 100 ng/ml K12-LPS incubated for a 
further 18h (-) = no LPS whereas (+) = LPS added for both pre-stimulated and stimulated 
cells. Cytokine production is expressed as the mean secretion ± SD in pg/ml/106 cells for 
IL-6 (a & b) and IL-10 (c & d). Data showed represents triplicate samples for n= 3 
replicate experiments. Significant effects on suppression compared to the untolerised 
LPS control (-/+) for the specified MΦ subset are indicated as * p < 0.05, ** p < 0.01 and 
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ns= no significant.   
 
 
4.2.3 Differential gene expression of TLR4, TLR2 and NOD2 like 
receptors in endotoxin-tolerant MΦs. 
The previous data clearly revealed the outcome of ET on regulation of both pro-
inflammatory and anti-inflammatory cytokines induced in MΦ subsets. As cell 
signalling controls the consequences of ET, the immunomodulation could occur via 
modulation of macrophage PRR expression including TLRs and NLRs. The data above 
leads to investigate the expression on TLRs and NLRs in endotoxin tolerised MΦ 
subsets.  
 TLR4  4.2.3.1
As LPS is mainly recognised by TLR4, it was the first PRRs to be examined. Regulation of 
TLR4, LPS agonist, mRNA expression was observed in cells stimulated with K12-LPS. 
Upon 4h of tolerisation, gene expression of TLR4 showed no difference in level 
compared to positive controls by both M1-like and M2-like MΦs. After re-stimulation 
with the same LPS for additional 24h, the levels of mRNA expression of TLR4 was 
decreased markedly in M1- and M2-like MΦs compared with those from cells 
stimulated with LPS only once. Down-regulation was significant as 77%, P= 0.001 and 
50%, P˂ 0.001 for M1 and M2, respectively (Figure ‎4.2-5 a & b). TLR4 protein after 24h 
tolerisation was also detected by Western blotting. Remarkably, M1-like MΦs 
presented a significant augmentation of TLR4 protein secretion, whereas M2-like 
showed slightly down regulation in TLR4 protein secretion comparing to positive 
control (Figure ‎4.2-6). The band density was measured for each band and the ratio to 
positive control was (3.31: 3.71) for M1-like and (1.36: 1.07) for M2-like MΦs. 
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Figure ‎4.2-5: Endotoxin tolerisation effect on MΦ TLR4 gene expression. 
M1 (Red) and M2 (Blue) MΦ subsets were pre-stimulated with 100 ng/ml K12-LPS for 4h 
(a) and 24h (b) prior to stimulation with 100 ng/ml K12-LPS incubated for a further 18h 
(-) = no LPS whereas (+) = LPS added for both pre-stimulated and stimulated cells. RNA 
was extracted from cells to test the mRNA expression of TLR4 gene. Gene expression 
(mRNA level) is expressed as fold change using GAPDH as reference gene and resting 
cells as a calibrator sample as described by (Livak et al, 2001) using 2-∆∆ct. Data displayed 
is a representative experiment with duplicate samples of n=2 replicate experiments. 
Significant effects compared to the LPS positive control (-/+) are indicated as *** 
P<0.001 and ns= no significant. 
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Figure ‎4.2-6: ET differentially modulate TLR4 in distinct MΦ subsets. 
M1 and M2 MΦ subsets were pre-stimulated with 100 ng/ml K12-LPS for 24h prior to 
stimulation with 100 ng/ml K12-LPS incubated for a further 18hours (-) = no LPS whereas 
(+) = LPS added for both pre-stimulated and stimulated cells. Protein activity of IRAK-M 
in K12-LPS tolerised MΦ subsets was detected by western blot. Western blot was used 
to explore IRAK-M protein expressions and levels of GAPDH were served as internal 
controls. The ratio of optical density compared to the negative control that was 
normalized to GAPDH controls One representative result of three independent 
experiments is shown. Results was obtained in corporation with Barbara Durante. 
 
 TLR2 4.2.3.2
In order to investigate the involvement of TLR2 in ET induced by K12-LPS, regulation of 
TLR2 gene expression was detected in MΦs stimulated with K12-LPS. Upon 4h of pre-
treatment, mRNA expression of TLR2 showed strong suppression by M1-like 40% P˂ 
0.001 and no change in gene expression level comparing to positive controls by M2-
like MΦs.  After pre-stimulation with the same LPS for 24h, the levels of mRNA 
expression of TLR2 were decreased markedly in M1- and M2-like MΦs compared with 
those from cells stimulated with LPS stimulation. Down-regulation was significant as 
75%, P= 0.001 and 60%, P= 0.001 for M1 and M2, respectively (Figure ‎4.2-7 a & b).  
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Figure ‎4.2-7: Endotoxin tolerisation effect on MΦ TLR2 gene expression. 
M1 (Red) and M2 (Blue) MΦ subsets were pre-stimulated with 100 ng/ml K12-LPS for 4h 
(a) and 24h (b) prior to stimulation with 100 ng/ml K12-LPS incubated for a further 18h 
(-) = no LPS whereas (+) = LPS added for both pre-stimulated and stimulated cells. RNA 
was extracted from cells to test the mRNA expression of TLR2 gene. Gene expression 
(mRNA level) is expressed as fold change using GAPDH as reference gene and resting 
cells as a calibrator sample as described by (Livak et al, 2001) using 2-∆∆ct. Data displayed 
is a representative experiment with duplicate samples of n= 2 replicate experiments. 
Significant effects compared to the positive control (-/+) are indicated as *** P < 0.001 
and ns= no significant. 
 
 NOD2 4.2.3.3
In addition to TLR2, the involvement of NOD2 in ET induced by K12-LPS was 
investigated.  Role of NOD2 mRNA expression was noticed in MΦs challenged with 
K12-LPS. After 4h of tolerisation, gene expression of NOD2 to LPS stimulation was 
strongly suppressed by M1-like 60% P= 0.001 and no change in gene expression level 
comparing to positive controls by M2-like MΦs P= 0.142.  Interestingly, after pre-
treatment with the same LPS for 24h, the levels of mRNA expression of NOD2 to LPS 
stimulation were increased significantly in M1- 60%, P= 0.01. However, it was 
decreased markedly in M2-like MΦs compared with those from cells stimulated with 
LPS only once with 85%, P= 0.01 (Figure ‎4.2-8 a & b).  
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Figure ‎4.2-8: Endotoxin tolerisation effect on MΦ NOD2 gene expression. 
M1 (Red) and M2 (Blue) MΦ subsets were pre-stimulated with 100 ng/ml K12-LPS for 4h 
(a) and 24h (b) prior to stimulation with 100 ng/ml K12-LPS incubated for a further 18h 
(-) = no LPS whereas (+) = LPS added for both pre-stimulated and stimulated cells. RNA 
was extracted from cells to test the mRNA expression of NOD2 gene. Gene expression 
(mRNA level) is expressed as fold change using GAPDH as reference gene and resting 
cells as a calibrator sample as described by (Livak et al, 2001) using 2-∆∆ct. Data displayed 
is a representative experiment with duplicate samples of n= 2 replicate experiments. 
Significant effects compared to the LPS positive control (-/+) are indicated as ** P< 0.01 
*** P< 0.001 and ns= no significant. 
 
4.2.4 Negative regulatory molecules are involved in endotoxin 
tolerisation mechanisms.  
To find more about the mechanism of ET and considering if there is any difference in 
ET process between M1-like and M2-like MΦs, further study of the consequence of ET 
on selected negative regulatory molecules was done, either in level of mRNA 
expression by RT-PCR or protein secretion by WB. Negative regulatory molecules in 
this study include IRAK-M, Tollip and SIGIRR (mRNA and protein levels), SOCS3 and 
STAT-3 (mRNA level only). Endotoxin-tolerised MΦ subsets exhibited diverse levels of 
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negative regulatory gene expression and differential modulation of negative protein 
levels. 
 IRAK-M 4.2.4.1
Endotoxin-tolerised M1-like MΦs showed a significant up-regulation for IRAK-M mRNA 
in both tolerisation times, 4h and 24h, 62%, P= 0.04 and 80%, P= 0.01. Although, IRAK-
M mRNA levels did not change in M2-like MΦs in 4h tolerisation time point, it was 
significantly up regulated by 75% and P= 0.001 in 24h tolerisation time point 
(Figure ‎4.2-9). Furthermore, IRAK-M protein, after 24hours of tolerisation, was also 
detected by Western blotting. Interestingly, M1-like MΦs failed to reflect similar 
results in IRAK-M protein level comparing to mRNA results. However, M2-like showed 
partly up-regulation in IRAK-M protein level (Figure ‎4.2-10). The band density was 
measured for each band and the ratio to LPS positive control (-/+) was (0.867: 1.025) 
for M1-like and (0.371: 0.985) for M2-like MΦs. 
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Figure ‎4.2-9: ET regulates IRAK-M gene expression in MΦ subsets. 
M1 (red) and M2 (blue) MΦ subsets were pre-stimulated with 100 ng/ml K12-LPS for 4h 
(a) and 24h (b) prior to stimulation with 100 ng/ml K12-LPS incubated for a further 18h 
(-)= no LPS whereas (+)= LPS added for both pre-stimulated and stimulated cells. RNA 
was extracted from cells to test the mRNA expression of IRAK-M gene. Gene expression 
is expressed as fold change using GAPDH as reference gene and resting cells as a 
calibrator sample as described by (Livak and Schmittgen, 2001) using 2-∆∆ct. Data 
displayed is a representative experiment with duplicate samples of n= 2 replicate 
experiments. Significant effects compared to the positive control (+LPS) are indicated as 
* P< 0.05, ** P< 0.01 *** P< 0.005 and ns= no significant. 
 
 
Figure ‎4.2-10: ET differentially modulate IRAK-M in MΦ subsets. 
M1 and M2 MΦ subsets were pre-stimulated with 100 ng/ml K12-LPS for 24h prior to 
stimulation with 100 ng/ml K12-LPS incubated for a further 18h (-) = no LPS whereas (+) 
= LPS added for both pre-stimulated and stimulated cells. Protein level of IRAK-M in K12-
LPS tolerised MΦ subsets was detected by western blot. Western blot was used to 
explore IRAK-M protein expressions and levels of GAPDH were served as internal 
controls. The ratio of optical density compared to the negative control that was 
normalized to GAPDH controls One representative result of three independent 
experiments is shown. 
 
122 
 
 
 Tollip 4.2.4.2
A significant up-regulation for Tollip mRNA was shown by endotoxin-tolerised , pro-
inflammatory, M1 MΦs in both tolerisation times, 4h and 24h, 47%, P= 0.02 and 53%, 
P= 0.02 respectively. Anti-inflammatory, M2 MΦs presented a downregulation of Tollip 
mRNA after 4h tolerisation by 40% and P= 0.01 and no change after 24h tolerisation 
(Figure ‎4.2-11). Tollip protein secretion, upon 24h tolerisation, was also detected by 
Western blotting. Remarkably, M1-like MΦs presented a significant augmentation of 
Tollip protein level, whereas M2-like showed no change in Tollip protein level 
comparing to positive control (Figure ‎4.2-12). The band density was measured for each 
band and the ratio to LPS positive control (-/+) was (0.167: 0.322) for M1-like and 
(0.0610: 0.0135) for M2-like MΦs. 
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Figure ‎4.2-11: ET regulates Tollip gene expression in MΦ subsets. 
M1 (red) and M2 (blue) MΦ subsets were pre-stimulated with 100 ng/ml K12-LPS for 4h 
(a) and 24h (b) to stimulation with 100 ng/ml K12-LPS incubated for a further 18h (-)= no 
LPS whereas (+)= LPS added for both pre-stimulated and stimulated cells. RNA was 
extracted from cells to test the mRNA expression of Tollip gene. Gene expression is 
expressed as fold change using GAPDH as reference gene and resting cells as a calibrator 
sample as described by (Livak and Schmittgen, 2001) using 2-∆∆ct. Data displayed is a 
representative experiment with duplicate samples of n= 2 replicate experiments. 
Significant effects compared to the positive control (+LPS) are indicated as * P < 0.05, ** 
P < 0.01 and ns= no significant. 
 
 
Figure ‎4.2-12: ET differentially modulate Tollip in MΦ subsets. 
M1 and M2 MΦ subsets were pre-stimulated with 100 ng/ml K12-LPS for 24h prior to 
stimulation with 100 ng/ml K12-LPS incubated for a further 18h (-) = no LPS whereas (+) 
= LPS added for both pre-stimulated and stimulated cells. Protein level of Tollip in K12-
LPS tolerised MΦ subsets was detected by western blot. Western blot was used to 
determine Tollip protein expressions and levels of GAPDH were served as internal 
controls. The ratio of optical density compared to the negative control that was 
normalized to GAPDH controls One representative result of three independent 
experiments is shown. 
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 SIGIRR 4.2.4.3
SIGIRR can limit NF-ĸB-dependent luciferase expression as controlled by TLR4 and TLR9 
(Zhao et al., 2012), was detected. M1-like MΦs presented a significant up-regulation 
for SIGIRR mRNA in both tolerisation times, 4h and 24h, 94%, P= 0.001 and 50%, P= 
0.03. While, SIGIRR mRNA levels did not change in M2-like MΦs at 4h tolerisation time 
point, it was significantly up regulated by 50% P= 0.001 at 24h tolerisation time point 
(Figure ‎4.2-13). Additionally, after 24h tolerisation, SIGIRR was also detected at protein 
level by Western blotting. M1-like MΦs presented a slight augmentation of SIGIRR 
protein level whereas, M2-like showed down regulation in SIGIRR protein level 
comparing to positive control (Figure ‎4.2-14). The band density was measured for each 
band and the ratio to LPS positive control (-/+) was (0.328: 0.398) for M1-like and 
(0.341: 0.1496) for M2-like MΦs. 
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Figure ‎4.2-13: ET regulates SIGIRR gene expression in MΦ subsets. 
M1 (red) and M2 (blue) MΦ subsets were pre-stimulated with 100 ng/ml K12-LPS for 
24h to stimulation with 100 ng/ml K12-LPS incubated for a further 18h (-) = no LPS 
whereas (+) = LPS added for both pre-stimulated and stimulated cells. RNA was 
extracted from cells to test the mRNA expression of SIGIRR gene. Gene expression is 
expressed as fold change using GAPDH as reference gene and resting cells as a calibrator 
sample as described by (Livak and Schmittgen, 2001) using 2-∆∆ct. Data displayed is a 
representative experiment with duplicate samples of n=2 replicate experiments. 
Significant effects compared to the positive control (+LPS) are indicated as * P<0.05, *** 
P<0.005 and ns= no significant. 
 
 
Figure ‎4.2-14: ET differentially modulate SIGIRR in MΦ subsets. 
M1 and M2 MΦ subsets were pre-stimulated with 100 ng/ml K12-LPS for 24h prior to 
stimulation with 100 ng/ml K12-LPS incubated for a further 18h (-) = no LPS whereas (+) 
= LPS added for both pre-stimulated and stimulated cells. Protein level of SIGIRR K12-LPS 
tolerised MΦ subsets was detected by western blot. Western blot was used to 
determine SIGIRR protein expressions and levels of GAPDH were served as internal 
controls. The ratio of optical density compared to the negative control that was 
normalized to GAPDH controls One representative result of three independent 
experiments is shown. 
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Figure ‎4.2-15: endotoxin activation versus endotoxin tolerisation.  
This diagram showed the effect of LPS activation and LPS tolerisation on M1- and M2-
like MΦs.  It exhibit the different in cytokine production (TNFα, IL-1β, IL-18, IL-6 and IL-
10), TLR2 and TLR4 expression and negative regulatory molecules Tollip, IRAK-M and 
SIGIRR. The diagram summaries results obtained in this chapter.  
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4.2.5 IL-10 modulates MΦ subsets response to K12-LPS 
MΦ subsets differentially produce secreted IL-10 and endogenous IL-10 activity upon 
K12-LPS challenge. To investigate the responsiveness of these MΦ subsets IL-10, 
another study was done to study the ability of IL-10 to suppress TNFα. Previous study 
has shown MΦ subsets  to be differentially sensitive to IL-10 upon stimulation by LPS 
determined from the oral pathogen, Porphyromonas gingivalis  (Foey et al., 2017). 
Interestingly, both MΦ subsets were sensitive to the anti-inflammatory effects of IL-10. 
Pro-inflammatory M1-like MΦ significantly suppressed K12-LPS-induced TNFα by 30%, 
65% and 74% at concentrations of 0.2 ng/ml, 2 ng/ml and 20 ng/ml respectively. Anti-
inflammatory M2-like MΦ also significantly suppressed K12-LPS-induced TNFα by 43%, 
57% and 77% at concentrations of 0.2 ng/ml, 2 ng/ml and 20 ng/ml, respectively 
(Figure ‎4.2-16). 
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Figure ‎4.2-16: Sensitivity of K12-LPS-induced MΦ TNFα to IL-10. 
M1 (Red) and M2 (Blue) MΦ subsets were stimulated with 100 ng/ml K12-LPS for 18h in 
the presence or absence of IL-10 at concentration range from 0 to 20 ng/ml. Anti-
inflammatory effect of IL-10 on TNFα cytokine production is expressed as percentage of 
LPS-induced TNFα production originally represented as mean ± SE in pg/ml. Data 
showed represents triplicate samples for n= 3 replicate experiments. Significant effects 
compared to K12-LPS control in the absence of IL- 10 (0 ng/ml) is indicated for MΦ 
subsets as * P< 0.05 and *** P< 0.001. 
 
4.2.6 STAT-3 activation in M1 and M2 MΦs. 
To elucidate the mechanisms by which IL-10 inhibits LPS-induced TNFα production in 
MΦs, the signaling pathways activated in MΦs stimulated by IL-10 were explored. 
 STAT-3 is differentially activated by K12-LPS and IL-10 in M1- 4.2.6.1
and M2-like MΦs. 
In order to understand the circumstances of the differential IL-10 profiles in response 
to K12-LPS and the similarity in responsiveness to IL-10 between M1- and M2-like MΦs, 
downstream of IL-10 receptor signalling have been investigated. STAT-3, downstream 
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of IL-10 receptor signalling, regulates anti-inflammatory responses. Therefore, STAT-3 
activation might clarify this sensitivity to IL-10. Interestingly, Phospho- Western blot 
analysis showed activation of STAT-3 in both MΦ subsets but with some slight 
differences. To illustrate, although M1-like MΦs displayed clear bands of STAT-3 upon 
stimulation with either K12-LPS, IL-10 or both together, M1 failed to show two bands 
of STAT-3 in response to K12-LPS in the presence or absence of IL-10 (Figure ‎4.2-17,a). 
In contrast, K12-LPS activated STAT-3 in M2 MΦs increased by exogenous IL-10. M2-
like MΦs showed one band in response to K12-LPS whereas two bands were displayed 
in respond to K12-LPS present in combination with IL-10 as well as in response to 
exogenous IL-10. The K12-LPS-induced second band of phospho-STAT-3 was 
dependent on endogenous IL-10 neutralisation of which abolished STAT-3 activation 
(Figure ‎4.2-17, b). 
 
 
130 
 
 
Figure ‎4.2-17: STAT-3 differentially activated by K12-LPS and IL-10 in M1 
and M2 MΦs. 
THP-1-derived M1 and M2 MΦs were plated out at 1 x106 cells/ml in a flat bottomed 12 
well plate and treated with K12-LPS (100 ng/ml) in the presence or absence of 
exogenously added IL-10 (10 ng/ml) or neutralising anti-IL-10 antibody (10 mg/ml 9D7). 
After 30 minutes stimulation time, cell lysates were harvested. Western blot analysis of 
activated phospho-STAT-3 shows IL-10-mediated activation of STAT-3 in M1 (a) and M2 
(b) MΦs. Loading controls are presented as total STAT-3 blots below the corresponding 
phospho-Westerns. Data displayed are representative of three replicate experiments. 
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 STAT-3 is differentially activated by PG-LPS and IL-10 in M1- 4.2.6.2
and M2-like MΦs. 
In order to understand the differential sensitivity in responsiveness to IL-10 between 
M1- and M2-like MΦs, (Foey et al., 2017), downstream of IL-10 receptor signalling 
have been investigated. STAT-3, downstream of IL-10 receptor signalling, regulates 
anti-inflammatory responses. Therefore, STAT-3 activation might clarify this similarity 
sensitivity to IL-10. Interestingly, Phospho- Western blot analysis showed M1 MΦs 
failed to activate STAT-3 in response to PG-LPS in the presence or absence of IL-10 and 
a slightly activated STAT-3 when treated with IL-10 only (Figure ‎4.2-18, a). In contrast, 
PG-LPS obviously activated STAT-3 in M2 MΦs, increased by exogenous IL-10. The PG-
LPS-induced phospho-STAT-3 was dependent on endogenous IL-10; neutralisation of 
which abolished STAT-3 activation (Figure ‎4.2-18, b). 
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Figure ‎4.2-18: STAT-3 is differentially activated by PG-LPS and IL-10 in M1 
and M2 MΦs. 
THP-1-derived M1 and M2 MΦs were plated out at 5 x106 cells per well in a flat 
bottomed 12 well plate and treated with PG-LPS (100 ng/ml) in the presence or absence 
of exogenously added IL-10 (10 ng/ml) or neutralising anti-IL-10 antibody (10 mg/ml 
9D7). After 30 minutes stimulation time, cell lysates were harvested. Western blot 
analysis of activated phospho-STAT-3 shows IL-10-mediated activation of STAT-3 in M1 
(a) and M2 (b) MΦs. Loading controls are presented as total STAT-3 blots below the 
corresponding phospho-Westerns. Data displayed are representative of three replicate 
experiments. 
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 The expression of SOCS3 and STAT-3 genes in endotoxin-4.2.6.3
tolerised MΦs. 
To obtain additional evidence that the JAK2-STAT-3 pathway functions in MΦ subsets, 
the effect of ET on SOCS3 mRNA expression was studied, which is inducible by STAT-3 
activation. RT-PCR analysis revealed that SOCS3 mRNA expression in endotoxin-
tolerised MΦs was upregulated only after long exposure to LPS followed by second 
challenge, 24h then 18h, by M2-like MΦs with 37%, P= 0.035.  However, upon 24h 
tolerisation followed by 18h challenge with K12-LPS, ET showed up-regulation of 
mRNA of STAT-3 by 66% P= 0.004 and 69% P= 0.0001 in both MΦ subsets, M1- and 
M2-like, respectively (Figure ‎4.2-19).  
 
Figure ‎4.2-19: ET regulates SOCS3  and STAT-3 gene expression in MΦ 
subsets. 
M1 (red) and M2 (blue) MΦ subsets were pre-stimulated with 100 ng/ml K12-LPS for 4h 
(a & b) and 24h (c & d) to stimulation with 100 ng/ml K12-LPS incubated for a further 
18h (-) = no LPS whereas (+) = LPS added for both pre-stimulated and stimulated cells. 
RNA was extracted from cells to test the mRNA expression of SOCS3 gene (a & c) and 
STAT-3 gene (b & d). Gene expression is expressed as fold change using GAPDH as 
reference gene and resting cells as a calibrator sample as described by (Livak and 
Schmittgen, 2001) using 2-∆∆ct. Data displayed is a representative experiment with 
duplicate samples of n=2 replicate experiments. Significant effects compared to the 
positive control (+LPS) are indicated as * P<0.05, ** P<0.01 *** P<0.005 and ns= no 
significant. 
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4.2.7 MΦ subsets response to homo- and hetero-tolerisation induced 
by different PAMPs. 
Homo- and hetero-tolerisation were defined between different bacterial species, their 
PAMPs and the corresponding PRRs, which might take a part in the inflammatory 
process. Different PAMPs were used as either pre-stimulus or stimulus and these 
PAMPs include K12-LPS (TLR4), LTA (TLR2) and PGN (NOD2). The concentration of each 
agonist was chosen based on the ability to elicit comparable TNFα between the two 
MΦ subsets (Figures: Figure ‎3.2-1, Figure ‎3.2-4 and Figure ‎3.2-5). In general, 
tolerisation was obtained by both M1- and M2-like MΦs whatever the PAMPs were i.e. 
the suppression of TNFα, pro-inflammatory cytokine, was clear and significant in all 
cross-tolerisation protocol. TNFα suppression, compared to positive controls, was 
significantly more than 90% suppression by M1-like in all tolerisation protocols except 
two treatments.  To illustrate, the case of LTA/LTA and LTA/LPS, the suppression was 
75% and 80% respectively (Figure ‎4.2-20 a). TNFα induced by M2-like MΦs was 
significant. The significant TNFα suppression was in the case of LPS/LTA 55%, LPS/PGN 
63% and PGN/PGN 60% less than positive controls (Figure ‎4.2-20 b) for P values see 
(Table ‎4.2-2). Upon pre-stimulation with LPS, the suppression of IL-1β by M1-like MΦs 
was 72% by LPS, 71% by LTA and 75% by PGN less than positive controls.  Remarkably, 
there was significant suppression in IL-1β by M1-like MΦs in the case of LTA 
stimulation followed by LPS (23%) and PGN (24%). However, LTA homo-tolerisation 
resulted in very significant decreased in IL-1β by 80% less than positive control. 
Similarly, pre-stimulation with PGN suppressed IL-1β 24% by LPS and 48% by LTA 
whereas, it was 74% less upon PGN homo-tolerisation compared to positive controls 
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(Figure ‎4.2-20 c). Additionally, upon pre-stimulation with LPS, the suppression of IL-1β 
by M2-like MΦs was 80% by LPS, 75% by LTA and 34% by PGN less than positive 
controls. Similarly, pre-treated M2-like MΦs by LTA resulted in significant decrease of 
IL-1β when stimulated with LPS 68%, LTA 48% and PGN 50%. Interestingly, LPS and 
PGN as stimulus increased IL-1β production by M2-like MΦs upon pre-stimulation by 
PGN where the increase level was 33% by LPS and 19% by PGN. However, in the case 
of PGN/LTA, IL-1β was suppressed by 38% compared to positive controls (Figure ‎4.2-20 
d). With regard to IL-6 production, there was some interesting differences i.e. M1-like 
MΦs presented a significant reduction of IL-6 cytokine upon all homo- and hetero-
tolerisation protocol (Figure ‎4.2-20 e). M1-like MΦs presented significant suppression 
for IL-6, when pre-stimulated with LPS followed by LPS by 89%, LTA by 67% and PGN by 
91%. M1-like MΦs presented significant suppression for IL-6, when pre-treated with 
LTA followed by LPS by 86%, LTA by 93% and PGN by 90%. Likewise, M1-like MΦs 
presented significant suppression for IL-6, when pre-treated with LPS followed by LPS 
by 74%, LTA by 45% and PGN by 90% (Figure ‎4.2-20 e). However, M2-like MΦs 
presented significant suppression for IL-6, when pre-stimulated with LPS followed by 
LPS by 48% and PGN by 75%. In the case of LPS/LTA and LTA/PGN hetero-tolerisation, 
M2-like MΦs displayed no change for IL6 by 0%. On the other hand, M2-like MΦs 
significantly increased IL-6 in the case of LTA/LPS hetero-tolerisation by 67%, whereas 
IL-6 decreased by 35% upon LTA/LTA homo-tolerisation. Interestingly, IL-6 level 
significantly increased upon PGN/LPS and PGN/LTA hetero-tolerisation by 85% and 
87%, respectively. Conversely, IL-6 decreased by 72% upon PGN/PGN homo-
tolerisation (Figure ‎4.2-20 f). Remarkably, IL-10 profile presented by MΦ subsets was 
different. To illustrate, with M1-like MΦs, LPS pre-treatment suppressed IL-10 upon 
LPS-stimulation by 82% and PGN-stimulation by 50%, whereas M1-like MΦs showed 
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no change in IL-10 (1%) upon LPS/LTA hetero-tolerisation. LTA pre-treated M1-like 
MΦs suppressed IL-10 upon LPS-stimulation by 20%, LTA-stimulation by 48% and PGN-
stimulation by 41%. However, IL-10 production showed no significant decrease upon 
PGN/LPS 19%, PGN/LTA 4% and PGN/PGN 16% (Figure ‎4.2-20 g). On the other hand, 
M2-like MΦs significantly increased IL-10 in the case of LPS/LPS homo-tolerisation by 
43%, whereas IL-10 decreased by 76% upon LPS/LTA hetero-tolerisation and no 
significant change upon LPS/PGN.  M2-like MΦs presented significant suppression for 
IL-10, when pre-stimulated with LTA followed by LPS by 68%, LTA by 95% and PGN by 
80%. Furthermore, M2-like MΦs showed no significant change in IL-10 in the case of 
PGN/LPS hetero-tolerisation by 15%, whereas IL-10 decreased by 81% upon PGN/LTA 
hetero-tolerisation and 33% upon PGN homo-tolerisation (Figure ‎4.2-20 h) for P values 
see (Table ‎4.2-2). 
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Figure ‎4.2-20: M1 and M2 MΦs subsets exhibit a differential cross-
tolerisation of cytokine production to PAMPs. 
M1 (a, c, e & g) and M2 (b, d, f & h) MΦ subsets were pre-stimulated with either 100 
ng/ml K12-LPS (red), 10 µg/ml LTA (blue) or 10 µg/ml PGN (green), in addition to 
medium only (control), for 24h (Tolerisation = pre-stimulation) prior further 18h 
(stimulation= second stimulation) with 100 ng/ml K12-LPS, 10 µg/ml LTA and /or 10 
µg/ml PGN. Cytokines production are expressed as the mean secretion ± SD in pg/ml for 
TNFα (a & b), IL-1β (c & d), IL-6 (e & f) and IL-10 (g & h). Data showed represents 
triplicate samples for n= 3 replicate experiments. Significant effects compared to the 
positive control (+LPS) are indicated as * P<0.05, ** P<0.01 *** P<0.005 and ns= no 
significant. 
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4.2.8 Summary of chapter 4 results 
Table ‎4.2-1: Modulation on cytokines, PRRs and negative regulatory molecules 
by MΦ subsets upon endotoxin tolerisation . 
 
Macrophages 
LPS tolerised- M1 LPS tolerised- M2 
 
4hours 24hours 4hours 24hours 
mRNA Protein mRNA Protein mRNA Protein mRNA Protein 
 
 
Cytokines 
TNF α ↓ ↓ ↓ ↓ ↔ ↓ ↓ ↓ 
IL-1β ↓ ↔ ↔ ↓ ↓ ↓ ↓ ↓ 
IL-18 ↓ ↓ ↓ ↓ ↔ ↓ ↓ ↓ 
IL-6 ↔ ↔ ↓ ↓ ↔ ↔ ↔ ↔ 
IL-10 ↑ ↔ ↔ ↓ ↑ ↑ ↑ ↔ 
 
 
PRRs 
TLR4 ↔  
N/A 
  
↑ ↑ ↔  
N/A 
 
↓ ↓ 
TLR2 ↓ ↔ N/A 
 
↓ ↓ N/A 
 NOD2 ↓ ↓ ↔ ↓ 
 
 
Negative 
Regulator 
Molecules  
IRAK-
M 
↑  
 
N/A 
 
↑ ↔ ↔  
 
N/A 
 
↑ ↑ 
Tollip ↑ ↑ ↑ ↔ ↑ ↔ 
SIGIRR ↑ ↑ ↑ ↔ ↑ ↓ 
SOCS3 ↔ ↔ N/A ↔ ↑ N/A 
  STAT3 ↔ ↑ ↔ ↑ 
 
↑= increased, ↓= decreased, ↔= not significant. 
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Table ‎4.2-2: Summery of cytokine profiles induced by MΦ subsets in response to 
homo- and hetero-tolerisation. 
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Discussion 
There are several conclusions from this investigation with respect to MΦ subsets 
behaviour responses to entropathogen E. coli. Firstly, ET induced by E. coli-K12-LPS 
failed to demonstrate a differential subset-specific response. K12-LPS tolerised M1- 
and M2-like MΦ subsets exhibited down-regulation of pro-inflammatory cytokines. 
However, with respect to anti-inflammatory cytokine secretion, M1-like MΦs showed 
down-regulation in IL-6 and IL-10 production, whereas M2-like MΦs showed no 
change in IL-16 and up-regulation in IL-10 level Secondly, the suppression of the pro-
inflammatory cytokine of these MΦs appeared to be linked to the down-regulation of 
TLR4 and the differential up-regulation of the negative regulators, IRAK-M and Tollip. 
Thirdly, K12-LPS differentially induced IL-10 secretion and endogenous IL-10 activity in 
M1- and M2-like subsets. Furthermore, these subsets displayed similar sensitivity to IL-
10-mediated suppression of K12-LPS induced TNFα, whereby M1 and M2 where both 
sensitive to IL-10.(Figure ‎4.2-16) This was in state in contrast to PG-LPS induced TNFα, 
where M2-like MΦs were suppressed by IL-10 and M-like MΦs were refractory to the 
suppressor added (Foey et al., 2017).  In addition, although both subsets had similar 
sensitivity to IL-10, they presented STAT-3 activation. Finally, These MΦs displayed 
differential sensitivities to homo- and/or hetero-tolerance induced by E. coli and other 
PAMPs. Generally, there was a down-regulation in the cytokine production in both 
MΦs subsets in this study apart from IL-1β and IL-10, which were upregulated in the 
presence of PGN in M2-like MΦs.  
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4.2.9 K12-LPS differentially suppresses M1 and M2 MΦs pro- and anti-
inflammatory cytokines. 
Stimulation and pre-stimulation protocols investigate tolerisation by K12-LPS, allowing 
the study of signals via TLR4. In contrast to PG-LPS tolerisation studies in our 
laboratory (Foey and Crean, 2013), ET induced by E. coli K12-LPS failed to demonstrate 
a differential subset-specific response. These MΦs displayed differential sensitivities to 
tolerance induced by E. coli- derived bacterial PAMPs. K12-LPS tolerised M1- and M2-
like MΦ subsets exhibited down-regulation of pro-inflammatory cytokines, whereas 
with respect to anti-inflammatory cytokine secretion; M2-like sonly showed increase in 
IL-10 production. Pro-inflammatory and anti-inflammatory MΦs performed an equal 
level of TNFα suppression in 24h, of pre-stimulation. The TNFα suppression in protein 
secretion was supported by the similar level of suppression shown in TNFα mRNA. 
Additionally, the suppression of IL-6 production in M1 MΦs might be associated with 
TNFα in some way. IL-10 mRNA produced by M1s is relatively stable in comparison to 
M2s according to results of time course of stimulated MΦ subsets (data not shown). 
This might clarify why M1 MΦs secreted higher level of IL-10 than M2 MΦs. Although 
the increase of gene expression of IL-6 and IL-10 by tolerised M2 MΦs is not significant 
but it could not be disregarded. ET is often related with over-secretion of anti-
inflammatory cytokines, such as IL-10 and TGF-β, which contribute to the deactivation 
of macrophages and the suppression of pro-inflammatory cytokine production (Biswas 
and Lopez-Collazo, 2009). Conversely, ET does not mean the total failure of all 
cytokines. Instead, it represents a selective reprogramming intended at reducing 
inflammatory damage (Melo et al., 2010). It might be very complicated to find out the 
reasons for differential cytokine production; however, it might be associated with 
distinct signaling pathways. The suppression of IL-1β might also result from the up-
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regulation of these negative regulators because of the association of these negative 
regulators, TLR signal cascade and NF-κB activation. To illustrate, IL-1β production 
required activation of NF-κB (Kwon et al., 1995).  
4.2.10 Signalling mechanisms in ET in M1 and M2 MΦs. 
E. coli LPS demonstrated different abilities to modulate expression levels of members 
of the TLR family. These results show that in response to repeated challenge of K12-
LPS, the expression of TLR4 was down-regulated by M2-like MΦ subsets, which might 
reduce excessive signal transduction activated by PAMPs stimulations. The diverse 
expression profiles of cytokines secreted by LPS tolerised MΦs could be related to the 
diverse regulatory mechanisms of the distinct expressions of TLR4. As a TLR4 agonist, 
K12-LPS, can activate MyD88-dependent and MyD88-independent pathways and 
present clear suppression in cytokine production in endotoxin-tolerised MΦs, whilst 
TLR2 signals only through a MyD88-dependent pathways (Sun et al., 2014). In this 
current investigation, protein expression levels of TLR4 were explored, as MΦ subsets 
showed differential regulation in protein level of this receptor. Therefore, further 
studies are needed to explore the expression status of TLR4 in endotoxin tolerised MΦ 
subsets. It was supposed that there might be crosstalk between TLR4 and other 
receptors such as TLR2 and NOD2 pathways and some key signaling cascade 
downstream of these receptors could play a role in ET. Interestingly, there was a clear 
suppression of TLR2 gene expression in both tolerised MΦ subsets. These outcomes 
showed that in response to frequent LPS stimulation, TLR2 or TLR4 gene expression 
was suppressed, which might stop extreme signaling transduction activated by 
persistent bacteria stimulations. The expression of TLR2 and TLR4 proposed the 
different regulatory mechanisms, which might be in charge for the different cytokine 
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profiles secreted by K12-LPS tolerised MΦs. E. coli LPS (TLR4 agonist), triggers both 
MyD88-dependent and MyD88-independent pathways and suppresses cytokine 
secretion in endotoxin-tolerised cells, whereas TLR2 downstream activation goes only 
via MyD88-dependent pathway (Sun et al., 2014). It was established that pretreatment 
of THP-1 cells with bacterial lipoprotein suppressed TLR2 initiation in response to 
following challenge (Li et al., 2006). Although, LPS is a TLR4 agonist, LPS seems to a 
play role in NOD2 modulation in ET. Studies have proposed that concomitant 
stimulation of TLRs and NOD2 synergistically induces cytokines, although disagreement 
occurs about this matter (van Heel et al., 2005, de Jong et al., 2006). This study 
demonstrated in ET induced by MΦ subsets interesting results with regard to NOD2 
gene expression. To illustrate, 24h after pre-treatment with the same LPS, the levels of 
mRNA expression of NOD2 was increased significantly in M1-like MΦs while it was 
decreased markedly in M2-like MΦs. In this research, the results proof the idea that 
NOD2 can specifically be modulated by TLR4 agonist, LPS. This might represent a vital 
mechanism via which overwhelming inflammatory responses to intestinal flora are 
suppressed. Nevertheless, these effects should be confirmed in future research on 
THP-1 derived MΦs. In addition, further studies on the specific molecular mechanism 
of the cross tolerance are also necessary. 
The read out of cytokine suppression or up-regulation give us an idea about 
inflammatory profile and lead to investigate some tolerogenic mechanisms. Therefore, 
further investigations were done to compare and contrast the modulation in gene 
expression and protein level of negative regulators of endotoxin tolerised M1- and M2-
like MΦs. Some negative regulators that have been studied; IRAK-M, Tollip and SIGIRR. 
IRAKs function is regulated through several mechanisms, such as the positive regulator 
IRAK4 and the negative regulator IRAK-M (Gottipati et al., 2008). IRAK-M is an effective 
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negative regulator of TLR signaling through MyD88, decreasing signaling through NF-ĸB 
and expression of pro-inflammatory such as TNFα and IL-1β (Kobayashi et al., 2002). It 
is assumed that the total expression levels of IRAK4 is suppressed in THP-1 cells and 
human monocytes in ET. Instead, ET reduced recruitment of IRAK4 to TLR4 and 
activation of IRAK4 (Xiong et al., 2011). Harada et al suggested that IRAK-M might 
inhibit the signaling between MyD88 and IRAK1 by binding to the complex, and then 
reduce the resulting cytokine production (Harada et al., 2006). IRAK-M is reported as; 
it is the only molecule whose expression has been confirmed in both mice and human 
ET models (Biswas and Lopez-Collazo, 2009). Tollip is associated with TLR expression 
and plays an inhibitory role in TLR-mediated cell activation. Zhang and Ghosh (2002) 
reported that Tollip associates directly with TLR2 and TLR4 and plays an inhibitory role 
in TLR-mediated cell activation, explaining that the inhibition by Tollip is mediated 
through its capability to suppress the activity of IL-1 receptor-associated kinase (IRAK) 
after TLR activation (Zhang and Ghosh, 2002). SIGIRR is a negative regulator involved in 
signal transduction of several receptors of the TLRs. Overexpression of SIGIRR can 
inhibit NF-ĸB-dependent luciferase expression mediated by TLR4 and TLR9 (Zhao et al., 
2012).  Interestingly, there was quite a difference in gene expression of these negative 
regulators between tolerised M1 MΦs and M2 MΦs. The significant up-regulation of 
expression of IRAK-M, Tollip and SIGIRR in tolerised M1 MΦs that seemed to be 
related with the TNFα suppression it does not necessarily to be reflected in secreted 
protein i.e. fold differences observed in IRAK-M mRNA in M1-like MΦs was less than 
fundamental mRNA expression after transcriptional alteration. ET deferentially up-
regulate negative regulatory molecules between M1 and M2 MΦs subsets. In this 
study, Tollip and SIGIRR are mainly involved in ET induced in M1-like MΦs whereas 
IRAK-M is associated with M2-like MΦs. Additionally; more regulatory molecules were 
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evaluated in our investigation about ET induced by MΦ subsets such as STAT-3 and 
SOCS3. It was reported that STAT-3 plays an important role in IL-10-mediated 
inhibition of LPS-induced TNFα production (Nishiki et al., 2004). Macrophages induce 
SOCS3 by different mechanisms in response to microbial challenge and it could be the 
key of suppressing JAK/STAT signalling. IL-6 and STAT-3 phosphorylation are crucial to 
the pathology associated with inflammation like Crohn’s disease, and raised SOCS3 
expression proposes that SOCS3 may also have a regulatory role in these diseases 
(Croker et al., 2008). Stimulated STAT-3 likewise encourages expression of SOCS3. 
SOCS3 in turn dismisses the JAK/STAT signalling cascade, creating a negative response 
loop that allows the MΦs to return to its basal (unstimulated) state (Babon et al., 
2014).  As mentioned above, the mutual association between SOCS-3 and STAT-3 
would seem to control pro- or anti-inflammatory outcome of IL-6 and the polarisation 
of MΦs between M1 and M2 subsets. The upregulation in gene expression of STAT-3 in 
(Figure ‎4.2-19 d) might be explained why IL-6 production did not affect in ET induced 
by M1 and M2 MΦs. In this study, we demonstrated that although K12-LPS is able to 
induce similar sensitivity to tolerisation by both MΦ subsets, the mechanism of ET 
induction is different. Further study is needed to focus more in endogenous 
mechanisms of ET induced by MΦs and how these may be selectively was related in 
distinct MΦs subsets induced in the case of harmful inflammatory response. 
Consequently, this research has described a differential, subset-dependent ET-induced 
up-regulation in separate negative regulators of TLR signal transduction pathways; 
where Tollip was increased in M1 MΦs and IRAK-M in M2s upon K12-LPS ET. 
Manipulation of the expression and binding activities of such regulators is likely to 
have a significant and discriminatory outcome on MΦ subset cytokine phenotype and 
therefore, regulation of ET may apply a reflective effect in the regulation of CD through 
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polarisation of MΦ subsets between anti-inflammatory, M2-like, and pro-
inflammatory, M1-like, phenotypes. 
4.2.11 The differential induction and responsiveness to 
interleukin-10 displayed by M1 and M2 MΦs.  
 The anti-inflammatory cytokine, IL-10, may be an important mediator of ET as it can 
discourage MΦs inflammatory responses (Moore et al., 2001). As discussed in the 
previous chapter (Figure ‎3.2-2), This study demonstrated that comparing to M1-like 
MΦs; M2-like MΦs differently produce IL-10 along with an endogenous cell-associated 
activity. The production of IL-10 is associated with functional dichotomy of MΦ subsets 
where M2 MΦs exhibited higher levels of both secreted and endogenous cell-
associated IL- 10 as result of K12-LPS stimulation. In contrast, M1 MΦs show lower 
level production as consequence of failure to exhibit an endogenous IL-10 activity. 
Similar finding was established previously in our laboratory with PG-LPS as well (Foey 
et al., 2017). It is well established that IL-10 plays important role in regulation the  pro-
inflammatory responses (Iyer and Cheng, 2012). IL-10 anti-inflammatory consequences 
is showed in various mechanisms such as TNFα activity down-regulation by 
encouraging TNF-R shedding or by modifying NF-ĸB signalling process producing TNFα 
cytokines (Foey et al., 2017). The hint of occurrence a level of cross-regulation and 
plasticity between M1 and M2 MΦ subsets leads to highlight the importance to study 
MΦ sensitivity to regulatory cytokines such as IL-10. In this study, we demonstrated 
that both M1 and M2 MΦs are sensitive to the anti-inflammatory effects of IL-10 in the 
presence of E. coli K12-LPS. Interestingly, previous studies demonstrated a differential 
sensitivity of MΦ subsets to IL-10, where M2 MΦs were sensitive and M1 MΦs were 
 
147 
 
refractory to the anti-inflammatory effects of IL-10 in the present of PG-LPS (Foey et al., 
2017).  
The differential IL-10 responsiveness in the present of PG-LPS was consequence effect 
of activation of the downstream transcription factor, STAT-3 (Foey et al., 2017). 
However, the case was different when we investigate The IL-10 responsiveness in the 
present of K12-LPS. To illustrate, both MΦ subset displayed similar sensitivity to IL-10 
in the present of K12-LPS, which seemed to be as result of STAT-3 activation despite 
the finding of that M2 MΦ showed second band which, exists in the present of IL-10 
(Figure ‎4.2-17). K12-LPS activates STAT-3 in M1 and M2 MΦs and PG-LPS activates 
STAT-3 in M2 MΦs only, this reaction is indirect via IL-10; neutralisation which 
abrogated the activation response. IL-10-dependency does not result from de novo IL-
10 production because of the short stimulation time used in this experiment (30 mins) 
but it is likely to result from a pre-existing endogenous IL-10 activity detected for M2s. 
The increase of STAT-3 activation seems to be both IL-10-dependent in early responses 
and IL-10-independent later. IL-10 and STAT-3 are associated directly with anti-
inflammatory and regulatory responses as well as indirectly through effects on MΦ 
polarisation. IL-10 and STAT-3 are essential key in MΦ plasticity and differentiation 
towards the M2 effector subset. STAT-3 is necessary for IL-10 signalling coupled with 
other pathways are essential for MΦ suppression. These mechanisms may include IL-
10-inducible STAT3-regulated gene expression of SOCS3 that negatively control IL-10 
signalling (Lang et al., 2003, Foey et al., 2017). In addition to its role in regulation of 
anti-inflammatory responses, SOCS3 plays another role in M2 to M1 switch by driving 
MΦ plasticity to pro-inflammatory phenotype (Liu et al., 2008). This ability of adjusting 
plasticity between M1 and M2 subsets is helping to detect suitable immune response 
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either pro-inflammatory or anti-inflammatory and this might be beneficial in the 
treatment of inflammatory diseases (Foey and Crean, 2013).  
4.2.12 Homo- and hetero-tolerisation induced by different PAMPs 
The different mechanisms of ET have been mostly studied with respect to LPS-TLR4-
mediated ET or Gram-negative sepsis (Biswas and Lopez-Collazo, 2009). Nevertheless, 
ET is derived across also upon pre-stimulation by other TLR ligands and in Gram 
positive (i.e. LPS negative) sepsis. Tolerance to an endotoxin induced by previous 
introduction to a dissimilar endotoxin is mentioned as hetero-tolerance or cross-
tolerance. For example, earlier exposure to TLR2 ligands or NOD2 ligand, such as 
Lipoteichoic acid (LTA) and peptidoglycan (PGN) followed by second exposure to K12-
LPS is presented as cross-tolerance and vice versa (Figure ‎4.2-20 and Table ‎4.2-2).  
In this investigation, it has been demonstrated that M1-like MΦ could induce a clear 
suppression in most pro- and anti-inflammatory cytokines produced in homo- and/or 
hetero-tolerisation. Interestingly, it was only IL-6 that was upregulated upon PGN/LTA 
tolerisation as well as IL-10 that displayed no significant change upon PGN/LPS and 
PNG/PGN tolerisation. M2-like MΦs showed similar suppression attitude apart from 
interesting deferent results especially when PGN is present. Remarkably, IL-1β was 
upregulated upon stimulation or tolerisation M2-like MΦs by PGN i.e. (LPS/PGN, 
PGN/LPS and PGN/PGN tolerisation). Wan et al., presented in his study that purified 
cell wall PGN was able to induce IL-1β in human cells (Wang et al., 2000). This 
upregulation of IL-1β in the present of PGN need more investigation especially in M2-
like MΦs where they showed unexpected IL-1β production as obtained before in 
(Figure ‎3.2-11) and later in (Figure ‎5.2-10). It was established that NOD2 activation 
resulted in cross-tolerance to TLR4-dependent production of TNFα, the dominant 
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cytokine mediating inflammation in Crohn’s disease (Kim et al., 2008). Although Kim et 
al presented in his investigation that the effect of NOD2 tolerisation is specific for TLR4 
stimulation and TLR2 ligands was not affected (Kim et al., 2008), we established that 
cross-tolerisation between LTA and PGN can be induced in both MΦ subsets. We 
found that TNFα, IL-1β and IL-10 was downregulated by both M1- and M2-like MΦs 
upon PGN/LTA and LTA/PGN tolerisation. However, PGN failed to suppress IL-6 
production by MΦ subsets upon LTA stimulation where M1-like exhibited a significant 
upregulation with 64% and M2-like showed no significant change in the level of IL-6. 
There were no cross-tolerisation found in some studies between MDP and TLR2 in 
human monocytes or TLR4 signaling in the secretion of IL-6 (Kullberg et al., 2008). It 
was also reported in different study that there was no change in IL-6 production in 
response to the several stimuli (Kullberg et al., 2008). 
This study gave additional characterisation for M1- and M2-like MΦ subsets with 
respect to K12-LPS-induced activation/ tolerogenic conditions, which showed the 
discrepancy of ET induced by K12-LPS and PG-LPS. Furthermore, the similar sensitivity 
to IL-10-mediated suppression observed that both MΦ subsets were sensitive to IL-10 
suppression in resent of K12-LPS whereas the pro-inflammatory pathological subset, 
M1 was less sensitive to IL-10 suppression in present of PG-LPS. This would suggest 
that to obtain more understanding of ET mechanisms, LPS types and characteristics 
need to be considered. The main objective is to improve the methods to induce a 
selective MΦ subset suppression’s manipulation. Therefore, the balance of activation 
and suppression between MΦ subsets may contribute to adaptable future beneficial 
method for the regulator of such destructive inflammatory bowel pathologies that can 
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only be occupied upon full thoughtful of the mechanisms driving such relapsing events 
characteristic  
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Chapter 5: Inflammatory 
responses in an epithelial cell & 
macrophage co-culture model 
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5.1 Introduction 
The connection between epithelial cells and macrophages is vital in mucosal immune 
processes. Intestinal homeostasis is dictated by epithelial tissue, which permits the gut 
to actively sample pathogens, resident bacteria and other antigens derived from 
digester such as CD28 and cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) (Read 
et al., 2000). The mucosal membrane is comprised of mucus, and it envelops the 
epithelial tissue, functioning as a defensive barrier that restricts pathogen access 
(Kenny et al., 2008). The crucial element in this functionality is mucosal macrophages 
that regulate suitable immune reactions to pathogens (Vajdy, 2008).  
In the GIT, epithelial cells have a range of roles, including forming the physical 
boundary to form the distinction between the external environment of microbiota and 
food antigens from the internal environment, where the cells of the lamina propria 
such as macrophages are resident. Elicited macrophage reactions are reliant upon the 
tissue situation and the subsequent cell subsets, with M1 subsets are representing 
inflammatory macrophages whereas, homeostatic macrophages are represented by 
M2 subset (Mantovani et al., 2007). The particular aetiology of IBD, the chronic 
inflammatory condition of the gastrointestinal tract that incorporates Crohn’s disease 
(CD) and Ulcerative Colitis (UC), remains a matter of debate. This said, an awareness of 
the pathophysiology of IBD has developed, and the conventional elements of these 
conditions present themselves in a range of research within in vivo and in vitro 
concepts. As CD is associated with cell mediated immunity more relate with Th1 
whereas UC is associated with humoral immunity which is related to Th2 and the 
cytokine that drive these responses are more associated with M1 and M2 subsets i.e. 
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the actual macrophage  subset allows a potential to study IBD through this delineation 
process. Therefore, M1 macrophage could be important in studying cell mediated 
immune pathology associated with IBD (CD), whereas M2 macrophages might be more 
appropriate to study humoral responses which is more related to UC.  
To resemble the in vivo situation, in vitro cell models of the gut utilising an array of 
varying cell forms was implemented to explore the PAMPs immunomodulation of pro-
inflammatory cytokines on each specific cell type in co-culture model and the barrier 
cell function and cytokine generation profile for epithelial-like cells. Expression of tight 
junction proteins is required for the creation of an epithelial barrier, integrity, and 
polarity. Epithelial cells undertake a range of different progressions to devise a 
monolayer with a regulated selectively porous membrane with a trans-epithelial 
restriction that can be quantified. Epithelial cells when linked with other cell lines 
comprise a model representing gut physiology, should react to environmental aspects, 
including cytokines and inflammatory molecules. Of these, a good concept for 
intestinal epithelial cells is Caco2, and THP-1 human monocytic cell line for monocyte 
derived M1-like and M2-like macrophage cell subsets. As such, these two cells were 
utilised to devise a model, where epithelial cells (Caco2) combined with M1-like MΦs 
to model inflammatory gut physiology or with M2-like MΦs as a conventional 
homeostasis model. Caco2 cells upon reaching confluence, express attributes of 
enterocytic variation and purpose, with aspects including microvilli, large vacuolated 
mitochondria, and smooth and rough endoplasmic reticulum (Lee et al., 2009). Lo et al. 
(2004) asserted that transwell based Caco2/Raji B cell culture model introduced 
differentiating enterocytes into M (microfold) cells (Lo et al., 2004). This indicated that 
the M-like Caco2 cells had in common aspects with M cells in FAE. Bacterial transport 
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of Salmonella – some alive, some dead – was additionally investigated via such 
concepts so as to verify the purpose of the concept for exploring transcytosis and cell 
signalling pathways in M-like cells (Martinez-Argudo and Jepson, 2008). Nevertheless, 
Caco2 cells are polyclonal and this high diversity has led to the necessity for set 
procedures, such as in relation to the passage number and the time of usage post-
seeding for adherence. Furthermore, the plan of Caco2 was co-cultured in relation to 
the other cell forms, including PBMCs and macrophages. Parlesak et al. (2004) asserted 
that the co-culturing of Caco2/PBMCs modulate the cytokine kinetics within a 
challenge with bacteria (non-pathogenic Escherichia coli) within a compartmentalized 
co-culture concept by Caco2. Additional bacteria was applied apically to the Caco-2 cell 
layer, the generation of TNFα, IL-12, IL-1β, IL-8, IL-6, IL-10, and TGF-β was significantly 
reduced in relation to the bacterial stimulation of leucocytes underneath the Caco2 
cells. The modulation of cytokine expression by Caco2 cells helps the model of 
leucocyte (neutrophils, mast cells, NK, T cells, B cells etc.)-epithelial cell crosstalk 
functions in modulating cytokine reactions in the gut mucosa (Parlesak et al., 2004). 
Results of a similar nature were identified by (Haller et al., 2000) when Caco2 co-
cultured with human blood leucocytes and profiles of TNF-α, IL-1β, IL-8, monocyte 
chemoattracting protein 1 (MCP-1), and IL-10 were modulated as a reaction to 
stimulation Caco2 cells with non-pathogenic (Lactobacillus sakei) and 
enteropathogenic bacteria. 
Epithelial cells indirectly communicate with other cells of the immune system; they 
achieve this through releasing cytokines and antimicrobial peptides (AMPs). Upon 
pathogenic challenge, epithelial cells secrete pro-inflammatory cytokines/chemokines 
(IL-8) that recruit pro-inflammatory cells from circulation such as neutrophils, or 
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release MCP-1 to recruit monocytes to the site of infection. In addition to cytokine 
secretion, they secrete AMPs, particularly human β defensin-2 (hBD-2) (Ganz, 2003). 
AMPs like hBD-2 are important regulators at gut mucosa, and result in many academics 
placing their emphasis on the prominent factors that regulate their expression. 
Tsutsumi-Ishii and Nagaoka in 2003 described a co-culture model of A549 pulmonary 
epithelial cells with mononuclear phagocytes (Mono-Mac-6 monocytic cells) 
stimulated with LPS to explore the modulation of hBD-2 in pulmonary epithelial cells 
(Tsutsumi-Ishii and Nagaoka, 2003). The role of LPS was found to notably up-regulated 
hBD-2 promoter activity, whilst A549 in itself did not react to LPS to initiate the hBD-2 
promoter. IL-1β and TNFα in the culture supernatants from LPS-stimulated 
macrophages initiated the hBD-2 promoter in A549 cells connected with NF-ĸB 
instigation. This co-culture model also addressed the epithelial cell barrier role. Tanoue 
et al in 2008 created a co-culture system of Caco2 cells (apical side) and macrophage 
RAW264.7 cells (basolateral side) for scrutinising the anti-inflammatory impact of food 
aspects (Tanoue et al., 2008). This study might not give an accurate reflection results 
as using human cells in combination with a mouse cells for a co-culture system. 
However, in this research, the stimulation of RAW264.7 cells with LPS led to a decline 
in trans-epithelial electrical resistance (TEER) and was connected with an expansion in 
TNFα generation from RAW264.7 cells and IL-8 mRNA expression in Caco2 cells. 
Treatment with anti-TNFα antibodies restricted TNFα generation and IL-8 mRNA 
expression. 
THP-1 cells are utilised in co-culture systems with varying cell forms, such as 
adipocytes, T-lymphocytes, platelets and intestinal cells. It is widely recognised that 
adipocytes obesity-associated inflammation improves macrophage infiltration in 
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adipose tissue by inflammatory cytokine generation, like TNFα and IL-6 (Berg and 
Scherer, 2005). An in vitro model system was established for human adipose tissue by 
the incubation of adipocytes (pre-adipocyte cell line) with THP-1 cells in indirect 
incubation with conditioned medium from THP-1 cells or else the direct co-culture of 
SBGS adipocytes with THP-1 cells. It was reported that macrophages contribute to 
regulate inflammation in human adipose tissue by secretion cytokines such as TNF 
and CD95L that block Akt2 in near fat cells thereby inducing insulin resistance i.e. 
macrophages can induce apoptosis to fat cells that are insulin resistant and therefore 
apoptosis sensitive. (Keuper et al., 2011). A co-culture system by co-culturing 
predominant human adipocytes and pre-adipocytes with THP-1 cells via the use of a 
transwell process also established to explore the gene expression trend of M1, M2a, 
M2b, and M2c macrophages so they  quantitated adipose macrophage phenotypes 
and adipose tissue fibrosis in lean and obese focuses (Spencer et al., 2010). The 
findings from this research suggested that the co-culture of adipocytes with either M1 
or M2 macrophages resulted in a general transition of macrophage gene expression via 
secreting soluble elements from adipocytes, which advocate a transition of the M1 to 
the M2-phenotype cell during co-culture. Examples of research utilising THP-1-derived 
macrophages co-cultured with intestinal epithelial cells are as follows. Research 
conducted by Watanabe et al., 2004a indicated that the  Caco2 cells barrier purposed 
could be disturbed by co-culturing with THP-1 macrophages distinct from PMA 
because of the secretion of TNFα by THP-1-derived macrophages (Watanabe et al., 
2004a). A similar conclusion was proposed by (Moyes et al., 2010) when Caco2 cells co-
cultured within a transwell process with THP-1 macrophages differentiated by PMA, 
generated a reduced, not so organised epithelium and enhanced micro particle uptake. 
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Within this chapter, an advanced transwell co-culture process was devised for the first 
time via a comparison of two varying status of gut physiology; inflammation (Caco-
2/M1) or homeostatic (Caco-2/M2) to explore the immunomodulatory outcomes of K-
12 LPS and/or TNFα and IL-1β on macrophages with or without LPS. Culturing entirely 
varying Caco-2 at apical compartment and THP-1 cells specified by PMA (M1-like MΦs), 
or cells distinguished by VitD3 (M2-like MΦs at lower compartment, apically treated 
with probiotics, and basolateral stimulated with LPS was undertaken to represent gut 
pathology (inflammatory) and conventional homeostasis concepts, respectively. The 
research placed its emphasis on the role of epithelial cytokine and TEER (intestinal 
epithelial barrier function) recorded by cytokine production in homeostatic and 
chronic inflammation model. 
The main questions addressed in this investigation are.  
Hypothesis 1: co-culture model, Caco2/M1- and Caco2/M2-like MΦs, differentially 
respond to E. coli LPS. 
Hypothesis 2: pro-inflammatory cytokines, TNFα and IL-1β, can modulate K12-LPS 
induced cytokine production in co-culture models. 
Hypothesis 3: Endotoxin tolerisation by E. coli LPS can be induced differentially by MΦ 
subsets in co-culture models in comparison with MΦs monoculture. 
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5.2 Results 
5.2.1 MΦ subsets exhibit different cytokine profiles in response to 
K12-LPS, TNFα and IL-1β stimulation. 
In order to create a database for the models that been investigated in this chapter, 
behaviour of MΦ subsets in response to different stimulus were re-studied and 
represented differently. As described in chapter 3, MΦ subsets displayed different 
cytokine profiles in response upon stimulation with 100 ng/ml K12-LPS, 10 ng/ml TNFα, 
or 5 ng/ml IL-1β. TNFα production by IL-1β-stimulated M1-like MΦs was 50% less than 
TNFα produced by LPS-stimulated MΦs. However, the level of TNFα was significantly 
high upon stimulation by both LPS and IL-1β (P= 0.001) compared to untreated M1-like 
MΦs. Interestingly, M2-like MΦs produced TNFα cytokine only in response to LPS 
stimulation and the level of TNFα was slightly significant high (P= 0.001), whereas 
TNFα production upon IL-1β stimulation was at the low level of unstimulated cells 
(Figure ‎5.2-1 a) compare to (Figure ‎3.2-1). In contrast, M1-like MΦs produced IL-1β 
cytokine in response to LPS stimulation at very low level similar to untreated cells, 
whereas IL-1β level was significantly high (P= 0.002) upon TNFα stimulation. M2-like 
MΦs produced a significant level of IL-1β upon stimulation by LPS (P= 0.008) and TNFα 
(P= 0.019) (Figure ‎5.2-1 b). Stimulation of either M1- or M2-like MΦs by LPS, TNFα or 
IL-1β resulted in production a significant high level of IL-6 cytokine (Figure ‎5.2-1 c). In 
contrast, both MΦ subsets secreted significant level of IL-10 cytokine upon LPS and 
TNFα while M2-like only produced a considerable level of IL-10 in response to IL-1β 
stimulated (Figure ‎5.2-1 d). 
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Figure ‎5.2-1: MΦ subsets exhibit different cytokine profiles in response to 
K12-LPS, TNFα and IL-1β stimulation. 
M1 (Red) and M2 (Blue) MΦ subsets were stimulated in the presence or absence of [100 
ng/ml] K12-LPS, *10 ng/ml+ TNFα, or *5 ng/ml+ IL-1β. Cytokine production; TNFα (a), IL-
1β (b), IL-6 (c) and IL-10 (d) is expressed as the mean ± SD in pg/ml. Data displayed 
represents duplicate samples for n= 3 replicate experiments. Significant differences in 
cytokine production between untreated and stimulus activated MΦs are indicated as * p 
< 0.05, ** p < 0.01, *** P < 0.001 and ns= not significant. Note; TNFα production was not 
measured when stimulus is TNFα and IL-1β production was not measured when stimulus 
is IL-1β.  
 
5.2.2 Epithelial cells exhibit cell barrier modulation and different 
cytokine profiles in response to K12-LPS, TNFα and IL-1β stimulation. 
To create a basement line of data about Caco2 epithelial cell behaviour and epithelial 
barrier function in the normal homeostasis or chronic inflammation status, either LPS, 
TNFα or IL-1β stimulated Caco2 cells. Figure ‎5.2-2 showed the experiment set up 
diagram (a), the effect of LPS, TNFα and IL-1β stimulation on epithelial barrier function 
by TEER technique (b) and epithelial cytokine production profile in response these 
stimuli (c, d, e, f). Results showed that TEER of LPS-stimulated Caco2 dropped down by 
28.6% and (P= 0.02) compared to untreated cells (919 ± 55) Ω/cm2. TEER results 
 
160 
 
decreased significantly by 61% and 51% upon stimulation with TNFα and IL-1β (P= 
0.003) (Figure ‎5.2-2 b). Caco2 epithelial cells exhibited differential cytokine profile in 
response to LPS, TNFα and IL-1β. LPS-stimulated Caco2 produced TNFα cytokine by 184 
pg/ml (P= 0.007) and IL-1β-stimulated produced 521 pg/ml (P= 0.001) of TNFα cytokine 
(Figure ‎5.2-2 c). LPS-stimulated Caco2 cells secreted slightly significant higher level of 
IL-1β cytokine (P= 0.02), whereas TNFα-stimulated Caco2 cells secreted a very low IL-
1β cytokine similar to unstimulated control levels (Figure ‎5.2-2 d). IL-6 production by 
Caco2 cells was significantly higher upon LPS stimulation (P= 0.002), less significant 
upon TNFα stimulation (P= 0.0160) and very low to control level upon IL-1β stimulation 
(Figure ‎5.2-2 e). Interestingly, Caco2 produced IL-10 cytokine in very low concentration 
to control level upon LPS stimulation.  However, IL-10 level was significantly produced 
by Caco2 cells upon TNFα stimulation with 342 pg/ml (P= 0.002) and upon IL-1β 
stimulation 198 pg/ml (P= 0.001) (Figure ‎5.2-2 f). 
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Figure ‎5.2-2: Epithelial cells exhibit cell barrier modulation and different 
cytokine profiles in response to K12-LPS, TNFα and IL-1β stimulation 
(apical administration of inflammatory stimuli). 
Caco-2 epithelial cells were differentiated in transwell inserts for 21 days followed by 
incubation in the presence or absence of [100 ng/ml] K12-LPS, *10 ng/ml+ TNFα, or *5 
ng/ml] IL-1β for 24h (a). TEER measurements (b) were performed using EVOM epithelial 
voltmeter for Caco-2 epithelial cells. Cytokine production is expressed as the mean ± SE 
in pg/ml for TNF-α (c), IL-1β (d), IL-6 (e) and IL-10 (f) secreted into apical compartment. 
Data displayed represents duplicate samples for n= 3 replicate experiments. Significant 
differences in cytokine production between stimulus-activated Caco-2 epithelial cells 
and unstimulated Caco2 cells are indicated as * p < 0.05, ** p < 0.01, *** P < 0.001 and 
ns= not significant. Note; TNFα production was not measured when stimulus is TNFα 
and IL-1β production was not measured when stimulus is IL-1β.  
 
 
 
162 
 
5.2.3 Barrier modulation and cytokine production induced by K12-LPS 
in co-culture models; caco-2/M1 and caco-2/M2. 
In order to evaluate endotoxin role in modulation of the co-culture models, caco-2/M1 
and caco-2/M2, and epithelial barrier function in normal homeostasis or chronic 
inflammation environment, K12-LPS was added to the co-culture either to apical side 
to mimic a homeostasis status or to basolateral side to mimic an inflammation status. 
Firstly, Figure ‎5.2-3 showed TEER measurements in single Caco2 cells and both co-
culture models in the presence or absence of LPS. Results displayed that TEER of 
untreated single Caco2 cells (898 ± 42) Ω/cm2 decreased significantly by 31% to (615 ± 
27) Ω/cm2 (P= 0.002) upon LPS stimulation. TEER dropped down after culturing with 
MΦ subsets, however, TEER value of Caco2/M1 was significantly lower than TEER of 
untreated cells (P= 0.02) , whereas it the reduction was not significant by Caco2/M2 
(P= 0.171). TEER values of co-culture of Caco2/M1-like MΦs decreased significantly in 
the presence of LPS in apical side by 31% (P= 0.002) and basolateral side by 33% (P= 
0.0008) comparing to untreated cells. They also decreased significantly in apical side by 
19% (P= 0.001) and basolateral side by 23% (P= 0.00075) comparing to untreated 
Caco2/M1-like MΦs. However, comparing to untreated cells, the reduction of TEER 
values of co-culture of Caco2/M2-like MΦs was slightly significant in the presence of 
LPS in apical side by 21% (P= 0.005) and basolateral side by 18% (P= 0.014). The 
reduction of TEER values of Caco2/M2-like MΦs, comparing to untreated Caco2/M2-
like MΦs, was slightly significant LPS in apical side by 15% (P= 0.015) and basolateral 
side by 13% (P= 0.047) (Figure ‎5.2-3). 
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Figure ‎5.2-3: Epithelial cells barrier modulation induced by K12-LPS in 
Caco2 and co-culture models, caco2/M1-like MΦs and caco2/M2-like MΦs. 
Caco-2 epithelial cells were differentiated in transwell inserts for 21 days. Three groups 
are shown include single Caco2 (yellow), co-culture of Caco2/M1- (net red) or 
Caco2/M2-like (net blue) MΦs where LPS was added either to Caco2 (apical) or to MΦ 
subsets (basolateral). K12-LPS concentration was 100 ng/ml and the incubation period 
was 18h. TEER measurements were performed using an EVOM epithelial voltmeter. Data 
displayed is a representative experiment with duplicate samples of n= 3 replicate 
experiments. Significant effects compared to the control are indicated as * P < 0.05, ** P 
< 0.01, *** P < 0.001 and ns= not significant. 
 
Secondly, Pro- and anti-inflammatory cytokine production by co-cultured Caco2/M1-
like and Caco2/M2-like MΦs was analysed where K12-LPS was added to apical side 
(homeostasis status) or to basolateral side (inflammation status). Secreted cytokine 
was measured by two sides in co-culture model i.e. cytokine production by Caco2 from 
apical supernatant and cytokine production by MΦ subsets either M1-like or M2-like 
from basolateral supernatant. So, results in figures below are identified as (1) mono-
culture (M1-like, M2-like MΦ and Caco2), (2) apical supernatant and basolateral 
supernatant for Caco2/M1-like MΦ and (3) apical supernatant and basolateral 
supernatant for Caco2/M2-like MΦ.  
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Homeostasis status in this results mean when LPS is added to apical side i.e. to Caco2 
cells in co-culture models (Figure ‎5.2-4). TNFα cytokine production in apical 
supernatant by both Caco2/M1-like and Caco2/M2-like MΦs showed similar level to 
TNFα produced by single Caco2 upon LPS stimulation. However, upon apical LPS 
stimulation, TNFα cytokine level in basolateral supernatant significantly reduced by 
Caco2/M1-like P= 0.001 and Caco2/M2-like MΦs P= 0.004 compared to monoculture 
M1-like and M2-like MΦs (Figure ‎5.2-4 a). Apical supernatant of Caco2/M1-like 
displayed similar level of IL-1β compared to single Caco2 upon LPS stimulation, 
whereas apical supernatant of Caco2/M2-like exhibited significant increase in IL-1β P= 
0.001. IL-1β production in basolateral supernatant significantly decreased by 
Caco2/M1-like P= 0.002 and Caco2/M2-like MΦs P= 0.01 upon apical LPS stimulation 
compared to monoculture M1-like and M2-like MΦs (Figure ‎5.2-4 b). Caco2/M1-like 
MΦs showed a significant reduction in IL-6 production in apical supernatant P= 0.002, 
whereas there was no significant change in all other supernatants (Figure ‎5.2-5 c). In 
apical supernatant, Caco2/M1-like MΦs displayed similar level of IL-10 compared to 
single Caco2 upon apical LPS stimulation while Caco2/M2-like MΦs, in apical 
supernatant, exhibited significant increase in IL-10 P= 0.01. However, IL-10 production 
in basolateral supernatant significantly decreased by Caco2/M1-like MΦs P= 0.031 and 
Caco2/M2-like MΦs P= 0.001 upon apical LPS stimulation compared to monoculture 
M1-like and M2-like MΦs (Figure ‎5.2-4 d). 
In inflammatory environment where LPS was added to basolateral side of the epithelial 
cell barrier, i.e. to MΦ cells underneath in co-culture models, the results were slight 
different (Figure ‎5.2-5). Compared to monoculture (M1-like, M2-like MΦ and Caco2), 
TNFα production was significantly decreased upon LPS treatment by both Caco2/M1-
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like and Caco2/M2-like MΦ apical and basolateral side. (P= 0.012 for Caco2/M1-like 
apical side, P= 0.0001 Caco2/M1-like basolateral side, P= 0.001 for Caco2/M2-like 
apical side and P= 0.004 Caco2/M2-like basolateral side) (Figure ‎5.2-5 a). Upon 
basolateral LPS stimulation, Caco2/M2-like MΦs showed a significant reduction in IL-
1β production in basolateral supernatant P= 0.01, whereas there was no significant 
change in all other supernatants (Figure ‎5.2-5 b). Caco2/M1-like MΦs showed no 
significant change in IL-6 production in both apical and basolateral supernatant. 
However, in apical side of Caco2/M2-like MΦs IL-6 was significantly reduced P= 0.001, 
while, interestingly, IL-6 slightly significant increased by Caco2/M2-like MΦs in 
basolateral side P= 0.001 upon basolateral LPS stimulation (Figure ‎5.2-5 c). In apical 
supernatant, Caco2/M1-like MΦs presented similar level of IL-10 compared to single 
Caco2 upon basolateral LPS stimulation while Caco2/M2-like MΦs, in apical 
supernatant, exhibited significant increase in IL-10 P= 0.006. However, IL-10 
production in basolateral supernatant significantly decreased by Caco2/M1-like MΦs 
P= 0.001 and Caco2/M2-like MΦs P˂ 0.001 upon basolateral LPS stimulation compared 
to monoculture M1-like and M2-like MΦs (Figure ‎5.2-5 d). 
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Figure ‎5.2-4: Cytokine production by co-culture models, Caco2/MΦ subsets, 
in homeostatic environment.  
Single cultures of M1-, M2-like MΦs, Caco2 cells and co-culture models of Caco2/M1 
and Caco2/M2 cells were stimulated with 100 ng/ml of K12-LPS and the incubation 
period was 18h. LPS was added to the apical side in the co-culture models. M1 (red), 
M2, (blue), Caco2 (yellow), Caco2/M1 apical supernatant (net red), Caco2/M2 apical 
supernatant (net blue), Caco2/M1 basolateral supernatant (strip red) and Caco2/M2 
basolateral supernatant (strip red). Cytokine production is expressed as the mean ± SD 
in pg/ml for TNFα (a), IL-1β (b), IL-6 (c) and IL-10 (d). Data displayed represents duplicate 
samples for n= 2 replicate experiments. Significant differences in cytokine production 
between K12-LPS activated M1-, M2-like MΦs or Caco2 and the co-culture models are 
indicated as * p < 0.05, ** p < 0.01, *** P < 0.001 and ns= not significant. 
 
 
167 
 
 
Figure ‎5.2-5: Cytokine production by co-culture models, Caco2/MΦ 
subsets, in inflammatory environment.  
Single cultures of M1-, M2-like MΦs, Caco2 cells and co-culture models of Caco2/M1 
and Caco2/M2 cells were stimulated with 100 ng/ml of K12-LPS and the incubation 
period was 18h. LPS was added to the basolateral side in the co-culture models. M1 
(red), M2, (blue), Caco2 (yellow), Caco2/M1 apical supernatant (net red), Caco2/M2 
apical supernatant (net blue), Caco2/M1 basolateral supernatant (strip red) and 
Caco2/M2 basolateral supernatant (strip red). Cytokine production is expressed as 
the mean ± SD in pg/ml for TNFα (a), IL-1β (b), IL-6 (c) and IL-10 (d). Data displayed 
represents duplicate samples for n= 2 replicate experiments. Significant differences 
in cytokine production between K12-LPS activated M1-, M2-like MΦs or Caco2 and 
the co-culture models are indicated as * p < 0.05, ** p < 0.01, *** P < 0.001 and ns= 
not significant. 
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The comparison in the previous results was between positive control results and the 
results of homeostasis or inflammatory treatments. However, these results can be 
presented differently. It might be a good observation when compare the results of this 
co-culture model in homeostasis environment to the same model in an inflammatory 
environment.  The production of the pro-inflammatory cytokine, TNFα, in the apical 
supernatant of Caco2/ MΦs significantly decreased in inflammatory environment in 
both co-culture models P= 0.009 for Caco2/M1-like and P= 0.048 for Caco2/M2-like 
MΦs. Interestingly, TNFα significantly increased P= 0.001 in Caco2/M1-like MΦs 
basolateral supernatant in inflammatory environment compared to homeostasis 
environment, while there was no significant change in Caco2/M2-like MΦs basolateral 
supernatant (Figure ‎5.2-6 a). There was no significant change in IL-1β level in the apical 
supernatant of Caco2/M1, whereas it slightly decreased in Caco2/M2 supernatant P= 
0.015. However, remarkably, IL-1β significantly increased in basolateral Caco2/M1 
supernatant P˂ 0.001, whereas as no significant change in the basolateral supernatant 
of Caco2/M2 (Figure ‎5.2-6 b). There was no significant change in IL-6 level in the apical 
supernatant of Caco2/M1, whereas it decreased in Caco2/M2 supernatant P= 0.001. 
Conversely, IL-6 significantly decreased in basolateral Caco2/M1 supernatant P= 0.02, 
whereas it significantly increased in the basolateral supernatant of Caco2/M2 P= 0.039 
(Figure ‎5.2-6 c). The production of the anti-inflammatory cytokine, IL-10, in the apical 
supernatant of Caco2/M1-like MΦs in inflammatory environment was similar to IL-10 
level in homeostasis environment. On the other hand, IL-10 slightly decreased in the 
apical supernatant of Caco2/M2-like MΦs (P= 0.029). Interestingly, in Caco2/M1-like 
MΦs, IL-10 significantly increased (P= 0.015), while in Caco2/M2-like MΦs, IL-10 
significantly decreased (P= 0.006) in inflammatory environment compared to 
homeostasis environment (Figure ‎5.2-6 d). 
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Figure ‎5.2-6: Cytokine production by co-culture models, Caco2/MΦ subsets, 
in homeostasis and inflammatory environment. 
Co-culture models of Caco2/M1 and Caco2/M2 cells were stimulated with 100 ng/ml of 
K12-LPS and the incubation period was 18h. LPS was added to the apical side 
(homeostasis) or basolateral side (inflammatory) in the co-culture models. Caco2/M1 
apical supernatant (net red), Caco2/M2 apical supernatant (net blue), Caco2/M1 
basolateral supernatant (strip red) and Caco2/M2 basolateral supernatant (strip red). 
Cytokine production is expressed as the mean ± SD in pg/ml for TNFα (a), IL-1β (b), IL-6 
(c) and IL-10 (d). Data displayed represents duplicate samples for n= 2 replicate 
experiments. Significant differences in cytokine production between homeostasis state 
and inflammatory state are indicated as * p< 0.05, ** p< 0.01, *** P< 0.001 and ns= not 
significant. Note, this figure is a re-representation of figures Figure ‎5.2-4 and 
Figure ‎5.2-5 directly comparing homeostasis with inflammatory  
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5.2.4 TNFα modulation of barrier function and cytokines production in 
different co-culture models. 
The first aim was to evaluate epithelial cell barrier function, TEER measurement was 
used to determine the epithelial cell integrity. Caco2 cells (838 ± 20) Ω/cm2 decreased 
significantly by 57% to (356 ± 15) Ω/cm2 (P= 0.001) upon TNFα stimulation. In 
Caco2/M1 co-culture model comparing to untreated Caco2/M1, TEER was significantly 
reduced by all stimuli treatments. To illustrate, TEER value decreased significantly by 
20% (P= 0.0001) upon LPS stimulation, 55% (P= 0.0006) upon stimulation by TNFα 
alone and 53% (P= 0.002) upon TNFα stimulation followed by LPS. However, data 
showed that reduction in TEER by Caco2/M2 co-culture model was less significant than 
suppression in Caco2/M1 co-culture model. TEER value, comparing to untreated 
Caco2/M2, decreased by 13% (P= 0.047) upon LPS stimulation, 28% (P= 0.007) upon 
stimulation by TNFα alone and 36% (P= 0.002) upon stimulation by TNFα followed by 
LPS (Figure ‎5.2-7).  
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Figure ‎5.2-7: TNFα modulated LPS-simulated epithelial cell barrier in 
Caco2 and co-culture models. 
Single Caco2 (yellow), co-culture of Caco2/M1- (net red) or Caco2/M2-like MΦs (net 
blue). Single Caco2 cells were stimulated by either 100 ng/ml LPS for 18h or 10 ng/ml 
TNFα for 24h. Co-culture models were stimulated by 100 ng/ml LPS for 18h in 
basolateral side, 10 ng/ml TNFα for 24h in apical side or 10 ng/ml TNFα for 24h in apical 
side prior to treatment with 100 ng/ml LPS for 18h in basolateral side. TEER 
measurements were performed using an EVOM epithelial voltmeter. Data displayed is a 
representative experiment with duplicate samples of n= 3 replicate experiments. 
Significant effects compared to the control are indicated as * P < 0.05, ** P < 0.01, *** P 
< 0.001 and ns= not significant. 
 
The second aim was to analyse cell/cell interactions between Caco2 cells and MΦ 
subsets, i.e. MΦ subsets effects on epithelial cell (homeostasis) and epithelial cells 
effects on MΦ subsets (inflammation) by measuring the cytokine level upon these 
different treatments. TNFα cytokine measurement was excluded to avoid any 
confusion as TNFα was used as a stimulus. Therefore, the measured cytokines were IL-
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1β, IL-6 and IL-10 and the comparison was applied between homeostasis (LPS 
treatment to basolateral surface) and inflammatory environment (TNFα with and 
without LPS).  Upon apical treatment with TNFα only, IL-1β in Caco2/M2 apical 
supernatant (P= 0.018) and Caco2/M1 basolateral supernatant (P= 0.004) was 
significantly higher than IL-1β in same supernatants in homeostasis environment. 
There was no significant change in IL-1β level in the apical supernatant of both 
Caco2/M1- and Caco2/M2-like MΦs upon TNFα challenge prior to LPS basolateral 
treatment. However, IL-1β level significantly increased in the basolateral supernatant 
of both Caco2/M1- (P= 0.008) and Caco2/M2-like MΦs (P˂ 0.001) (Figure ‎5.2-8 a).  
Interestingly, there was no significant difference in IL-6 level upon TNFα-stimulation or 
TNFα challenge prior LPS stimulation compared to LPS stimulation. The only change 
was in the apical supernatant of Caco2/M2-like MΦs upon TNFα challenge prior to LPS 
basolateral stimulation, which showed a significant increase in IL-6 (P= 0.003) 
(Figure ‎5.2-8 b). Surprisingly, in all supernatant, IL-10 production was extremely high 
upon TNFα stimulation and TNFα challenge followed by LPS re-challenge in basolateral 
side. Upon treatment with TNFα alone, the p value of the apical supernatant of 
Caco2/M1- was (P= 0.018) and Caco2/M2-like MΦs (P= 0.005) and for basolateral 
supernatant of Caco2/M1- (P= 0.007) and Caco2/M2-like MΦs (P= 0.009). Upon 
treatment with TNFα prior to LPS challenge, the p value of the apical supernatant of 
Caco2/M1- was (P= 0.036) and Caco2/M2-like MΦs (P= 0.007) and for basolateral 
supernatant of Caco2/M1- (P= 0.003) and Caco2/M2-like MΦs (P= 0.034) (Figure ‎5.2-8 
d). 
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Figure ‎5.2-8: Differential sensitivity of LPS-induced co-culture model 
cytokines to TNFα. 
Co-culture models were stimulated by: (1) 100 ng/ml LPS in basolateral side for 18h, 
(2) 10 ng/ml TNFα in apical side for 24h or (3) 10 ng/ml TNFα in apical side for 24h 
prior to treatment with 100 ng/ml LPS in basolateral side for 18h.  Caco2/M1 apical 
supernatant (net red), Caco2/M2 apical supernatant (net blue), Caco2/M1 
basolateral supernatant (striped red) and Caco2/M2 basolateral supernatant (striped 
blue). Cytokine production is expressed as the mean ± SD in pg/ml for IL-1β (a), IL-6 
(b) and IL-10 (c). Data displayed represents duplicate samples for n= 2 replicate 
experiments. Significant differences in cytokine production between TNFα modulated 
LPS-induced cells are indicated as * p< 0.05, ** p< 0.01, *** P< 0.001 and ns= not 
significant. 
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5.2.5 IL-1β modulation of barrier function and cytokine production 
and in different MΦ subsets/co-culture models. 
Firstly, to determine the epithelial cell integrity, TEER measurement was applied.  
Caco2 cells (838 ± 20) Ω/cm2 decreased significantly by 47% to (439 ± 20) Ω/cm2 (P= 
0.001) upon IL-1β stimulation. In Caco2/M1 co-culture model, TEER was significantly 
suppressed by all stimuli treatments. TEER value decreased significantly comparing to 
untreated Caco2/M1 by 44% (P= 0.0001) upon stimulation by IL-1β alone and 48% (P= 
0.002) upon IL-1β stimulation followed by LPS. However, similar to data in 
(Figure ‎5.2-7), data showed that disruption of barrier (reduction in TEER) by Caco2/M2 
co-culture model was less significant than suppression in Caco2/M1 co-culture model. 
TEER value decreased by 28% upon stimulation by either IL-1β alone and (P= 0.005) or 
IL-1β followed by LPS and (P= 0.006) (Figure ‎5.2-9). 
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Figure ‎5.2-9: Modulation of LPS-induced epithelial cells barrier to IL-1β. 
Single Caco2 (yellow), co-culture of Caco2/M1- (net red) or Caco2/M2-like MΦs (net 
blue). 100 ng/ml LPS for 18h or 5 ng/ml IL-1β for 24h stimulated single Caco2 cells. Co-
culture models were stimulated by 100 ng/ml LPS for 18h in basolateral side, 5 ng/ml 
IL-1β for 24h in apical side or 5 ng/ml IL-1β for 24h in apical side prior to treatment 
with 100 ng/ml LPS for 18h in basolateral side. TEER measurements were performed 
using an EVOM epithelial voltmeter. Data displayed is a representative experiment 
with duplicate samples of n= 3 replicate experiments. Significant effects compared to 
the control are indicated as * P < 0.05, ** P < 0.01, *** P < 0.001 and ns= not 
significant. 
Secondly, upon apical treatment with IL-1β alone compared to LPS stimulation, TNFα 
production was significant low in the apical supernatant of both Caco2/M1- (P= 0.010) 
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and Caco2/M2-like MΦs (P= 0.006), whereas TNFα level was significantly higher in the 
basolateral supernatant of Caco2/M1-like MΦs (P= 0.003) whereas the basolateral 
supernatant of Caco2/M2-like MΦs showed no significant change. Moreover, upon 
apical treatment with IL-1β prior to basolateral LPS stimulation, the apical supernatant 
of Caco2/M1 showed no significant change, while apical supernatant of Caco2/M2 
showed slight decrease in TNFα (P= 0.027). Interestingly, TNFα production was 
significantly higher in the basolateral supernatant of both Caco2/M1- (P= 0.001) and 
Caco2/M2-like MΦs (P= 0.001) (Figure ‎5.2-10 a). There was no significant change in IL-
6 level in the apical supernatant of Caco2/M1 and Caco2/M2 and the basolateral 
supernatant of Caco2/M1-like MΦs upon apical treatment with IL-1β alone, whereas, 
interestingly, it was significantly higher in the basolateral supernatant of Caco2/M2-
like MΦs (P= 0.037). Likewise, upon apical treatment with IL-1β prior to basolateral LPS 
stimulation, there was no significant change in IL-6 level in the apical supernatant of 
Caco2/M1 and the basolateral supernatant of Caco2/M1- and Caco2/M2-ike MΦs, 
while IL-6 was significantly higher in the apical supernatant of Caco2/M2-like MΦs ( P= 
0.012) (Figure ‎5.2-10 b). Similar to IL-6, there was no significant change in IL-10 level in 
the apical supernatant of Caco2/M1 and Caco2/M2 and the basolateral supernatant of 
Caco2/M1-like MΦs upon apical treatment with IL-1β alone, whereas, interestingly, IL-
10 level  was significantly higher in the basolateral supernatant of Caco2/M2-like MΦs 
(P= 0.008). Also, upon apical treatment with IL-1β prior to basolateral LPS stimulation, 
there was no significant change in IL-10 level in the apical supernatant of Caco2/M1 
and the basolateral supernatant of Caco2/M1- and Caco2/M2-ike MΦs, while IL-10 
was significant high in the apical supernatant of Caco2/M2-like MΦs ( P= 0.002) 
(Figure ‎5.2-10 c). 
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Figure ‎5.2-10: IL-1β differentially modulated LPS-induced co-culture models 
cytokines. 
Co-culture models were stimulated by: (1) 100 ng/ml LPS in basolateral side for 18h, (2) 
5 ng/ml IL-1β in apical side for 24h or (3) 5 ng/ml IL-1β in apical side for 24h prior to 
treatment with 100 ng/ml LPS in basolateral side for 18h.  Caco2/M1 apical supernatant 
(net red), Caco2/M2 apical supernatant (net blue), Caco2/M1 basolateral supernatant 
(striped red) and Caco2/M2 basolateral supernatant (striped blue). Cytokine production 
is expressed as the mean ± SD in pg/ml for TNFα (a), IL-6 (b) and IL-10 (c). Data displayed 
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represents duplicate samples for n= 2 replicate experiments. Significant differences in 
cytokine production between IL-1β modulated LPS-induced cells are indicated as * p < 
0.05, ** p < 0.01, *** P < 0.001 and ns= not significant. 
 
5.2.6 Endotoxin tolerisation and barrier modulation induced by K12-
LPS in epithelial cells/MΦ subsets co-culture models. 
In order for expand more investigation about ET, effect of ET on co-culture of epithelial 
cells and MΦs in co-culture model was investigated. The main target in this 
investigation is MΦs subsets, however, as Caco2 cells are involved in this model, ET 
effect on Caco2 was considered.  ET research on co-culture model, Caco2/M1 and 
Caco2 M2 MΦs, was applied in two different ways; (1) treatment of LPS as pre-
stimulus and stimulus was added to apical side (Caco2 cells), (2) treatment of LPS as 
pre-stimulus and stimulus was added to basolateral cells (either M1- or M2-like MΦs). 
The first readout was identifying the direct and indirect effect of ET on epithelial 
barrier function by measuring TEER. Interestingly, the trend of results of TEER upon ET 
on apical side (direct) and basolateral side (indirect) was similar (Figure ‎5.2-11 and 
Figure ‎5.2-12). Results of direct effect of ET in (Figure ‎5.2-11) showed that compared 
to TEER of untreated Caco2 cells (918 ± 35) Ω/cm2 , TEER significantly decreased by 30% 
(P= 0.002) in both stimulated and tolerised Caco2/M1 MΦs, while TEER decreased by 
15% (P= 0.005) in stimulated Caco2/M2 MΦs similarly 15% but (P= 0.02) in tolerised 
cells.  Similarly, TEER results of indirect effect of ET significantly decreased by 32% (P= 
0.001) in stimulated Caco2/M1 MΦs and 25% (P= 0.04) in tolerised Caco2/M1 MΦs, 
while TEER slightly decreased by 15% (P= 0.014) in stimulated Caco2/M2 MΦs similarly 
15% but (P= 0.02) in tolerised cells (Figure ‎5.2-12). However, the more important read 
out is to show the significant effects of the compression between the control (-/+) and 
tolerisation treatment (+/+). Interestingly, there was no significant change in TEER 
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level (P= 0.135) of Caco2/M1 MΦs (+/+) upon ET on apical side (direct) compared to 
control (-/+), while TEER increased by 10% (P= 0.033) in tolerised Caco2/M2 MΦs (+/+) 
compared to stimulated Caco2/M2 MΦs (-/+) (Figure ‎5.2-11). All the same, there was 
no significant change in TEER level in both Caco2/M1 MΦs (+/+) P= 0.114 and 
Caco2/M2 MΦs (+/+) P= 0.353 upon ET on basolateral side (indirect) compared to 
stimulated Caco2/MΦs (-/+) (Figure ‎5.2-12). 
 
a 
 
 
 
 
 
 
 
 
b 
 
Figure ‎5.2-11: Direct effect of endotoxin tolerisation on TEER in co-
culture models (Apical LPS stimulation). 
Caco-2 epithelial cells were differentiated in transwell inserts for 21 days (a). Single 
Caco2 (yellow), co-culture of Caco2/M1-like MΦs (net red) or Caco2/M2-like MΦs 
(net blue) in the presence or absence of LPS, where LPS was added to Caco2 (apical). 
Caco2 were pre-stimulated with 100 ng/ml K12-LPS for 24h prior to stimulation with 
100 ng/ml K12-LPS incubated for a further 18h (-) = no LPS, whereas (+) = LPS. TEER 
measurements were performed using an EVOM epithelial voltmeter. Data displayed 
is a representative experiment with duplicate samples of n= 2 replicate experiments. 
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Significant effects compared between the control (-/+) and tolerisation treatment 
(+/+) are indicated as * P<0.05, ** P<0.01 and ns= not significant. Diagram shows 
how LPS was added (b). 
 
a   
 
 
 
 
 
 
 
 
 
b 
 
Figure ‎5.2-12: Indirect effect of endotoxin tolerisation on TEER in co-culture 
models (Basolateral LPS stimulation). 
Caco-2 epithelial cells were differentiated in transwell inserts for 21 days (a). Single 
Caco2 (yellow), co-culture of Caco2/M1-like MΦs (net red) or Caco2/M2-like MΦs (net 
blue) in the presence or absence of LPS, where LPS was added to Caco2 (basolateral). 
M1- and M2-like MΦs were pre-stimulated with 100 ng/ml K12-LPS for 24h prior to 
stimulation with 100 ng/ml K12-LPS incubated for a further 18h (-) = no LPS, whereas (+) 
= LPS. TEER measurements were performed using an EVOM epithelial voltmeter. Data 
displayed is a representative experiment with duplicate samples of n= 2 replicate 
experiments. Significant effects compared between the control (-/+) and tolerisation 
treatment (+/+) are indicated as * P< 0.05, ** P< 0.01, *** P< 0.001 and n s= not 
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significant. Diagram shows how LPS was added (b). 
 
The second readout was finding the modulation of ET, whether added to apical or 
basolateral side, on pro- and anti-inflammatory cytokine production by both epithelial 
cells and macrophage subsets in co-culture models. 
 Firstly, data in (Figure ‎5.2-13) showed the effect of ET on cytokine production where 
LPS was added to apical side of co-culture model i.e. to Caco2 cells. In co-culture model 
(Caco2/M1-like MΦs), TNFα cytokine was significantly suppressed upon LPS 
tolerisation by Caco2 cells by 95% (P= 0.002) and by M1-like MΦs by 74% (P= 0.01). 
However, there was no significant change in TNFα production in Caco2/M2-like MΦs 
by either Caco2 cells or M2-like MΦs (Figure ‎5.2-13 a).  Apical supernatant of Caco2 
cells in (Caco2/M1-like MΦs) exhibited no significant change in IL-1β cytokine upon ET, 
whereas basolateral supernatant, M1-like MΦs, in the same model significantly 
suppressed IL-1β by 70% (P= 0.024). In co-culture model (Caco2/M2-like MΦs), IL-1β 
level was suppressed by Caco2 cells by 50% (P= 0.03) and by M2-like MΦs by 50% (P= 
0.096) (Figure ‎5.2-13 b). Remarkably, IL-6 cytokine was significantly up-regulated by 70% 
(P= 0.001) by Caco2 cells, while it was slightly down-regulated by 50% (P= 0.049) by 
M1-like MΦs in (Caco2/M1-like MΦs) upon endotoxin tolerisation. On the other hand, 
in (Caco2/M2-like MΦs), IL-6 was significantly down-regulated by 65% (P= 0.001) by 
Caco2 cells, whereas M2-like MΦs showed no significant change upon endotoxin 
tolerisation (Figure ‎5.2-13 c). Caco2 cells in both co-culture model, (Caco2/M1-like 
MΦs and Caco2/M2-like MΦs), exhibited no significant change in IL-10 level upon LPS 
tolerisation compared to LPS stimulation. Nevertheless, in basolateral side in co-
culture, IL-10 cytokine level was significantly up-regulated by M1-like MΦs by 42% (P= 
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0.005), whereas, interestingly, it was significantly down-regulated by M2-like MΦs by 
23% (P= 0.006) (Figure ‎5.2-13 d).  
 
 
a 
 
 
b 
 
 
 
C 
 
 
 
d 
 
Figure ‎5.2-13: Effects of endotoxin tolerisation on co-culture model in 
homeostatic state (Apical LPS stimulation). 
Caco2 cells in co-culture of Caco2/M1-like MΦs or Caco2/M2-like MΦs were 
incubated  with or without 100 ng/ml LPS for 24h prior to stimulation with 100 
ng/ml LPS for a further 18h as (-) = no LPS, whereas (+) = LPS i.e. LPS added in 
apical side.  Caco2/M1 apical supernatant (net red), Caco2/M1 basolateral 
supernatant (red), Caco2/M2 apical supernatant (net blue), and Caco2/M2 
basolateral supernatant (blue). Cytokine production is expressed as the mean ± 
SD in pg/ml for TNFα (a), IL-1β (b), IL-6 (c) and IL-10 (d). Data displayed 
represents duplicate samples for n= 2 replicate experiments. Significant 
differences in cytokine production between untolerised (-/+) and tolerised (+/+) 
MΦs are indicated as * p < 0.05, ** p < 0.01, *** P < 0.001 and ns= not 
significant. 
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Secondly, data in (Figure ‎5.2-14) presented the influence of ET on cytokine production 
where LPS was added to basolateral side i.e. representative of barrier disruption and 
chronic inflammation to MΦ subsets in co-culture model. In both co-culture model 
(Caco2/M1-like MΦs and Caco2/M2-like MΦs), TNFα cytokine was significantly 
suppressed upon LPS tolerisation either apical or basolateral supernatant. In 
Caco2/M1-like MΦs, TNFα suppression by Caco2 by 60% (P= 0.20) and M1-like MΦs by 
88% (P=0.001). Likewise, in Caco2/M2-like MΦs, TNFα suppression by Caco2 by 93% 
(P=0.001) and M1-like MΦs by 91% (P= 0.001) (Figure ‎5.2-14 a). Apical supernatant of 
Caco2 cells in (Caco2/M1-like MΦs) presented no significant change in IL-1β cytokine 
upon ET, whereas M1-like MΦs in the same model significantly suppressed IL-1β by 64% 
(P= 0.009). Furthermore, Caco2/M2-like MΦs co-culture showed same sort of 
response to ET as Caco2 cells displayed no significant change in IL-1β level, while M2-
like MΦs significantly suppressed IL-1β by 33% (P= 0.028)(Figure ‎5.2-14 b). There was 
no significant change in IL-6 level induced by Caco2 cells, while, surprisingly, IL-6 
cytokine was significantly up-regulated by 43% (P= 0.004) by M1-like MΦs in 
(Caco2/M1-like MΦs) upon endotoxin tolerisation. In contrast, in (Caco2/M2-like MΦs), 
IL-6 was significantly up-regulated by 62% (P= 0.003) by Caco2 cells and significantly 
down-regulated by 48% (P= 0.036) by M2-like MΦs upon endotoxin tolerisation 
(Figure ‎5.2-14 c). Caco2 cells in (Caco2/M1-like MΦs) exhibited significant reduction in 
IL-10 cytokine by 42% (P= 0.05) upon ET, whereas M1-like MΦs in the same model 
significantly increased IL-10 cytokine by 32% (P= 0.047). IL-10 cytokine was significantly 
up-regulated by 20% (P= 0.013) by Caco2 cells and 58% (P= 0.005) by M2-like MΦs 
upon endotoxin tolerisation (Figure ‎5.2-14 d). 
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Figure ‎5.2-14: Effects of endotoxin tolerisation on co-culture model in 
inflammatory state (Basolateral LPS stimulation). 
MΦs in co-culture of Caco2/M1-like MΦs or Caco2/M2-like MΦs were incubated  
with or without 100 ng/ml LPS for 24h prior to stimulation with 100 ng/ml LPS for 
a further 18h as (-) = no LPS, whereas (+) = LPS i.e. LPS added in basolateral side. 
Caco2/M1 apical supernatant (net red), Caco2/M1 basolateral supernatant (red), 
Caco2/M2 apical supernatant (net blue), and Caco2/M2 basolateral supernatant 
(blue). Cytokine production is expressed as the mean ± SD in pg/ml for TNFα (a), 
IL-1β (b), IL-6 (c) and IL-10 (d). Data displayed represents duplicate samples for n= 
2 replicate experiments. Significant differences in cytokine production between 
untolerised and tolerised MΦs are indicated as * p < 0.05, ** p < 0.01, *** P < 
0.001 and ns= not significant. 
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5.2.7 Summary of chapter 5 results 
Table ‎5.2-1: Epithelial barrier sensitivity (TEER measurements). 
 
TEER measurements unit = Ω/cm2 and      = decrease in % compared to untreated Caco2 
cells. 
 
Ω/cm2 
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Table ‎5.2-2: Caco2 and MΦ subsets exhibit different cytokine profiles in 
response to K12-LPS, TNFα and IL-1β stimulation 
 
= decrease, = increase and  = ns/ * P < 0.05, ** P < 0.01, *** P < 0.001 and ns= 
not significant. 
 
 
 
 
 
 
 Caco2 M1-like 
MΦs 
M2-like 
MΦs stimulus secreted 
cytokine 
 TNFα ** *** ** 
LPS IL-1β * ns ** 
 IL-6 ** *** *** 
 IL-10 * *** ** 
 TNFα NA NA NA 
TNFα IL-1β ns ** * 
 IL-6 * ** ** 
 IL-10 ** ** *** 
 TNFα *** *** ns 
IL-1β IL-1β NA NA NA 
 IL-6 ns ** ** 
 IL-10 *** ns * 
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Table ‎5.2-3: Cytokine production by co-culture models, Caco2/MΦ subsets, in 
homeostasis and inflammatory environment. 
 
 
Table (a) show a compression of cytokine production between untreated and stimulus 
activated co-culture model in both homeostatic and inflammatory status. Table (b) show 
a compression of cytokine production in inflammatory status compared to homeostatic 
status. = decrease, = increase and  = ns/ * P < 0.05, ** P < 0.01, *** P < 0.001 and 
ns= not significant. 
 
a) 
b) 
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Table ‎5.2-4: Differential sensitivity of LPS-induced co-culture model cytokines 
to TNFα and IL-1β. 
 
 
= decrease, = increase and  = ns/ * P < 0.05, ** P < 0.01, *** P < 0.001 and ns= 
not significant. 
 
a) 
b) 
 
189 
 
Table ‎5.2-5: Effects of endotoxin tolerisation on co-culture model in homeostatic 
and inflammatory state.    
 
= decrease, = increase and  = ns/ * P < 0.05, ** P < 0.01, *** P < 0.001 and ns= 
not significant. 
 
5.3 Discussion 
To mimic a complex interaction of the epithelium with nearby immune cells in the 
intestinal mucosa, we established epithelial–immune cell co-culture system, 
demonstrating a role for MΦ subsets in initiating and regulating tolerance and 
inflammation of epithelial cells. Caco2 cells have been widely used to study intestinal 
epithelial barrier function. However, these cells are cancer derived and not 
hypothetical to reflect the pathophysiological modifications in the case of 
inflammation. The complexity of the tissue in vivo is another point to be taken into 
attention. Immune cells are predominantly vital in the pathogenesis of inflammatory 
bowel disease as they are very dysregulated take up harmless non-pathogenic 
intestinal flora, processing them as an antigen (Van Deventer, 2002). Macrophages are 
able to consume some microbes or infected/ cancerous cells. Subsequently processing 
 Endotoxin tolerisation  
Apical LPS stimulation 
Endotoxin tolerisation  
Basolateral LPS stimulation 
 Caco2/M1  Caco2/M2 Caco2/M1 Caco2/M2 
secreted 
cytokine 
Apical 
surface 
Basolateral 
surface 
Apical 
surface 
Basolateral 
surface 
Apical 
surface 
Basolateral 
surface 
Apical 
surface 
Basolateral 
surface 
TNFα 
 
** 
 
** 
 
ns 
       
ns 
      
* 
 
*** 
    
*** 
  
*** 
IL-1β  
ns 
            
* 
      
* 
            
* 
 
ns 
  
** 
 
ns 
           
* 
IL-6 
    
** 
            
* 
            
*** 
       
ns 
 
ns 
  
** 
        
** 
           
* 
IL-10    
ns 
           
**  
   
ns 
         
** 
  
* 
           
*  
       
* 
         
** 
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they also present the antigen to helper T-cells, consequently activating adaptive 
immune responses. Several studies were published using a combination of different 
cell types (co-culture model), focussed on the immunomodulatory effects of probiotics 
into a range of gut mucosa such as DCs and epithelial cells. Therefore, the objective of 
this study was to expand on the cell characteristic and establish a model of intestinal 
mucosa in the state of both homeostasis and inflammation. This was accomplished by 
stimulating intestinal epithelial cells with pro-inflammatory compounds such as LPS 
from intestinal microflora and several cytokines such as TNFα and IL-1β.  The current 
study was designed to determine the immunomodulation of different stimuli (K12-LPS, 
TNFα and IL-1β) on epithelial cell barrier function (cytokine production and TEER) and 
MΦ subset roles in two status; normal/homeostatic and chronic inflammation. 
Experiments for stimulation of homeostasis were conducted by addition of LPS to the 
apical surface, whereas for induction of inflammation were conducted by addition of 
either TNFα or IL-1β to apical side and/or LPS to basolateral surface.   
LPS, TNF or IL-1β could alter or disturb the barrier function of intestinal epithelia 
resulting in increased permeability or disrupted tight junctions (TJs).The effects of 
these stimuli on the TJs permeability of Caco2 monolayer were first determined by 
TEER measurement. The results suggested that TNFα is the most stimulus that able to 
alter the barrier of Caco2 whereas LPS showed less disruption. 
Previously (in chapter 3) this study has shown that K12-LPS, TNFα and IL-1β have the 
potential role to initiate innate immune responses in MΦ subsets M1- and M2-like. In 
the present study, the Caco2 cell line is differentially sensitive to a range of stimuli. To 
illustrate, in response to IL-1β, Caco2 secreted TNFα 100% higher than LPS stimulation, 
whereas Caco2 produce IL-1β and IL-6 more upon LPS stimulation. However, Caco2 did 
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not secrete IL-10 upon LPS stimulation, whereas TNFα-induced IL-10 by Caco2 cells was 
significantly higher than IL-1β-induced IL-10 (Figure ‎5.2-2). In comparison to 
monoculture experiment, this study showed immunosuppressive effects of Caco2 cells 
on E. coli LPS-stimulated MΦs. Similar suppression was shown on E. coli LPS-stimulated 
Caco2 in presence of MΦs. The secretion of the pro-inflammatory cytokines TNFα, IL-6 
and, to some extent, IL-1β was significantly suppressed compared to monoculture 
results. On the other hand, anti-inflammatory cytokine, IL-10, which can suppress the 
synthesis of pro-inflammatory cytokines (de Waal Malefyt et al., 1991, Fiorentino et al., 
1991), was not significantly affected by the presence of Caco2 cells with M1-like MΦs, 
while it significantly increased in Caco2/M2-like MΦs (Figure ‎5.2-4 and Figure ‎5.2-5).  
The use of semi-permeable transwell inserts, which prevented direct contact between 
Caco2 cells and MΦs, suggesting that immunosuppressive factors were secreted from 
Caco2 cells. Previous studies exhibited that IEC profoundly inhibit monocyte activation 
(Haller et al., 2002, Nathens et al., 1995) and T-cell function (Christ et al., 1997) 
through both secreted mediators and cell–cell interactions. However, from the present 
experiments, the factor responsible for the suppression of TNFα, IL-1β and IL-6 
synthesis remains unknown.  Evidence had shown that chronic inflammatory damage 
in IBD is highlighted by a weakness in barrier function of the intestinal epithelium as 
well as dysregulation of intestinal mucosal immunity (Deuring et al., 2013). However, 
these results can be analysed from different angle instead of comparing this results to 
the monoculture results (controls), the compression could be done between the two 
ways of treatment for the co-culture model where LPS was added either to apical side 
(homeostasis) or to basolateral side (inflammation). Interestingly, in the inflammatory 
environment, Caco2/M1-like MΦs (inflammatory Model) (Figure ‎5.2-6) exhibited 
significant up-regulation of the pro-inflammatory cytokines, TNFα and IL-1β. Similar 
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observation about the significant upregulation of pro-inflammatory cytokines TNFα 
and IL-1β was obtained upon the combination stimulation of pro-inflammatory 
cytokines with LPS (Figure ‎5.2-8 and Figure ‎5.2-10). These data reflect the nature of 
pro-inflammatory M1 MΦ in the initiation the inflammation. 
The production of IL-6 cytokine, in these results, can explain its dual function in pro- 
and anti-inflammatory role. IL-6 applies its anti-inflammatory effects through induction 
of SOCS proteins and STAT-3 activation (Xing et al., 1998). Certainly, SOCS3 is related 
with M1 MΦs polarisation and is suppressive to anti-inflammatory signal and 
expression of IL-6 and IL-10. In opposition, SOCS3 expression knockdown M2 
polarisation (Liu et al., 2008). Consequently, the mutual relationship between STAT-3 
and SOCS3 would seem to regulate pro- or anti-inflammatory consequence of IL-6 and 
the MΦ polarisation between M1 and M2 effector subsets. 
 In contrast, IL-1β high production by Caco2/M2-like co-culture in the mentioned 
figures could facilitate anti-inflammatory responses through its ability to induce IL-10 
expression (Foey et al., 1998); certainly, consequences from this research are 
suggestive of a positive association between IL-1β and IL-10, as these cytokines are 
produced strongest by the anti-inflammatory Caco2/M2-like model. Moreover, IL-1β 
production has been verified to be negatively related with the pro-inflammatory IKKβ-
dependent NF-kB pathway (Greten et al., 2007); indicative of a non-pro-inflammatory 
character for IL-1β and the complex process of the NF-kB pathway in defining cell 
effector phenotype (Foey, 2014). In addition to the fact that IL-10 has a certain ability 
to suppress pro-inflammatory signaling, it also conserve intestinal epithelial barrier 
function (Jarry et al., 2008). Interestingly, the production of IL-10 upon LPS stimulation 
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was not significant, but it was induced significantly high in the inflammatory 
environment particularly upon TNFα stimulation.  
Similar to results obtained in chapter 4, K12-LPS was able to induce endotoxin 
tolerisation to these two distinct models. In other words, MΦ subsets in combination 
with Caco2 cell line, as co-culture, exhibited endotoxin tolerisation similar to ET 
induced by mono-cultured MΦs. ET induced by E. coli K12-LPS failed to demonstrate a 
differential subset-specific response. K12-LPS tolerised Caco2/M1- and Caco2/M2-like 
MΦs exhibited down-regulation of pro-inflammatory cytokines and up-regulation of 
anti-inflammatory cytokine, IL-10, which plays a protective role following endotoxin 
challenge. IL-10 level was only decreased in Caco2/M2 supernatant where ET was 
induced to apical side. However, as discussed previously, the M2-like MΦs exhibited 
endogenous or bond membrane IL-10.  Endogenous IL-10 assembly might be a part of 
the of endotoxin tolerisation. 
The importance of these data in the context of IBD is difficult to interpret. In overall, 
encouraging tolerance by any mechanism is possible to be beneficial to chronic 
pathologies that result from over initiation of immune responses. These data obviously 
establish a role for E. coli LPS in tolerance induction MΦ subsets. It is speculated that 
endotoxin tolerance is important in maintaining innate immune homeostasis and that 
an impaired tolerance to LPS is associated with IBD. 
Although this model displayed some characteristic and pathological variations, the 
reproducibility is difficult since the induced inflammatory effects depend on the dose, 
species and strain of the animal used. Caco2 cell lines were used as models to obtain 
significant figures about IEC involvement in the immune response of the mucosal 
intestine, particularly to assess the pathology of entropathogens (Kagnoff and 
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Eckmann, 1997, Jung et al., 1995). The present model cannot mimic the all processes 
within the GALT leading to specific immunity as some tissue specific cells exist in the 
GALT such as  dendritic cells, intraepithelial lymphocytes, lamina propria lymphocytes, 
mast cells are missing. However, the model allows the validation of Caco2/MΦs 
interaction and representative two dimensional (2D) cell model for investigation, 
whose results will justify and rationalised the development of multicellular 3D models 
more representative of both the healthy/homeostatic and the inflammatory gut 
mucosal tissue.  
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Chapter 6: General discussion and 
conclusions 
 
 
196 
 
 
6.1 General discussion 
Three lines in this research were designed (monoculture of macrophage subsets, 
monoculture of Caco-2 epithelial cells, and co-culture models of Caco-2/M1 or Caco-
2/M1, (Figure ‎1.3-1) to build up a good platform of knowledge about mucosal MΦ 
subsets characters in homeostasis and inflammatory. 
E. coli K12-LPS differentially modulate MΦ subsets in a homeostatic or an 
inflammatory environment. 
This study aims to explore the gut mucosal MΦ subsets roles in homeostatic and 
inflammatory environment using a monocytic THP-1 cell line. It might be a 
disadvantage where the use of cell lines outside their usual environment because it 
might showed different sensitivity and responses compared with standard cells in the 
body. However, according to the homogeneous genetic background, which minimises 
the level of variability in the cell phenotype, which eases reproducibility of conclusions, 
THP-1 cells have some advantages over recently isolated PBMCs. It is essential to 
appreciate that differentiated THP-1 macrophages are different from macrophages 
derived from PBMCs, for example the regulation of apoptosis (Rogers et al., 2003). The 
THP-1 cell line is commonly used to study immune responses since of their ability to be 
differentiated into MΦ-like phenotype upon treatment by PMA and Vit.D3 (Auwerx, 
1991, Chanput et al., 2010, Schwende et al., 1996). The similarities between THP-1 
derived MΦs and human PBMCs derived MΦs were shown in a number of publications 
with respect to several features such as polarizing ability (plasticity), macrophage 
morphology and adherence (Tsuchiya et al., 1982), the expression of macrophage 
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receptors (CD14, CD11b and CD36) (Schwende et al., 1996, Daigneault et al., 2010) and  
MΦ functions like phagocytosis, antigen presentation and accumulation of lipids 
(Gupta et al., 2005). It was established that THP-1 cells deliver a valid cell model 
system for assessing the response of macrophages to LPS (Sharif et al., 2007). In this 
investigation, THP-1 monocytes were differentiated into M1- or M2-like MΦs in order 
to use them for showing possible immune-regulation of K12-LPS to either macrophage 
monoculture (chapter 3 and 4) or macrophages/epithelial cells in co-culture models 
(chapter 5). Data in chapter 3 showed that macrophage subsets, which were generated 
using pro-monocytic THP-1 differentiation towards MФs with M1-like and M2-like 
using PMA and vitamin D3, respectively, are differentially sensitive to challenging 
PAMPs. The profile of pro-inflammatory cytokine production induced by PAMPs is 
dependent on MΦ differentiation pathway. In general, M1-like MΦs were 
characterised as TNFαhi, IL-1βlo, IL-18hi and IL-6hi whereas, M2-like MΦs were TNFαlo, 
IL-1βhi, IL-18lo and IL-6lo. Apart from IL-18 profile, these data is supported by previous 
published data from our laboratory (Foey and Crean, 2013). The production of IL-18 by 
THP-1 derived MΦ subsets added extra validation markers for THP-1 differentiation by 
PMA and vitamin D3. From this platform, further experiments were applied to 
investigate more about mucosal MΦ behaviour in chronic inflammatory status and in 
the phenomenon of endotoxin tolerisation. 
MΦ subsets showed further comparable features related with their regulation function. 
To illustrate, in chapter 3, long-term treatment with the pro-inflammatory cytokine, 
TNFα, was used to mimic a chronic inflammatory environment.  No data was found in 
the literature on the question of how MΦ subsets can respond to TNFα stimulation. 
However, the long-term effects of TNF in disease associated with T cells was well 
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established  (Cope et al., 1994). The results showed the ability of pro-inflammatory 
M1-like MΦs to initiate and increase inflammation upon TNFα-LPS-stimulation by 
producing more pro-inflammatory cytokines (TNFα and IL-18). On the other hand, 
under the same condition, M2-like MΦs suppressed pro-inflammatory cytokine 
production and increased anti-inflammatory cytokine production (IL-6 and IL-10). This 
helps to highlight the reparative and regulatory nature of M2 MΦ. Whereas M1 MΦs 
are normally considered the predominant MΦ involved in pathogen killing.  Moreover, 
although M2 MΦs can produce TNFα, IL-1β, IL-6 and IL-10, these cytokines are less 
strongly related with the M2 phenotype (Foey, 2014, Mills and Ley, 2014, Baay et al., 
2011).  It was reported that TNFα, IFN-γ, LPS and GM-CSF are a group of stimului that 
are mainly associated with M1 MΦs whereas the M2 stimulus group includes different 
stimuli that length different levels of recognition and response (Martinez and Gordon, 
2014). Mucosal MΦs drive tolerogenic features in a homeostatic environment, while, 
keeping an effective phagocytic reaction at the same time. The homeostatic mucosal 
tolerance that associated with M2-like phenotype are dominated by the production of 
anti-inflammatory cytokines (TGFβ and IL-10) and phagocytic scavenger receptors 
(CD36, CD68 and CD206) (Smith et al., 2005, Platt and Mowat, 2008). It was reported 
that mucosal MΦs, in homeostatic tolerogenic state, produce TGFβ and IL-10, but fail 
to produce the pro-inflammatory cytokines such as  TNFα, IL-1β, IL-6, IL-8, IL-12, IL-18 
and IL-23. Alongside the expression of the regulatory molecules CD33, CD200R and 
TGFβRI/RII, this suppression is more reflected by the lack of expression of the pro-
inflammatory molecule, TREM-1, CD14/TLRs, FcRs and  costimulatory molecules (CD40, 
CD80, CD86) (Foey, 2015, Foey, 2012). However, with respect to inflammatory diseases 
such as Crohn’s disease and Chronic periodontitis and increased in immune 
suppression – related diseases such as colorectal cancer and oral squamous cell 
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carcinoma, this tolerogenic/homeostatic role of MΦs is dysregulated and mucosal 
tolerance is broken. These pathologies display mechanisms associated to M1- or M2-
driven responses. MΦs show an inflammatory phenotype, which is comparable to the 
M1 MΦ subset in the situation of pro-inflammatory diseases. This inflammatory state 
leads to M1-like MΦ activation/ differentiation with the parallel pro-inflammatory 
cytokine up-regulation and co-stimulatory molecule expression (Bouma and Strober, 
2003). Therefore, the pro-inflammatory MΦs produce/secrete a wide variety of 
effector molecules that include: PRRs (CD14, TLR2, TLR4, TLR5), chemokine receptors 
(CCR5, CXCR4), FcRs (CD16, CD32, CD64, CD89), and the pro-inflammatory 
markers/cytokines (TNFα, IL-1β, IL-6, IL-18, TREM-1 and CCL20) HLA-DR and CRs (Foey, 
2012, Rogler et al., 1999, Smythies et al., 2005). Perhaps the most compelling note of 
this study is the fact that, upon long-time TNFα stimulation prior to LPS challenge, M1-
like MΦs increase inflammation by producing pro-inflammatory cytokines whereas 
M2-like show suppression/regulation roles by producing anti-inflammatory cytokines.  
Consequently, more research aiming M1 MΦs therapeutically or indeed the increase 
of M2-mediated reactions can characterise a realistic treatment in the control of this 
chronic inflammatory disease. 
As mentioned earlier, in this investigation THP-1 derived macrophage subsets 
differentially secreted IL-1β and IL-18 upon K12-LPS stimulation.  IL-1β and IL-18 
cytokines are associated with inflammasome activity where PAMPs (LPS) trigger 
assembly of the intracellular innate immune sensor Nlrp3, causing caspase-1 activation 
and production of pro-inflammatory cytokines; IL-1β and IL-18 (Dinarello et al., 2013b). 
The precise mechanism of the Nlrp3 inflammasome activation and the subsequent 
activation of caspase-1 is unclear. In chapter 3, it has been shown that IL-1β and IL-18 
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production in M1-like MΦs was caspase-1-dependent while, IL-1β only was caspase-1 
dependent in M2-like MΦs. However, activation of caspase-1 is just one mechanism 
for cleavage of IL-1β and IL-18. Therefore, the reality of alternative pathways of IL-β 
and IL-18 activation that are independent of the inflammasome should be 
acknowledged. One of the most interesting results in this study is IL-1β / M2-like MΦs 
production and responsiveness. To illustrate, it is remarkable that (chapter 3/5) M2-
like MΦs were a good producer of IL-1β but on the other hand, they did not response 
to IL-1β stimulation.  More studies need to be applied to explore the mechanism of the 
recognition of IL-1β cytokine by MΦ subsets. Taken together the results from chapter 
3 with data from the literature, it can be accomplish that THP-1 derived MΦ subsets 
cells seem to represent a basic, reliable  and suitable model to explore macrophage 
polarisation, macrophages roles/responses, and possible their immunomodulatory 
effects.  
Endotoxin tolerisation induced in MΦ subsets in a homeostatic or an inflammatory 
environment. 
Besides the influence of differentiation signals and polarising activation, MΦ division 
to different subsets is possible to be firmed by suppressive signals or tolerisation. ET 
was first termed by the observation that LPS pre-stimulation suppressed innate 
immune cells response to activation upon LPS retreatment. Subsequently, ET has been 
presented in MΦs for a range of pro-inflammatory cytokine such as TNFα and IL-1β 
and TLR-mediated signals  include LPS, LTA, PGN,  and Flagellin (Biswas and Lopez-
Collazo, 2009). MΦ functionality suppression might benefit infectious microbes but at 
the same time positively prevent damaging inflammatory responses, therefore 
allowing for a good environment for the pathogen to recover its numbers through 
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growth. In the case of the gut pathogen Escherichia coli, associated with wide variety 
of intestinal diseases, such as Crohn’s disease and neonatal meningitis (Martinez‐
Medina et al., 2009). Both MΦ subsets were sensitive to K12-LPS-induced ET, where 
M1- and M2-like MΦ subsets displayed down-regulation of pro-inflammatory 
cytokines and no significant change was shown in anti-inflammatory cytokine 
production, IL-10, by both M1- and M2-like MΦs. It remains to be find out if ET 
involves a single critical signaling pathway or serial multiple changes in signaling events 
during tolerance induction. It was suggested that many endogenous suppressors exist 
can suppress TLR-mediated activatory or polarising responses. The endogenous 
suppressors include Tollip, IRAK-M, SIGIRR. Interestingly, not all signaling pathways are 
down-regulated and some proteins are up regulated. In this investigation, Tollip was 
more associated with M1-like MΦ whereas IRAK-M and SIGIRR were more associated 
with M1-ike MΦs (chapter 4). The likely reason is that up-regulation of Tollip and 
SIGIRR expression in M1s, IRAK-M expression in M2s is not a unique mechanism, and, 
obviously, there are other additional regulatory mechanisms to control the response to 
LPS. These include MD2, Myd88s, TRIAD3A, and several further suppressive molecules 
show a role in regulating MΦ responses such as CD200R, CD47/SIRP1α, Siglecs 3-10 
and CD32 reviewed in (Foey, 2015). However, ET may be reflective of action 
suppression or might modify polarisation status of the MΦ from M1 to M2. The 
amplification of such regulatory molecules could characterise a realistic method in 
controlling chronic inflammatory diseases such as Crohn’s disease and chronic 
periodontitis. Further studies need to be done on the effect of ET on cellular signaling, 
mediator production, and transcription factors. Therapeutic interference will be 
dependent on amplification of MΦ polarisation plasticity, MΦ subset precise ET 
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mechanisms and downstream effects on polarisation of T cell reactions (Foey and 
Crean, 2013). 
 
E. coli K12-LPS differentially modulate Intestinal epithelial barrier function in a 
homeostatic or inflammatory environment. 
The intestinal epithelium functions as vital cell barrier between the gut lumen and the 
lamina propria. It is recognised for its strength against attack of luminal bacteria that 
may be accrue with bacterial cell density of more than 1014 CFU/ml. This barrier 
typically does not respond to commensal bacteria, but triggers the pro-inflammatory 
signaling pathway in the response to pathogenic bacteria. Conversely, in IBD, together 
with an augmented permeability, the barrier fails to achieve such initial recognition, 
perhaps as a result of lack of defence molecules, exhibiting no response before the 
bacteria attack the basolateral side (Elphick et al., 2008). The exact signaling 
procedures are still unclear. Previous in vitro investigations, targeting IBD, have been 
shown in typical mono-culture of cell lines. These cell lines characterise the normal 
mucosa with integral tight junctions and strong barrier features. Nevertheless, such a 
procedure does not necessarily reflect the pathophysiological modifications happening 
in an inflamed area of IBD. Furthermore, a single cell line can never describe the 
compound interaction of different cell types during an inflammation (Leonard et al., 
2010).  
Caco2 cell line are widely established as a model of normal, healthy intestinal mucosa. 
However, as this model consist only of enterocytes, it cannot mimic the complex 
connections with other cells particularly the immune system cells. These interactions 
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could be very important for the epithelial barrier role (Leonard et al., 2010). In chapter 
5 of this study, THP-1 derived MΦs and Caco2 cells were used to develop in vitro co-
culture system, which mimics the interaction of gut epithelial cells with immune cells 
(M2-like or M1-like macrophages) of normal homeostasis (Caco-2/M2) or chronic 
inflammation model (Caco-2/M1). THP-1 cell line and Caco-2 have been widely used to 
study intestinal epithelial barrier function. However, these cells are cancer-derived and 
not thought to reflect the pathophysiological modifications in the state of 
inflammation. Consequently, the objective of this study was to develop on the cell 
characteristic and establish a model of intestinal mucosa in the condition of 
homeostasis. This was done by stimulating intestinal epithelial cells with pro-
inflammatory compounds such as LPS. However, the second object was to determine 
the role of pro- and anti-inflammatory MΦs in response to pro-inflammatory cytokines 
(TNFα and IL-1β) in the presence or absence of LPS in mono- and co-culture. TNFα and 
IL-1β overproduction by uncontrolled immune cells such as mucosal macrophage 
contributes to initiation of tissue harm in IBD (Strober and Fuss, 2011). The main idea 
of the use of TNFα and IL-1β in this experiment was to mimic a chronic inflammatory 
environment, which will allow exploring more of MΦ subsets functions. The co-culture 
itself displayed the estimated arrangement of Caco2 construction the multiple layer on 
top of the culture, while macrophages were settled in the bottom of the wells. 
Therefore, this situation appeared to be not perfect as in several areas we find 
immunocompetent cells generally located directly below the epithelial layer and even 
reaching out to the apical side of the model. Some studies assumed the result that 
antigen transfer through the intestinal barrier is conducted by specialised M-cells 
(Iwasaki, 2007). Therefore, it might be a good idea to design an experiment where 
Caco2 cells contact physically and directly with MΦ subsets although this co-culture 
 
204 
 
model was an efficient tool for narrowing the gap between animal testing and typical 
cell culture system and delivered a relevance of inflamed tissue, where it preserved 
the suitability of cell culture. Thus, transwell investigated the effect of soluble secreted 
signals. Direct cell-to-cell contact will go a step further in investigating physical contact 
signals between both cells, Caco2 and MΦ subsets. 
 Former studies showed that co-culture with Caco2 cells and triggered monocyte cell 
line THP-1 presented apoptotic and necrotic result to the Caco2 cells and damaging 
monolayer integrity. Another model has also been designed to mimic the respiratory 
tract using epithelial cells and immunocompetent cells to investigate the particle 
circulation (Rothen-Rutishauser et al., 2005). With regard to the inflammatory bowel 
disease model, there have been a couple of methods using primary blood cells from 
IBD patients and Caco2 or primary colonic crypt cells. This model has presented that 
cells from IBD patients displayed more IFN-γ than the healthy model but might not 
show any pathophysiological significance since they are not cultured to gather the 
physiological procedure in the intestine, although cells were cultured together (Bisping 
et al., 2001). Consequently, the experiment was designed for this model, which, 
consists of the relevant cells for the inflammation and antigen presenting signaling, to 
allow controlling stimulation, and mimic major pathophysiological modifications 
happening in IBD. 
Macrophage cells are involved in the initiation of CD according their ability to 
dysregulate pro- and anti-inflammatory cytokine production as a result of stimulation 
of endogenous and exogenous stimuli, microbial PAMPs and cytokines, (Butcher et al., 
2005, Pull et al., 2005, Smith et al., 2011).  Results, in this study, presented the pro-
inflammatory M1-like MΦs ability to recruit and increase inflammation upon TNFα-
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LPS-stimulation by producing more TNFα and IL-18 while M2-like MΦs suppressed pro-
inflammatory cytokine production and increased anti-inflammatory cytokine 
production, IL-6 and IL-10. It also showed that both MΦ subsets were sensitive to K12-
LPS-induced ET and Tollip and SIGIRR were associated with M1-like MΦs, whereas 
IRAK-M was associated with M2-ike MΦs. 
 Taking these finding together considering that M2-like MΦ is responsible to initiate 
homeostatic environment and the inflammatory environment, which is contributing to 
M1-like MΦ activation in the line where ET status is broken in the case of CD.  
This subset-independent manner sensitivity to ET, coupled with the transmural skip-
lesion-associated nature of this chronic inflammatory disease, is typically suggestive 
that inflammation or immune activation is tissue-destructive while tolerisation or 
immune suppression is of advantage to the host through ending the mechanisms of 
these tissue-destructive. Future therapeutic intervention will be reliant on clarification 
of MΦ polarisation plasticity, MΦ subset specific ET mechanisms and downstream 
effects on polarisation of T cells responses, which are involved in CD. Additionally, the 
therapeutic targeting of M1 MΦs via the encouragement of the negative regulators 
augmentation (TOLLIP and SIGIRR) or certainly the development of M2-mediated 
responses or development a mechanism of IRAK-M recruitment and increase IL-10 
production could represent a raw treatment in the regulation of this chronic 
inflammatory disease. 
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6.2 Limitation and future work 
Results in the research create a platform of knowledge about the polarisation and 
behaviour of PMA and Vitamin D3 THP-1 differentiated MΦ subsets, M1-like and M2-like 
MΦ, respectively, and Caco-2 epithelial cells. Additionally, these cells were used to 
improve in vitro co-culture models while Caco-2 epithelial cells were co-cultured with M1-
like MΦs, resembling a chronic inflammation model, and Caco-2 co-cultured with M2-like 
MΦs, resembling a model of normal gut homeostasis, were used to explore PAMPs 
modulation of macrophage behaviour and macrophage -influenced epithelial barrier 
function. Results in chapter 3 showed that MΦ subsets differentially sensitive to TNFα 
and IL-1β stimulation in present or absent of LPS. Further studies need to be applied 
on this stimulus receptor and signalling. In addition, this experiment could be 
redesigned to be applied on the co-culture models used in chapter 5. MΦ subsets 
differentially produced IL-18 and differentially produced and respond to IL-1β. The role 
caspase-1 is different between M1 and M2-like MΦs. Taking together, it is recommended 
to investigate more about inflammasome activation in MΦ subsets include inflammasome 
signaling cascade, NLRP3 initiation. The main finding in chapter 4 was the role of 
negative regulatory molecules in the induction of ET in MΦ subsets where TOLLIP and 
SIGIRR were more associated with M1-like and IRAK-M was associated with M2-like 
MΦs. It was suggested to do more study to confirm these results by using siRNA 
technique, a method of preventing translation of specific genes by interferes it with 
the expression with complementary nucleotide sequences by degrading mRNA after 
transcription (Agrawal et al., 2003). It is also recommended to investigate about the 
production of another anti-inflammatory cytokine in ET such as TGF-β. Results of IL-6 
production by endotoxin tolerised-M2-like MΦs in parallel with of STAT-3 and SOCS-3 
results in chapter 4 gave an indication to study the association between JAK/STAT 
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signalling pathway and ET in MΦ subsets. Furthermore, homo-tolerisation experiments 
showed interesting results especially the relation between K12-LPS and PGN, which 
ignited more ideas to be investigated. Finally, as the model in chapter 5 presents a 
validation of interaction of Caco2/MΦs and characterise two dimensional 2D cell 
model for study, these outcomes will restructure and rationalise the improvement of 
multicellular 3D models. 
6.3 Conclusion 
In conclusion, as this investigation has focused on the mucosal interactions in health 
and disease, further characterised M1-and M2-like MΦ subsets with respect to pro-
inflammatory cytokine profile upon stimulation especially with E. coli K12-LPS. Firstly, a 
dichotomy in cytokine secretion was demonstrated where M1 MΦs are indeed the 
predominant pro-inflammatory cell. M1 MΦs, representative of pro-inflammatory 
pathological cells, were mainly pro-inflammatory and strongly produced TNFαhi, IL-1βlo, 
IL-18hi, IL-6hi and secreted IL-10hi, whereas M2 subset, representative of regulatory, 
anti-inflammatory cells, was indeed a low-level producer of TNFαlo, IL-1βhi, IL-18lo, IL-6lo 
and secreted IL-10lo. Furthermore, in the chronic inflammation (long term TNFα 
stimulation), M1-like MΦs increased the inflammation by production of pro-
inflammatory cytokines such as TNFα, in the presence of LPS, whereas M2-like MΦs, 
representative of homeostasis, showed remarkable tolerance condition with high level 
of anti-inflammatory cytokines, such as IL-10. However, MΦ subsets showed similar 
sensitivity to inflammation induced by IL-1β. Additionally, with regards to the 
inflammasome activity in MΦ subsets, IL-1β and IL-18 secretion was dependent on the 
activation of caspase-1 pathway in M1-like MΦs, whereas only IL-1β production was 
caspase-1 dependent in M2-like MΦs. 
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Secondly, upon investigation of sensitivity of these subsets to tolerisation, it was 
observed that both subset were sensitive to E. coli-induced suppression of pro-
inflammatory cytokines. This cytokine profile is likely to be associated with the up-
regulation of TLR4 and Tollip in M1-like MΦs, whereas it might be as a consequence of 
IL-10 and IRAK-M up-regulation. This would suggest that such mechanisms of ET might 
be beneficial for survival and immunopathological mechanisms driven by the pathogen. 
It was also established that comparing to M1-like MΦs; M2-like MΦs differently 
produce IL-10 cytokine along with an endogenous cell-associated activity. However, 
both M1 and M2 MΦ were sensitive to the anti-inflammatory effects of IL-10 in the 
present of E. coli K12-LPS. M1- and M2-like MΦs were able to performed homo- and 
hetero-tolerisation induced by different PAMPs. 
Finally, in this study, epithelial–macrophages cells co-culture system was established 
and the role for MΦ subsets in initiating and regulating tolerance and inflammation of 
epithelial cells was demonstrated. LPS, TNF and IL-1β stimulation was able to disturb 
the barrier function of intestinal epithelia resulting in increased permeability or 
disrupted tight junctions TJs as TNFα was the most stimulus that showed disruption. In 
the present study, the Caco2 cell line is differentially sensitive to a range of stimuli i.e. 
more sensitive to pro-inflammatory cytokines, TNFα and less sensitive to LPS. In 
comparison to monoculture experiment, the co-culture system  showed 
immunosuppressive effects of Caco2 cells on E. coli LPS-stimulated MΦs. Similar 
suppression was shown on E. coli LPS-stimulated Caco2 in presence of MΦs. To 
illustrate, Caco2/M1-like MΦs (inflammatory Model) displayed significant up-
regulation of the pro-inflammatory cytokines, TNFα and IL-1β in the inflammatory 
environment, which reflect the nature of pro-inflammatory M1 MΦ in the initiation 
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the inflammation. Interestingly, in homeostatic state, K12-LPS induced suppression of 
inflammatory cytokines in M1-like subset in co-culture model whereas M2-like subset 
in Caco2/M2 model was refractory to tolerisation. However, in the inflammatory 
condition, K12-LPS induced ET in both subsets in the co-culture system. 
To conclude, any future investigation on MΦ subset tolerisation can be achieved 
realistically upon a full understanding of the immunopathological pathways behind 
such inflammatory diseases as CD and by development of multicellular 3D models 
more representative of both the healthy/homeostatic and the inflammatory gut 
mucosal tissue.
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Appendix 1  
General material  
1 Tissue culture reagents and material  
Table ‎1-1: Tissue culture reagents and material 
Product  Product code Supplier 
1, 25-(OH)2 Vitamin D3 D1530 Sigma-Aldrich, Poole, 
UK 
Bovine serum albumin (BSA) A8531-1VL Sigma-Aldrich, Poole, 
UK 
Caco-2 cell line  ECACC, Salisbury, UK 
Caspase-1/ICE Inhibitor Z-WEHD-FMK                       FMK002 Bio-Techne Ltd, 
Abingdon, UK 
Cell culture costumes (Flasks, plates. Tips, 
pipettes)  
Greiner Bio-one-Ltd, 
Stonehouse, UK 
DMEM    BE12-614F/12  Lonza Bioscience ltd, 
UK. 
Dulbecco’s Phosphate Buffered Saline
  
D5652-10X1L Sigma-Aldrich, Poole, 
UK 
dimethyl sulfoxide (DMSO) D8418 Sigma-Aldrich, Poole, 
UK 
Escherichia coli K12-LPS tlrl-peklps Invivogen, UK 
Ethyl alcohol 
E7023 
Sigma-Aldrich, Poole, 
UK 
Foetal Calf Serum FCS-SA-10545/500 Labtech International 
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Limited, East Sussex, 
UK  
IL-10 standard antibody 93/722 NIBSC, Hertfordshire, 
UK 
IL-1β standard antibody 86/680 NIBSC, Hertfordshire, 
UK 
L-Glutamine 200nM  Fisher Scientific UK Ltd 
Penicillin/streptomycin A 2213 Source Bioscienc 
Peptidoglycan (PGN) 77145 Sigma-Aldrich, Poole, 
UK 
phorbol-12-myristate acetate (PMA) P1585 Sigma-Aldrich, Poole, 
UK 
Purified anti-human anti-IL-10  501402  Biolegend, London, UK 
Purified Rat IgG1, κ Isotype Ctrl 
Antibody 
400402 Biolegend, London, UK 
RMPI 1640 12-167F Lonza Bioscience ltd, 
UK. 
THINCERT CELL CULTURE INSERT-WELL 
PLATES 
665640  Greiner Bio-one-Ltd, 
Stonehouse, UK 
THP-1 cells line  ECACC, Salisbury, UK 
TLR2-ligand, lipoteichoic acid (LTA) tlrl-pslta InvivoGen, UK 
TNFα standard antibody 12/154 NIBSC, Hertfordshire, 
UK 
Ultrapure Porphyromonas gingivalis 
LPS 
tlrl-ppglps InvivoGen, UK 
Cryopreservation Storage media  
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20%v/v FBS/10% v/v dimethyl sulfoxide (DMSO)/ DMEM or RPMI 
 
2 ELISA  
Table ‎2-1: ELISA reagents and Antibodies. 
Product  Product code Supplier 
 Bovine serum albumin (BSA) A8531-1VL Sigma-Aldrich, Poole, 
UK 
IL-10 Purified Rat Anti-Human capture 
antibody 
554497 BD Pharmingen, UK 
IL-10 Biotin Anti-Human detect 
antibody 
554499 BD Pharmingen, UK 
IL-1β capture antibody MAB601 R&D Systems, 
Abingdon, UK 
IL-1β detection antibody BAF201 R&D Systems, 
Abingdon, UK 
IL-1β standard antibody 1989 NIBSC, Hertfordshire, 
UK 
IL-6 Purified Rat Anti-Human capture 
antibody 
554543 BD Pharmingen, UK 
IL-6 Biotin Anti-Human  detection 
antibody 
554546 BD Pharmingen, UK 
IL-6 standard antibody 89/548 NIBSC, Hertfordshire, 
UK 
IL-8  Purified Rat Anti-Human capture 
antibody 
554716 BD Pharmingen, UK 
IL-8  Biotin Anti-Human detection 554718 BD Pharmingen, UK 
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antibody 
IL-8 standard antibody 89/520 NIBSC, Hertfordshire, 
UK 
L-18 Human Matched Antibody Pair BMS267/2MST eBioscience, Thermo 
Fisher Scientific Inc, UK 
Nunc ELISA Plates Immunosorbent. 10547781 Fisher Scientific, UK 
Phosphate buffered saline tablets P4417 Sigma-Aldrich, Poole, 
UK 
Purified anti-human IL-10 Antibody 501402 Biolegend, London, UK 
Streptavidin HRP DY998 R&D Systems, 
Abingdon, UK 
TMB microwell peroxidase 50-76-00 Insight Biotechnology 
TNFα anti-human capture antibody 551220 BD Pharmingen, UK 
TNFα Biotin Mouse Anti-Human 
detection antibody 
554511 BD Pharmingen, UK 
TNFα standard antibody 12/154 NIBSC, Hertfordshire, 
UK 
Tween 20 P2287-100ML Sigma-Aldrich, Poole, 
UK 
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3 Protein analysis 
Table ‎3-1: Western Blotting solutions 
Western Blotting reagents were obtained from 
Sigma-Aldrich, Poole, UK 
Lysis Buffer 
 Ripa buffer  
Protease Inhibitor Cocktail  
1:20 = for 200μl lysis buffer add 10μl 
Phosphatase Inhibitor Cocktail  
1:100 = for 200μl lysis buffer add 2μl 
SDS-PAGE reagents  
Acrylamide, electrophoresis grade  
Bis- acryl amide (N.N –methylenebisacrylamide)  
Tris (2-hydroxymethyl-2-methyl-1, 3-propanediol)  
SDS (sodium dodecyl sulphate or sodium lauryl sulphate)  
TEMED (N, N, N, N,-tertamethylene-ethylenediamine)  
APS (Ammonium per sulphate)  
2-mercaptoethanol 
Glycerol  
Bromophenol blue  
Glycine  
HCl (Hydrochloric acid)  
Solution A (separating gel buffer)  
Acrylamide Stock Solution, 100 ml 30% (w/v) acrylamide 
(w/v) bis- acrylamide  
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Solution B (separating gel buffer):  
1.125 M Tris base 68.14 g per 500 ml  
0.3%w/v SDS 1.5 g per 500 ml  
Dissolved in DW to 450 ml adjusted to pH 8.8 with HCl. 
Top up to 500 ml with DW.  
Solution C (Stacking buffer)  
140 mM Tris 8.42 g per 500 ml  
0.11%w/v SDS 0.55 g per 500 ml  
Dissolve in DW to 450 ml. Adjust to pH 6.8 with 
concentrated HCl 100%. Top up to 500 ml with DW  
10%w/v APS (0.1g APS dissolved into 1ml DW)  
Electrophoresis buffer (Running buffer)  
Tris 3 g  
Glycine 14.4 g  
SDS 1 g  
Dissolved in DW 1L, pH 8.3 
Transfer buffer stock (10X Exc. Methanol)  
Tris base 30.3g  
Glycine 144g  
DW 1L.  
Transfer buffer working solution  
10X transfer buffer 100 ml  
Methanol 200 ml  
DW 700 ml  
Washing solution 
 tris buffered saline with tween 20 (TBST)  
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TBS-Tween-20 (0.1% v/v)/TBS  
10xTBS ( tris buffered saline)  
NaCl 80g  
Tris 24.4g  
DW Mix in 800ml of DW, adjust to pH 7.6, and make up 
to 1L with DW  
TBS-Tween-20 (TBST)  
10x TBS 40ml  
DW 959ml  
Tween-20 1ml 
Blocking solution  
TBST 100 ml  
5% w/v BSA 5g  
Stripping buffer  
Mild stripping  
15 g glycine  
1 g SDS  
10 ml Tween 20  
Adjust pH to 2.2 Top up to 1 L with DW 
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Table 3-2: Protein analysis reagents. 
Product  Product code Supplier 
Anti-rabbit IgG, HRP-linked Antibody 7074P2 
New England Biolabs, 
Herts, UK 
Anti-SIGIRR antibody  ab22053 Abcam, Cambridge,UK 
Biotinylated Protein Ladder Detection  
7727S 
New England Biolabs, 
Herts, UK 
 Bovine serum albumin (BSA) A8531-1VL Sigma-Aldrich, Poole, 
UK 
Criterion Xt precast gel, 4-12% Bis-Tris 345-0123 Bio-Rad Laboratories 
Ltd, Hertfordshire, UK 
Deoxynucleotide Mix,10mM D7295-.5ML Sigma-Aldrich, Poole, 
UK 
Ethyl alcohol 
E7023 
Sigma-Aldrich, Poole, 
UK 
Gel loading Tips LW1100 Alpha Laboratories Ltd, 
Hampshire, UK. 
Goat Anti-Rabbit IgG (H+L)-HRP 
Conjugate 
172-1019 Bio-Rad Laboratories 
Ltd, Hertfordshire, UK 
Halt Protease and Phosphatase 
Inhibitor Single-Use Cocktail (100X 
78442 Thermo Scientific, UK 
IRAK-M Antibody PA5-17473 Fisher Scientific - UK Ltd 
Luminata Crescendo Western HRP 
substrate 
WBLUR0100 Millipore 
Micro BCA Protein Assay Kit  
     
23235  Thermo Fisher 
Scientific, UK 
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Pierce Prestained Protein MW Marker 26612 Thermo Fisher 
Scientific, UK 
PVDF Transfer Membrane 88518 Thermo Fisher 
Scientific, UK 
Rabbit anti-Mouse IgG (H+L) 
Secondary Antibody [Biotin] 
NB720-B R&D Systems, 
Abingdon, UK 
Restore Western Blot Stripping Buffer 21062 Thermo Fisher 
Scientific , UK 
RIPA Lysis and Extraction Buffer  
     
89900 Thermo Fisher 
Scientific,UK  
STAT-3 (79D7) Rabbit mAb 4904P New England Biolabs, 
Herts, UK 
TLR4 Antibody  NB100-56566 
R&D Systems, 
Abingdon, UK 
Tollip Antibody 4748  
New England Biolabs, 
Herts, UK 
Water ,Molecular Biology Reagent W4502-1L Sigma-Aldrich, Poole, 
UK 
Western Blotting Filter Paper 88620 Thermo Fisher 
Scientific, UK 
 
4 RNA qualification  
Table 4-‎4-1: RNA qualification reagents 
Product  Product code Supplier 
 Bovine serum albumin (BSA) A8531-1VL Sigma-Aldrich, Poole, UK 
Deoxynucleotide Mix,10mM D7295-.5ML Sigma-Aldrich, Poole, UK 
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RNA extraction and PCR costumes (plates, Tips and 
pipettes)  
Fisher Scientific UK 
Ethyl alcohol E7023 Sigma-Aldrich, Poole, UK 
GenElute mammalian total RNA 
extraction kit 
RTN350-1KT  Sigma-Aldrich, Poole, UK 
Ladder 100 bp DNA ladder 15628019 Invitrogen-Gibco 
M-MLV Reverse Transcriptase M1302-40KU Sigma-Aldrich, Poole, UK 
On-Column DNase I Digestion Set DNASE70 Sigma-Aldrich, Poole, UK 
Phosphate buffered saline tablets P4417 Sigma-Aldrich, Poole, UK 
Primers  Eurofins Genomics, 
Wolverhampton, UK 
Random Nonamers R7647-100UL Sigma-Aldrich, Poole, UK 
Ribonuclease inhibitor human R2520-2.5KU Sigma-Aldrich, Poole, UK 
SYBR® Green Master Mix   4472908 Applied Biosystems, 
Cheshire - UK 
Water ,Molecular Biology Reagent W4502-1L Sigma-Aldrich, Poole, UK 
 
Table 4-‎4-2: Summary of primers used in this study and the amplicon product size 
Target Forward primer 5’ Size(base 
pair bp) 
Reverse primer 3’ Size(base 
pair bp) 
Product 
size bp 
ß-actin  CCTGTACGCCAACACAGTGC 20 ATACTCCTGCTTGCTGATCC 20 211 
GAPDH CTGCTCCTCCTGTTCGACAGT 21 CCGTTGACTCCGACCTTCAC 23 100 
TNFα ACATCCAACCTTCCCAAACG 20 GCCCCCAATTCTCTTTTTGAG 22 151 
IL-10 AGGAGGTGATGCCCCAAGCT
GA 
22 TCGATGACAGCGCCGTAGCC
T 
21 110 
IL-6 TGGCTGCAGGACATGACAAC 20 TGAGGTGCCCATGCTACATTT 20 100 
IL-1 β GCCAATCTTCATTGCTCAAGT 21 AGCCATCATTTCACTGGCGA 20 73 
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TLR4 AGCCCTTCACCCCGATTC 18 TAGAAATTCAGCTCCATGCAT
TG 
23 100 
TLR2 GGCATGTGCTGTGCTCTGTT 20 GGAGCCAGGCCCACATC 17 100 
Nod-2 CAGAATTTCAAACGGCCTCAC
TA 
23 ATGAAATGGAACTGCCTCTT
GTG 
23 102 
Tollip TCTCATGCCGTTCTGGAAAAT 21 TCACATCACAAAATGCCATGA
A 
22 110 
IRAK-M  TTCAACCATGCTCGGTCATCT 21 CATACCAGGAGAACTACAGC
AGA 
23 137 
SIGIRR (1) GACCTGGCTTGTGTCTTTGT 20 GGGTGGGGTTTAGGGTTAGG
A 
21 94 
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Published papers: 
Foey, A.D., Habil, N., Al-Shaghdali, K. and Crean, S.J. (2017): Porphyromonas gingivalis-stimulated 
macrophage subsets exhibit differential induction and responsiveness to interleukin-10.  Archives of 
Oral Biology 73:282-288. 
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Macrophage subset sensitivity to endotoxin tolerance is determine by 
distinct expression profiles of batrecognetion receptors and negative 
regulators 
To be published in mid of November 
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